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INTRODUCTION 
 
Part I Computational Biology Study of Mitochondrial DNA Replication 
 
Mitochondria are essential for energy production through oxidative phosphorylation 
and have their own genome, which is maternally inherited and harbors 37 genes in a circular 
molecule of approximately 16.6 kb that is present in hundreds to thousands of copies per cell. 
The proteins involved in mtDNA replication, which are all encoded by the nuclear DNA, include 
the DNA polymerase gamma (pol γ) and its accessory protein POLG2, the single stranded DNA 
binding protein (mtSSB), the mtDNA helicase (Twinkle), and a number of accessory proteins and 
transcription factors (Graziewicz et al. 2004). The minimal protein set required to replicate 
mtDNA in vitro includes the two subunits of pol γ, the mitochondrial helicase and mtSSB 
(Korhonen et al. 2004). However, typically in experiments measuring the kinetics of pol γ, 
neither Twinkle nor mtSSB are added in the assay (Johnson and Johnson 2001; Johnson and 
Johnson 2001). Generally, these proteins are unnecessary since the kinetics assays only involve 
the replication of a short length of DNA. 
The holoenzyme of human pol γ consists of a catalytic subunit (encoded by POLG at 
chromosomal locus 15q25) and a homodimer of its accessory subunit (encoded by POLG2 at 
chromosomal locus 17q24.1) (Yakubovskaya et al. 2006). The catalytic subunit is a 140 kDa 
enzyme (p140) that has DNA polymerase, 3’-5’ exonuclease and 5’ dRP lyase activities. The 
accessory subunit is a 55 kDa protein (p55) required for tight DNA binding (Lim et al. 1999).  
The function of pol γ is far more complicated than the function of a typical enzyme that 
converts a substrate into a product. For this reason, the analysis of the enzyme kinetics of pol γ 
must also be far more complicated. The function of pol γ is the replication of a complete 
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mitochondrial DNA molecule, while the enzyme kinetics data for pol γ are at the level of 
individual reactions at the base-pair level. One tool that can be used to bridge that large gap 
between the enzyme kinetics data and the final product of a replicated DNA molecule is 
simulation. A computational simulation can reproduce each individual reaction of the 
polymerase activity, at the lowest level for which we have experimental data on the relevant 
reaction kinetics of the polymerase. The simulation can tirelessly repeat this process for the 
several tens of thousands of reactions necessary for the replication of a single strand of human 
mtDNA.  Since mutations introduced through polymerase errors are of great practical interest, 
we need to use a stochastic simulation approach that will allow such replication errors to occur 
with probabilities that are calculated from the experimentally measured enzyme kinetics. 
 
Create mtDNA Replication Model of Pol γ Using The Gillespie Algorithm 
The Gillespie algorithm (or Stochastic Simulation Algorithm) is a well-known Monte 
Carlo simulation method for chemical reactions (Gillespie 1976). This algorithm takes a defined 
list of possible reactions and uses the reaction rates, based on the measured enzyme kinetics 
data and the substrate concentrations, to calculate the probability of each reaction on the list. 
These probabilities are then used to randomly choose the sequence of reactions that occur. The 
original Gillespie algorithm is particularly useful for simulating reactions involving a small 
number of molecules, while more elaborate and approximate versions of the basic algorithm 
have been created in order to handle large numbers of molecules (Cao and Samuels 2009). For 
modeling pol γ activity we are generally concerned with only a single enzyme molecule, the one 
molecule of pol γ that is replicating a particular strand of mtDNA. In this special case, the original 
Gillespie algorithm is the preferred simulation method. 
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mtDNA deletion/depletion 
The replication of DNA by a polymerase may not progress at a steady rate. How do 
replication pauses of pol γ relate to the commonly observed pathological phenotypes of mtDNA 
deletions and depletion? In theory, once a replication fork pauses, it can restart to continue the 
replication process without problems. However, if a pause is lengthy enough it might allow time 
for low-probability events such as double strand breaks. A double strand break can be repaired 
through blunt-ended rejoining, or homologous annealing of 5’- and 3’-repeat sequences 
(Krishnan et al. 2008), or nonhomologous end-joining (Graziewicz et al. 2006) that will form 
deleted mtDNA. If the double strand break cannot be repaired, it will cause a failed replication. 
Repeated failed replications eventually would lead to depletion of the amount of mtDNA within 
the cell. These concepts are illustrated in Figure 1. Under this hypothetical mechanism, mtDNA 
deletions and depletion may both be possible outcomes from the same initial event, the pausing 
of the polymerase. Of course, other mechanisms for deletion formation are also possible 
(Krishnan et al. 2008). 
 
 
 
 
Figure 1. Possible consequences after mtDNA replication fork pauses. 
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Pathogenic Mutated Pol γ 
Pathogenic mutations in POLG have been identified in patients with neurological or 
muscular diseases including progressive external ophthalmoplegia (PEO), Alpers syndrome, 
ataxia-neuropathy syndromes, idiopathic Parkinsonism, and nucleoside reverse-transcriptase 
inhibitor (NRTI) toxicity (Copeland 2008; Hudson and Chinnery 2006). All these diseases were 
characterized by mtDNA deletions and/or depletion in symptomatic tissues (Chan and Copeland 
2009). PEO, as a mitochondrial disorder, is associated with the depletion of mtDNA and/or the 
accumulation of point mutations and deletions within mtDNA, caused by autosomal dominant 
mutations in POLG (Longley et al. 2005). In Alpers syndrome, the identified pol γ mutations are 
either homozygous A467T (MIM 174763.0002) or heterozygous A467T paired in trans with other 
mutations in POLG (Ferrari et al. 2005; Naviaux and Nguyen 2004). 
The A467T mutation has been found in all of the major POLG related diseases, i.e. Alpers 
syndrome, ataxia-neuropathy syndromes and PEO (Chan and Copeland 2009). The frequency of 
the A467T mutation varies from less than 0.2% to approximately 1% in different European 
control populations (Horvath et al. 2006; Luoma et al. 2005; Van Goethem et al. 2001; 
Winterthun et al. 2005). In mitochondrial disease populations, however, the A467T allele was 
estimated to be the most common alleles associated with POLG diseases (Chan and Copeland 
2009). Even the homozygous A467T substitution of POLG has been found in patients with highly 
varied phenotypes. For example, in Alpers syndrome (Boes et al. 2009; Utzig et al. 2007), two 
unrelated teenage boys with homozygous A467T POLG had ataxia and severe epilepsy. In 
contrast, in a case of concurrent progressive sensory ataxia, dysarthria, and ophthalmoparesis 
(McHugh et al. 2010), two siblings also homozygous for POLG A467T developed disease 
symptoms only late in life, with onset in their 40s. The kinetic parameters of the A467T mutant 
for both polymerase and exonuclease activity have been measured experimentally (Chan et al. 
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2005). Compared to the wild-type catalytic subunit, the A467T substitution increased the Km of 
the enzyme 5-fold while also reducing the kpol value approximately 5-fold for DNA synthesis. As 
determined by the ratio of kpol/Km, the A467T substitution reduces DNA synthesis efficiency to 4% 
of the wild-type activity. In contrast, the exonuclease activity of the A467T variant is only 
decreased 2-fold compared to the wild-type (Chan et al. 2005). Besides altering the kinetics of 
pol γ, the A467T variant in POLG also decreases the protein’s physical association of the POLG2 
subunit (Chan et al. 2005). 
In addition to the identified pathogenic A467T substitution of pol γ in human, proof-
reading deficient versions of the catalytic subunit of mtDNA polymerases have been created in 
two independent homozygous knock-in mouse models, one published in 2004 (Trifunovic et al. 
2004) and the other one in 2005 (Kujoth et al. 2005). For simplicity, the first will be referred as 
Stockholm mouse model and the second will be referred as Madison mouse model. Both mouse 
models showed similar progeria-like phenotypes and shared the same D257A mutation on the 
second exonuclease domain of PolgA (the mouse homolog of POLG) that caused a profound 
reduction of the exonuclease activity but no decrease in DNA polymerase activity. Both mouse 
models (Kujoth et al. 2005; Trifunovic et al. 2004) were reported to have accumulated mtDNA 
point mutations. Using these two mouse models, other mitochondrial genome variations 
besides point mutation have been studied. For the Stockholm mouse model, after Trifunovic et 
al. (Trifunovic et al. 2004) reported increased mtDNA deletion, Bailey et al. (Bailey et al. 2009) 
using one- and two-dimensional agarose gel electrophoresis interpreted these non-replicating 
linear mtDNAs as the result of double-strand breaks of cyclic mtDNA caused by stalled 
replication intermediates. Ameur et al. (Ameur A. et al. 2011) further stated that mutator mice 
have abundant linear deleted mtDNA molecules but extremely low levels of circular mtDNA 
molecules with large deletions. For the Madison mouse model, Williams et al. (Williams et al. 
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2010) applying next-generation sequencing to native mtDNA did not observe the accumulation 
of mtDNA deletions but instead reported multiple copies of the mtDNA control region in brain 
or heart. However, Vermulst et al. (Vermulst et al. 2008; Vermulst et al. 2009) have identified 
mtDNA deletions as a critical driving factor behind the premature aging phenotype in Madison 
mouse models and have suggested there is a homology-directed DNA repair mechanism directly 
linked to mtDNA deletion formation. As this description shows, the data on the amount of 
deletions in these two mouse models is currently mixed and this is a research area that is rapidly 
developing. 
 
Pol γ Dependent Toxicity of NRTI Drugs in HIV Treatment 
In their activated tri-phosphorylated forms, each NRTI (nucleoside reverse transcriptase 
inhibitor) drug acts as a nucleotide analog interacting with the HIV viral reverse transcriptase 
(Anderson et al. 2004; Ray 2005). NRTIs are an alternative substrate to the natural nucleotides, 
which lacks the 3’ OH group necessary for incorporation of the next nucleotide thereby 
terminating viral DNA strand elongation. Although NRTIs are effective drugs and have helped 
usher HIV into the category of a controllable chronic disease, they are also often toxic, inducing 
side effects such as lactic acidosis, peripheral neuropathy, lipoatrophy, and pancreatitis in 
patients. Intolerance of such side effects is a common reason for treatment discontinuation 
(d'Arminio Monforte et al. 2000). Any decrease in patient compliance to the treatment regimen 
is a serious concern that can lead to poor HIV virologic control, the increased potential for the 
development of HIV-1 genotypic drug resistance, and ultimately treatment failure. The first step 
in ameliorating these side effects and preventing them in future antiviral treatments is to 
understand the mechanisms behind the mitochondrial toxicity of the NRTIs that are in use today. 
As we discuss below, many mechanisms of the mitochondrial toxicity have been proposed. In 
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this paper we specifically consider the plausibility of the most widely accepted hypothesis for 
the toxicity mechanism for this class of drugs; interference of mitochondrial DNA replication by 
the activated drug. 
In a study conducted by Martin et al. (Martin et al. 1994) the approved NRTIs were 
shown to inhibit various host DNA polymerases. After the HIV Reverse Transcriptase, the highest 
affinity of the NRTIs was for pol γ. This, along with the fact that many of the NRTI side-effects 
resemble symptoms of mitochondrial genetic disorders, implicated interaction with pol γ and 
subsequent depletion of mtDNA as a potential cause of NRTI toxicity giving rise to the pol γ 
hypothesis (Lewis et al. 2003). Indeed, experiments have demonstrated decreased mtDNA 
amounts in various tissue types of NRTI-treated HIV positive patients (Cherry et al. 2002; Cote et 
al. 2002; Haugaard et al. 2005; Walker et al. 2004). In addition, mtDNA depletion was observed 
in parallel with cell death, mitochondrial morphological changes, and increased lactate 
production in liver, heart, neuron, skeletal muscle, adipose, and blood cell cultures after 
incubation with different NRTIs (Azzam et al. 2006; Benbrik et al. 1997; Biesecker et al. 2003; 
Birkus et al. 2002; Cui et al. 1997; Galluzzi et al. 2005; Pan-Zhou et al. 2000; Setzer et al. 2005; 
Walker et al. 2002). 
There are three possible pol γ dependent toxicity mechanisms that comprise the pol γ 
hypothesis: 1) direct inhibition of pol γ by NRTI-triphosphate without incorporation into the 
mtDNA, 2) chain termination of mtDNA replication following incorporation of the NRTI 
triphosphate, and 3) incorporation of the analog triphosphate into mtDNA without chain-
termination allowing the NRTI to continue as a point mutation in mtDNA (Lewis et al. 2006). 
However, there also exists a substantial body of data that are not consistent with 
toxicity mechanisms resulting in depletion of mtDNA and indicate a weak relationship between 
mtDNA copy number and nucleoside analog toxicity. Martin et al. (Martin et al. 1994) showed 
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no association between inhibition of pol γ by NRTIs and mtDNA depletion. Mitochondrial 
dysfunction has been observed in vitro in mouse muscle, white adipose, brain, liver, and heart 
tissue (Note et al. 2003), hepatoma cell lines (Walker et al. 2002) as well as CD4 cells (Setzer et 
al. 2005) after incubation with NRTIs although no significant decrease in mtDNA amount was 
observed. In clinical settings mtDNA depletion has been seen in parallel with normal cytochrome 
c oxidase activity, a sign of correct mitochondrial function (Piechota et al. 2006), and was not 
associated with lipoatrophy (McComsey et al. 2005) (although that study measured mtDNA 
depletion in blood samples, not fat cells). This warrants a deeper look at the data concerning the 
interaction of different NRTIs with pol γ. 
To this end, we have simulated the DNA replication process of mitochondria. Using 
enzyme kinetics data gathered from Johnson et al. (Johnson et al. 2001), Feng et al. (Feng et al. 
2004), and Hanes et al. (Hanes and Johnson 2007; Hanes et al. 2007) we have carried out a 
series of simulations of mtDNA replication in the presence of various nucleoside analogs that 
interact with pol γ (Table 3.2). These simulations bridge the gap between the basic enzyme 
kinetics data and the probability of failure of the mtDNA replication process. 
 
Related Chapters 
Chapter I describes the computational stochastic model of the replication of pol γ in 
detail, which is the 1st model on the single nucleotide incorporation level. This model could be a 
great tool for the analysis of enzyme kinetic data for mtDNA replication, which is capable of 
dealing with different substrates - natural nucleotide and nucleotide analogs and both wild-type 
and pathogenic mutated pol γ. 
Chapter II studies replication pauses of pol γ. The stochastic model made it possible to 
quantify the pause lengths for the wild-type pol γ and for the pathogenic A467T and the 
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exonuclease deficient pol γ variants. Our model of the exo- polymerase had extremely long 
pauses, with a 30 to 300-fold increase in the time required for the longest single forward step 
compared to the wild-type, while the naturally occurring A467T variant showed at most a 
doubling in the length of the pauses compared to the wild-type. We identified the cause of 
these differences in the polymerase pausing time to be the number of disassociations occurring 
in each forward step of the polymerase. 
Chapter III studies pol γ dependent side effect of NRTI drugs. The model has been used 
to analyze the inhibition of pol γ replication and toxicity caused by nucleoside analogs in 
antiretroviral treatment. The model predicts an approximate 1000 fold difference in the 
activated drug concentration required for a 50% probability of mtDNA strand termination 
between the activated di-deoxy analogs stavudine (d4T), zalcitabine (ddC), and didanosine (ddI) 
and the activated forms of the analogs lamuvidine (3TC), tenofovir (TDF), zidovudine (AZT/ZDV), 
emtricitabine (FTC), and abacavir (ABC). These predictions are supported by experimental and 
clinical data showing significantly greater mtDNA depletion in cell culture and patient samples 
caused by the di-deoxy analog drugs. 
 
  
 10 
 
Part II Methodology for Sequencing Data Analysis 
 
Enrich Rare Disease Alleles in GWAS Samples 
In genetic epidemiology, a genome-wide association study (GWAS) is based on the 
premise that densely genotyped common alleles will have statistical power to detect causal 
associations with traits at nearby, ungenotyped common variants, through short-range linkage 
disequilibrium (LD). The foundation for this strategy is the common disease common variant 
(CDCV) hypothesis (Reich and Lander 2001). This approach has been proven to be very effective 
in different scenarios for mapping small genomic regions to traits (see the National Human 
Genome Research Institute Catalog of Published Genome-Wide Association Studies) (Manolio et 
al. 2008; McCarthy et al. 2008). However, the predominantly small effect sizes encountered thus 
far in investigations of most traits do not provide an explanation for a large proportion of the 
trait variance attributable to heritable factors (Maher 2008; Manolio et al. 2009). This 
phenomenon has been described by Purcell et al. who suggested that hundreds or thousands of 
SNPs may each have a very subtle influence on the risk of some psychiatric traits (Purcell et al. 
2009). These observations seem to support an adjustment of the CDCV model to allow for the 
probability that rare alleles might also exert a major influence on common traits (Bodmer and 
Bonilla 2008; Pritchard 2001; Schork et al. 2009). 
The common disease rare variant (CDRV), derived from CDCV, assumes that alleles with 
strong effects on traits are likely to be rare due to purifying selective pressure and recent time 
to coalescence due to the rapid expansion of human populations (Pritchard 2001). In addition, it 
has been shown in simulations that multiple rare alleles with strong effects can stochastically 
aggregate onto the haplotypic background of a common allele and produce genome-wide 
significant association signals, a scenario termed synthetic association (Dickson et al. 2010). The 
 11 
 
CDRV hypothesis has further support coming from observational studies where the average 
allele frequency of SNPs with predicted effects on proteins was smaller than the average allele 
frequency of intronic or synonymous variants (Cargill et al. 1999; Gorlov et al. 2008; Wong et al. 
2003). Estimates from human Mendelian traits, human–chimpanzee divergence data and human 
genetic variation suggested that ~53% of new missense mutations have mildly deleterious 
effects, and that up to 70% of low-frequency missense alleles are mildly deleterious (Kryukov et 
al. 2007). 
A rare trait allele may not be annotated in the databases of common variants 
maintained by either dbSNP or the International HapMap Organization. As a consequence, the 
possibility of detecting that SNP will be excluded through imputation and subsequent 
association analysis. The constellation of causal alleles may also be unique for each population 
of human subjects, where sensitive functional gene or regulatory regions are perturbed by 
independent sets of rare mutations that occurred after geographic or cultural barriers led to 
increased genetic distance (Tishkoff et al. 2009). Thus, the same associated allele from GWAS 
across multiple ethnic groups does not necessarily imply the same underlying architecture of 
causal alleles in LD. Then resequencing becomes the best available means of discovering these 
rare SNPs in a GWAS sample and ultimately detecting the relationship between these alleles and 
traits. 
To successfully discover the variants that determine trait susceptibility, it is necessary to 
directly capture all genetic mutations in a region (Cirulli and Goldstein 2010). This can be 
accomplished most efficiently by using next-generation sequencing technology to resequence 
subjects for the implicated loci (Service 2006), which has substantially decreased the financial 
cost of resequencing large genomic regions relative to Sanger sequencing technology. However, 
next-generation sequencing technologies are still not generally feasible for resequencing all the 
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subjects that were used to isolate a genomic region via GWAS. Thus, some strategies are 
necessary for employing sequencing technology that is cost-effective. One possibility is to 
resequence a small number of cases and controls or persons with extreme trait values and 
evaluate the observed genetic variation for association with traits to screen rare variants prior 
to larger genotyping experiments. This approach, however, will suffer from low statistical power 
at the screening step due to the infrequent exposure rate of rare alleles, and potentially suffer 
from inflated type I error rates (Li and Leal 2009) as a result of ascertainment bias in cases. 
Another alternative approach is not to attempt to associate alleles from resequencing data with 
the trait, but instead, to discover rare alleles by resequencing and then examine these SNPs with 
conventional genotyping methods in the entire available pool of study subjects. The limitation of 
this approach is the power to capture rare alleles in the targeted loci, which is directly related to 
the selection of subjects for the resequencing experiment (Li and Leal 2009). Using the 
information available at nearby trait-associated SNPs, targeted resequencing study designs can 
be tailored for efficient capture of rare disease alleles in small samples. 
 
Detect Tumor Somatic Mutations in Sequencing Data 
Cancer, as a class of complex genetic diseases, is responsible for one in eight deaths 
worldwide (Blecher et al. 2008). It is characterized by uncontrolled proliferation of malignant 
cells that can intrude into surrounding tissues and metastasize to distant organs because of 
somatically accumulated mutations and epigenetic changes (Esteller 2007; Stratton et al. 2009). 
Somatic genomic abnormalities of cancer encompass distinct classes of DNA and chromosomal 
changes, including base substitutions, insertions and deletions (indels), copy number variants 
(CNVs), and inter- and intra-chromosomal rearrangements. Exogenous DNA from viruses may 
also have been obtained in cells of some cancer types (Talbot and Crawford 2004). 
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Somatic mutations are distributed across all the genome (Stratton 2011). Only a small 
subset of them has been implicated in oncogenesis. The rate of somatic mutations may vary by 
cell type and can be influenced by mutagenesis exposures endogenously and exogenously. 
Generally, different cancer types have different mutation profiles. Some cancers display very 
disordered genomes while others have few genomic aberrations (Stratton 2011). It is crucial to 
understand the overall mutation profiles for different cancer types and in different patient 
individuals as mutation profiles may influence choice of treatments and a patient’s reaction to a 
treatment. In early cytogenetic studies of cancer, most genomic abnormalities found were 
chromosomal translocations and CNVs. Thanks to the development of next-generation 
sequencing (NGS) technologies, we are on the edge of creating a complete catalogue of 
mutations for each cancer type (Singer 2011) by screening the cancer genome at the finest 
resolution. 
Recently, the NGS technologies have been used to study somatic mutations in cancers, 
including melanoma (Pleasance et al. 2010), lung cancer (Lee et al. 2010; Pleasance et al. 2010), 
colorectal cancer (Timmermann et al. 2010), renal carcinoma (Varela et al. 2011), breast cancer 
(Ding et al. 2010; Shah et al. 2009), acute myeloid leukemia (Mardis et al. 2009), mesothelioma 
(Bueno et al. 2010), and prostate cancer (Berger et al. 2011). 
In these studies, sequencing was typically carried out on high-throughput sequencers to 
generate billions of single-end or paired-end reads that are then aligned to the reference 
genome. Figure 2 shows short reads (paired-end) aligned against the reference genome. The 
number of reads that cover one site is defined as the depth or coverage of that site. The 
genotype of each site can be called using the information of the bases on the reads mapped that 
site. 
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Figure 2. Paired-end reads aligned to the reference genome. 
 
 
Although the methods for mutation detection differ in details, these studies all relied on 
comparing SNP calls across samples in their primary mutation screening. Several efficient 
analysis tools for NGS data have been developed. For example, the Genome Analysis Toolkit 
(GATK) (McKenna et al. 2010), is a suite of tools for sequence data processing and genotype 
calling, which provides a rich software library for developing additional analysis tools. The GATK 
Unified Genotyper and other SNP calling programs perform well on calling genotypes for 
homogeneous samples such as blood and normal tissues. However, in cancer genomes, sample 
cells taken from a tumor tissue may include non-cancer cells. Additionally, cancer cells in a 
tumor sample can be heterogeneous with respect to somatic mutations. Therefore, a somatic 
mutation may exist only in a fraction of cells in a tumor sample, decreasing the likelihood of 
detecting it through genotype calls. The resulting allelic imbalance may also lead to tumor 
genotype calls being flagged as problematic and excluded from analysis.  
There are a few existing tools for detecting somatic mutations. However, they mostly 
rely on genotype calls for tumor samples. For instance, VarScan (Koboldt et al. 2009) screens 
data for mutation sites by comparing genotype calls between normal and tumor samples, and 
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SomaticSniper (Mardis et al. 2009) uses a genotype likelihood model (Li et al. 2009) to calculate 
the probability that the tumor and normal genotypes are diﬀerent. VarScan (Koboldt et al. 2009) 
does use allele frequency information to evaluate significance, but only for sites that show 
genotype difference between normal and tumor samples. 
 
Related Chapters 
Chapter IV presents SampleSeq, an algorithm for enriching the yield of rare or 
uncommon disease alleles in a sample of unrelated study subjects by choosing subjects 
according to their observed associated alleles and trait information. When multiple regions are 
to be sequenced, SampleSeq selects subjects with a balanced representation of all the regions. 
SampleSeq can also estimate the sample size required to detect a hypothetical disease allele, 
and thus can optimize a resequencing study to preserve resources for subsequent genotyping or 
other investigations. 
Chapter V introduces two novel algorithms for detecting two major types of somatic 
mutations, base substitution and loss of heterozygosity (LOH), by directly examining the 
sequence reads of tumor samples. We applied our methods, named Somatic Mutation Gleaner 
(SMUG), to whole exome sequencing data of eight breast cancer tumors and their matched 
blood samples, and detected somatic mutations that are missed by comparison of genotype 
calls between normal and tumor samples. 
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CHAPTER I 
 
ANALYSIS OF ENZYME KINETIC DATA FOR mtDNA REPLICATION1 
 
Introduction 
 
The Function of Polymerase Gamma 
Mitochondrial polymerase gamma is the sole DNA polymerase active in mitochondria 
(Kaguni 2004) and is responsible for the replication of mitochondrial DNA (mtDNA). Vertebrate 
polymerase gamma is composed of two subunits: a catalytic core, Pol γ-α, that contains the DNA 
polymerase and 3’-5’ exonuclease activities, and an accessory subunit, Pol γ-β, which enhances 
catalytic activity and serves as a processivity factor during DNA synthesis (Fan et al. 2006). 
The function of polymerase gamma is the replication of a complete mitochondrial DNA 
molecule, while the enzyme kinetics data for polymerase gamma are at the level of individual 
reactions at the base-pair level. To bridge the large gap between the enzyme kinetics data and 
the final product of a replicated DNA molecule, I build a computational simulation that can 
reproduce each individual reaction of the polymerase activity at the lowest level for which we 
have experimental data on the relevant reaction kinetics of the polymerase. The simulation can 
repeat this process for the several tens of thousands of reactions necessary for the replication of 
a single strand of human mtDNA. Since mutations introduced through polymerase errors are of 
great practical interest, we need to use a stochastic simulation approach that will allow such 
                                                          
1 Song, Z., and Samuels, D. C. (2010). Analysis of enzyme kinetic data for mtDNA replication. 
Methods 51(4), 385-391. Author contributions: Conceived and designed the experiments: ZS DCS. 
Performed the experiments: ZS. Analyzed the data: ZS DCS. Wrote the paper: ZS DCS. 
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replication errors to occur with probabilities that are calculated from the experimentally 
measured enzyme kinetics. 
 
The Gillespie Algorithm 
The Gillespie algorithm is a well-known Monte Carlo simulation method for chemical 
reactions (Gillespie 1976). This algorithm takes a defined list of possible reactions and uses the 
reaction rates, based on the measured enzyme kinetics data and the substrate concentrations, 
to calculate the probability of each reaction on the list. These probabilities are then used to 
randomly choose the sequence of reactions which occur. The original Gillespie algorithm is 
particularly useful for simulating reactions involving a small number of molecules, while more 
elaborate and approximate versions of the basic algorithm have been created in order to handle 
large numbers of molecules (Cao and Samuels 2009). 
Traditional continuous and deterministic biochemical rate equations are modeled as a 
set of coupled ordinary differential equations but these methods rely on bulk reactions that 
require the interactions of millions of molecules. In contrast, the Gillespie algorithm allows a 
discrete and stochastic simulation of a system with few reactants because every individual 
reaction is explicitly simulated. The physical basis of the Gillespie algorithm is the collision of 
molecules within a reaction vessel where the reaction environment is assumed to be well mixed. 
The general Gillespie algorithm can be summarized by the following series of steps: 
Step 1, Initialization: Initialize the number of molecules in the system, the reaction 
kinetics constants, and the random number generators. 
Step 2, Calculate Reaction Probabilities From Reaction Rates: Based on the substrate 
concentrations and the enzyme kinetics data, reaction rates Ri are calculated for each possible 
reaction, where i is an index denoting the particular reaction from the reaction list. The 
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probability Pi for each reaction is then calculated from the list of n reaction rates through the 
following equation. 
/i i totalP R R   (1) 
The parameter Rtotal is the sum of all of the reaction rates, as follows. 
1
n
total j
j
R R

   (2) 
Note that the sum of the probabilities is 1, with this definition. 
Step 3, Choose A Reaction: Use a pseudo-random number generator to generate a 
uniform random number rreaction in the range [0,1] and use this random number to choose the 
one reaction that occurs from the list of n possible reactions. The reaction number j is chosen if 
it satisfies the following condition. 
1
1 1
j j
i reaction i
i i
P r P

 
     (3) 
Then a second uniform random number rtime, also in the range [0,1] is chosen. This 
random number is used to set the time τ required for this reaction by the following equation. 
   1/ lntotal timeR r     (4) 
It is important to note here that the sum of all of the reaction rates is used in defining 
the time τ, not just the rate of the one particular reaction that was chosen. 
Step 4, Update the Variables: Increase the time by τ. Update the molecule count based 
on the reaction that occurred. 
Step 5, Iterate the Process: Check to see if any stopping condition has been met. If not, 
return to step 2 to recalculate the reaction rates, which may have changed due to the reaction 
chosen and carried out in steps 3-4. 
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These five steps define the basic Gillespie method for stochastic simulation. For 
applications of the stochastic simulation that involve large numbers of interacting molecules this 
basic method is inefficient in many ways, though it is an exact solution of the relevant stochastic 
master equation. In those cases more advanced and efficient methods should be used (Cao and 
Samuels 2009). However, for modeling polymerase gamma activity we are generally concerned 
with only a single enzyme molecule, the one molecule of polymerase gamma that is replicating a 
particular strand of mtDNA. In this special case, the simple Gillespie algorithm outlined above is 
the preferred simulation method. 
 
Applying the Gillespie Algorithm to Polymerase Gamma 
 
The Gillespie algorithm is fundamentally a way of analyzing the outcome of a set of 
defined reactions which are competing with each other. The heart of this method is the 
definition of the reaction list. As we stated above, the function of polymerase gamma is 
complicated, and the reaction list could conceivably be defined in many different ways. 
However, our purpose is the analysis of the measured enzyme kinetics data, and for that 
purpose the available kinetics data are the primary determinant of the level of the reaction that 
can be modeled. There is no doubt that many of these kinetics values actually represent the 
cumulative effect of a number of subreactions. But unless there are enzyme kinetics data 
available for these subreactions, it is futile to attempt to model the subreactions. The available 
experimental kinetics data determine the lowest level of reactions which can be modeled 
reasonably. 
Some DNA polymerases, such as the bacteriophage T7 DNA polymerase, have had their 
kinetics examined in great detail by transient-state analysis of single nucleotide incorporation 
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(Patel et al. 1991). However, the kinetics of the mitochondrial DNA polymerase gamma have not 
been measured in that high level of detail. A series of papers from the Johnson group (Johnson 
and Johnson 2001; Johnson and Johnson 2001; Johnson et al. 2001; Johnson et al. 2000) have 
reported kinetic parameters for polymerase gamma at the level of polymerization, exonuclease 
and the disassociation of the polymerase gamma holoenzyme from the mtDNA molecule. Based 
on these experiments, we have developed a stochastic model to simulate the replication of an 
individual strand of mtDNA based on the Gillespie algorithm (Wendelsdorf et al. 2009). This 
model operates at the level of individual nucleotide insertions in the new DNA strand, using a 
reference mtDNA sequence (generally the human reference sequence) for the template strand.  
Of course, polymerase gamma does not operate in a vacuum. It uses 
deoxyribonucleoside triphosphates (dNTPs) as substrates and these chemicals are created 
through some combination of a salvage pathway within mitochondria and the transport of 
substrates or their precursors into mitochondria from the cytoplasm (Bradshaw and Samuels 
2005; Saada 2004). One must choose an artificial boundary for every computational model and 
events outside of that boundary are ignored in the model. In the following description we will 
assume that only the actions of polymerase gamma are modeled and that the concentrations of 
the dNTPs within the mitochondria are held constant. Alternatively, one could reasonably 
extend the model to include the reactions of the salvage pathway. A practical limitation on this 
extension of the model is our current lack of knowledge of the correct transport kinetics of 
deoxyribonucleotides between the cytoplasm and the mitochondrial matrix (Kang and Samuels 
2008). Another alternative would be to extend the model to include the function of other 
proteins critical to mtDNA replication, such as the helicase (Kaguni 2004). All such extensions of 
the model are limited by the availability of kinetics data for the relevant enzymes. 
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Definition of the Reaction List for Polymerase Gamma 
In this model, polymerase gamma carries out four basic classes of reactions: DNA 
polymerase activity (inserting a correct or incorrect nucleotide into the new DNA strand), 
exonuclease activity (removing a nucleotide from the new DNA strand), disassociation of the 
polymerase from the DNA, and reassociation of the polymerase with the DNA molecule. In the 
DNA polymerase reaction a single nucleotide is added to the new DNA strand. This nucleotide 
may be the correct base indicated by the template strand, or it may be an incorrect one which 
does not complement the template. In the exonuclease reaction one nucleotide is removed 
from the new DNA strand. Again the removed nucleotide may be either a correct match to the 
template strand or an incorrect match. The exonuclease reaction is an error correction 
mechanism, as the rate for removal of incorrectly incorporated nucleotides is faster than that 
for correctly incorporated nucleotides. In the disassociation reaction the polymerase 
holoenzyme separates from the DNA molecule. The reassociation reaction re-attaches the 
polymerase to the DNA molecule after a disassociation event occurs. 
In our basic model of polymerase gamma function at each position on the replicating 
mtDNA strand polymerase gamma will randomly undergo one of a set of six reactions; one 
correct polymerase reaction, three incorrect polymerase reactions, the exonuclease reaction, or 
disassociation (Figure I.1). Which reaction polymerase gamma undergoes at each time is 
determined by the probability of each reaction, calculated using the reactions rates as 
introduced in the Gillespie algorithm (Gillespie 1976) and described above. The probability for 
each possible reaction is proportional to the reaction rate, so that fast reactions occur more 
often than slow reactions. Currently, kinetics data for the reassociation reaction rate for 
polymerase gamma are not available to the best of our knowledge. For this model we assume 
that once disassociation occurs the only possible reaction is then reassociation of the 
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polymerase with the DNA template. Considering the lack of kinetics for the reassociation 
reaction, we make the choice to immediately reassociate the polymerase to the DNA after a 
disassociation event. This choice neglects the time that this reassociation event requires, but 
without kinetics data for this reaction little else can be done. 
 
 
 
 
Figure I.1. Diagram of the six basic competing reaction of the mitochondrial DNA polymerase. 
 
 
Michaelis-Menten kinetics were used for all of the DNA polymerization reactions. The 
exonuclease reaction and the disassociation reaction were set to have constant reaction rates 
based on the experimental data. For the two scenarios of a correctly inserted and incorrectly 
inserted previous nucleotide we have separate sets of kinetic parameters from Lee and Johnson 
(Lee and Johnson 2006) and Johnson and Johnson (Johnson and Johnson 2001; Johnson and 
Johnson 2001). These studies have reported an increase in exonuclease and disassociation rates, 
but a decrease in incorporation rates by polymerase gamma following an incorrect 
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incorporation. This is included in the simulation model by using two sets of enzyme kinetics 
parameters, one set for reactions following a correct incorporation and another set for reactions 
following an incorrect incorporation. The full set of enzyme kinetics data used in the model is 
listed in Tables I.1-I.5, which are reproduced from reference (Wendelsdorf et al. 2009). Details 
of how the parameter values were set or estimated based on experiments are given in the next 
section “Enzyme Kinetics Data” on pages 26-32. 
 
 
Table I.1. Kinetic parameters kcat (s
-1) for base pairings when the previously inserted nucleotide 
pair is a correct Watson-Crick pair ordered by template strand (rows) and the new strand 
(columns). 
 
Base pairings T G C A 
A 25 0.08 0.1 0.0036 
C 0.012 37 0.003 0.1 
G 0.16 0.066 43 0.042 
T 0.013 1.16 0.038 45 
 
Table I.2. Kinetic parameters Km (μM) for base pairings when the previously inserted 
nucleotide is a correct Watson-Crick pair. The array order is the same as in Table I.1. 
 
Base pairings T G C A 
A 0.6 800 540 25 
C 180 0.8 140 160 
G 200 150 0.9 250 
T 57 70 360 0.8 
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Table I.3. Estimated kcat (s
-1) kinetic parameters for base pairings when the previously inserted 
nucleotide forms a non-Watson-Crick pair. The array order is the same as in Table I.1. 
 
Base pairings T G C A 
A 0.52 0.00052 0.00052 0.00052 
C 0.00052 0.52 0.00052 0.00052 
G 0.00052 0.00052 0.52 0.00052 
T 0.00052 0.00052 0.00052 0.52 
 
Table I.4. Estimated Km (μM) kinetic parameters for base pairings when the previously inserted 
nucleotide forms a non-Watson-Crick pair. The array order is the same as in Table I.1. 
 
Base pairings T G C A 
A 404 40400 40400 40400 
C 40400 404 40400 40400 
G 40400 40400 404 40400 
T 40400 40400 40400 404 
 
Table I.5. Reaction rates for the exonuclease and disassociation reactions of polymerase 
gamma when the previous base pair is a Watson-Crick pair or a non-Watson-Crick pair. 
 
Previous base pairs Exonuclease rate (s-1) Disassociation rate (s-1) 
Watson-Crick pair 0.05 0.02 
Non-Watson-Crick pair 0.4 0.2 
 
 
Modified Nucleotide Reactions 
The reaction list illustrated in Figure I.1 may be considered as a minimum list of 
reactions needed to model the activity of polymerase gamma. This list can be extended in a 
number of different ways. In addition to the four natural deoxyribonucleotide tri-phosphate 
substrates, several chemically altered forms of these substrates can also interact with 
polymerase gamma, albeit with altered, and generally poorer, enzyme kinetics. One important 
class of these chemically altered substrates is the nucleoside analogs commonly used in the 
treatment of HIV infection. Many of these medications have mitochondrial toxicity (Anderson et 
al. 2004; Lewis et al. 2003) which may be due to their interaction with polymerase gamma 
(Hanes et al. 2007; Johnson et al. 2001; Kaguni 2004; Martin et al. 1994; Wendelsdorf et al. 2009) 
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and their subsequent incorporation into mtDNA, generally causing the disruption of the mtDNA 
replication event. Due to this toxicity, which is very important in the long-term treatment of HIV 
infection, the kinetics data for the interaction of many nucleotide analog drugs have been 
measured (Feng et al. 2004; Hanes and Johnson 2007; Hanes et al. 2007; Johnson et al. 2001) 
(see Table I.6, reproduced in part from reference (Wendelsdorf et al. 2009). Details on how the 
parameter values were set or estimated based on experiments are given in the next section 
“Enzyme Kinetics Data” on pages 32-33). 
 
 
Table I.6. Enzyme kinetics parameter values used for polymerase gamma reactions with 
clinically relevant nucleoside analog drugs. 
 
NRTI Km (μM) Kcat (s
-1) Exonuclease rate (s-1) Disassociation rate (s-1) 
ddC 0.041 0.660 <0.00002 0.02 
ddA 0.022 0.310 0.0005 0.02 
FIAU 2.9 24 0.06 0.02 
d4T 0.045 0.24 0.0004 0.02 
FTC(+) 0.79 0.84 0.0048 0.02 
3TC(-) 9.2 0.125 0.015 0.02 
3TC(+) 1.5 0.35 0.02 0.02 
Acyclovir 6 1.03 0.0021 0.02 
ddI 6.3 0.15 0.0007 0.02 
TDF 40.3 0.21 0.0007 0.02 
ABC 13 0.0018 0.0016 0.02 
AZT2001 187 0.2 0.001 0.02 
AZT2007 280 0.001 Not reported 0.02 
FTC(-) 62.9 0.0086 0.0048 0.02 
Enzyme kinetics data taken from references (Feng et al. 2004; Hanes and Johnson 2007; Hanes 
et al. 2007; Johnson et al. 2001). 
 
 
Based on these data, we have included these alternate substrates in a model of 
polymerase gamma function (Wendelsdorf et al. 2009). Other naturally occurring alternative 
substrates could also be modeled. The most important of these are arguably ribonucleotide tri-
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phosphates (Yasukawa et al. 2006) or oxidatively damaged substrates such as 8-oxo-dGTP 
(Pursell et al. 2008). The only practical limitation to the additional reactions that could be 
modeled is the availability of the reaction kinetics data for the new reaction. 
 
Enzyme Kinetics Data 
 
Michaelis-Menten kinetics for incorporation rates after a matched or an unmatched base pair 
The reaction kinetics for polymerization reactions are given in Tables I.1-I.4. The 
reaction rates for the polymerization are calculated using a standard Michaelis-Menten 
equation, using assumed values for the four dNTP substrate concentrations. The dNTP 
concentrations are the major parameters for the simulation, and the results of the simulation 
depend greatly on the pattern of these four concentrations. 
Given the complexity of polymerase gamma activity, it should not be surprising 
that even with the large set of kinetic parameters that have been measured our 
knowledge of the relevant enzyme kinetics parameters for this enzyme is still 
incomplete. For example, the data used in Tables I.1 and I.2 was measured only in the 
case where the previous base pair was an A:T pair. In principle the reaction rates could 
be different for other preceding bases, however in the absence of this data we have 
applied these reaction kinetics to all cases where the previous base pair is a standard 
Watson-Crick pairing. The data on kinetics following a non-Watson-Crick base pair are 
even more limited. The kcat and Km values reported by reference (Johnson and Johnson 
2001) for this case were only determined for the correct pairing of a C opposite to a G in 
the template strand, where the previous base pairing was an incorrect T:T pairing. The 
kinetics values for other pairings, such as an A opposite to a T, are not available, and the 
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kinetics for any incorporations following incorrect pairings other than T:T are also not 
available. The last point is of perhaps great practical importance since the incorrect T:T 
pairing represents an A to T (or T to A) transversion, which is actually a rare event in 
mitochondrial DNA. It would be far more valuable to have kinetics after a G:T incorrect 
pairing, as this represents the very common A to G transition mutation. One important 
application of this analysis of the kinetics data for polymerase gamma is to discover such 
limitations in the experimental data. 
Since there are holes in the available experimental data for polymerase gamma, we 
must make some practical assumptions to fill these holes. We defined an approximate model by 
setting the kinetic coefficients for all correct incorporations following an incorrect incorporation 
to be equal (Table I.3 and I.4) to the values reported for the C:G pairing. Reaction kinetics for the 
incorporation of an incorrect nucleotide following an incorrect nucleotide are not available at all, 
to the best of our knowledge. To fill this gap we chose to assume values for these missing 
parameters (Table I.3, off-diagonal elements) based on the observation from Table I.1 that kcat 
values were approximately 1000 times less for non-Watson-Crick pairing compared to regular 
Watson-Crick pairings. Similarly, based on Table I.2 Km values were estimated to be 
approximately 100 times greater for the non-Watson-Crick pairings and this was used to 
estimate Km values in Table I.4 for the off-diagonal elements. 
 
Reaction rates for the exonuclease and disassociation reactions 
Reaction rates for the exonuclease and disassociation reactions of polymerase gamma 
are listed in Table I.5. As with the polymerase reaction, the exonuclease and disassociation 
reaction rates were measured for the two DNA template conditions where the previous base 
pair was a Watson-Crick pair or a non-Watson-Crick pair. 
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Reassociation of the polymerase with the DNA 
Data regarding the reassociation reaction rate is not available to the best of our 
knowledge. For this model we assume that once disassociation occurs the only possible reaction 
is reassociation of the polymerase with the DNA template. That reassociation is modeled as 
occurring immediately, since we lack any experimental data on this process. 
 
Details of the Experiments Measuring the Enzyme Kinetics of Polymerase Gamma 
 
One must take care to consider the idealized conditions under which the experiments 
measuring the enzyme kinetics of polymerase gamma were conducted. Differences between 
these idealized conditions and the real in-vivo conditions must always be kept in mind. In this 
section we summarize the conditions of the experiments as described in references (Johnson 
and Johnson 2001; Johnson and Johnson 2001; Johnson et al. 2001; Johnson et al. 2000; Lee and 
Johnson 2006). 
 
The polymerization rate kinetics 
Lee and Johnson examined each incorporation of a nucleotide into the new mtDNA 
strand by polymerase gamma under all possible 16-base pair combinations conditions using 
synthetic DNA oligonucleotides and a recombinant holoenzyme of human mitochondrial DNA 
polymerase gamma. The recombinant holoenzyme consisted of a catalytic subunit containing a 
29-amino acid truncation and an accessory subunit containing a His6 tag and a 56-amino acid 
terminal truncation. The catalytic and accessory subunits were combined at a molar ratio of 1:5 
to saturate the binding to reconstitute the holoenzyme. The kinetics of incorporation for all 
correct nucleotides were similar, with an average Kd of 0.8 μM and an average kpol of 37 s
-1. 
 29 
 
However, the kinetics of misincorporation varied widely. The ground state binding Kd of 
incorrect bases ranged from a low of 25 μM for an A:A mispair to a high of 360 μM for a C:T 
mispair. The rates of incorporation of incorrect bases varied from a low of 0.0031 s-1 for a C:C 
mispair to a high of 1.16 s-1 for a G:T mispair. (Lee and Johnson 2006) 
Johnson and Johnson created an exonuclease-deficient (EXO−) catalytic subunit to allow 
examination of the polymerization reaction in the absence of proofreading. Mutagenesis of Glu-
200 to alanine (E200A) produced a modified enzyme with reduced exonuclease activity of single 
base excision from duplex DNA, but this was shown to bind DNA and to catalyze the correct 
base pair insertion with kinetics identical to the wild type enzyme. This mutant polymerase 
gamma enzyme was treated identically to the wild type for purification and experimental 
purposes. The wild-type polymerase was used to determine polymerization parameters for 
correct incorporation after a correct Watson-Crick match, for exonuclease experiments, and for 
the disassociation kinetics measurements following mismatched DNA. The exonuclease deficient 
mutant polymerase gamma was used for measuring the enzyme kinetics for the correct 
incorporations after a Watson-Crick mismatch and for the enzyme kinetics of incorrect 
incorporations (Johnson and Johnson 2001). 
Johnson and Johnson preformed single nucleotide incorporation assays at various 
concentrations of the nucleotide substrates to examine the effects of nucleotide concentration 
on the incorporation rate. Burst conditions and a range of deoxyribonucleoside tri-phosphate 
(dNTP) concentrations were used to examine the enzyme kinetics for correct nucleotide 
incorporations. A reaction time course was determined for each concentration of nucleotide, 
and the product formation rate was plotted against time and fit to a burst equation. The burst 
rates (k) were then plotted against dNTP concentration and fit to a hyperbola to obtain the Kd 
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and the maximum rate of polymerization, kpol, for each correct dNTP (Johnson and Johnson 
2001). 
Because the rate of incorporation after a non-Watson-Crick pair was comparable to the 
rate of exonuclease by polymerase gamma, Johnson and Johnson used the EXO− polymerase to 
perform the experiment to determine the enzyme kinetics of a correct polymerization following 
an incorrect pairing. Incorporation of a dCTP was examined opposite a template G, following a 
T:T mismatch. The rate of the single turnover correct incorporation of dCTP was measured and 
the data were fit to a hyperbola, providing a Kd of 404 ± 51 μM and maximum incorporation rate 
of kpol = 0.52 ± 0.03 s
-1 (Johnson and Johnson 2001). 
The wild-type human polymerase gamma cannot be used to measure the enzyme 
kinetics for incorrect polymerizations because the misincorporation is almost always corrected 
by the efficient exonuclease function. Therefore, Johnson and Johnson used EXO− polymerase 
gamma to measure the kinetics of incorrect polymerizations. In order to limit the effects of 
disassociation these experiments were carried out with high polymerase gamma concentrations 
in excess of the template concentrations so that whenever disassociations did occur a rapid 
reassociation of another polymerase molecule was likely to occur, “canceling out” the 
disassociation event (Johnson and Johnson 2001). For each incorrect nucleotide, Lee and 
Johnson plotted the reaction product formation against time and fit to a single exponential. 
They plotted rates of polymerization determined from the single exponential against nucleotide 
concentration and fit to a hyperbola to determine the disassociation constant, Kd, and the 
maximum rate of polymerization, kpol (Lee and Johnson 2006). 
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The exonuclease rate kinetics 
To measure the exonuclease reaction rate, Johnson and Johnson reconstituted the wild-
type polymerase gamma holoenzyme by mixing catalytic and accessory subunits in a 1:5 ratio. 
To quantify the excision reaction, the loss of full-length substrate primer due to exonuclease 
hydrolysis was plotted against time and fit to a single exponential (Johnson and Johnson 2001). 
To measure the exonuclease rate of polymerase gamma following a Watson-Crick matched base 
pair excision of the 3’-end base from the primer strand of correctly base-paired DNA was 
examined. The rate was obtained by fitting to a single exponential defining the kinetics of 
excision of the first base from the 3’-terminal of the primer and yielded a rate of 0.05 s-1 
(Johnson and Johnson 2001). 
To determine the effect of a mismatched non-Watson-Crick base pair on the 
exonuclease rate, Johnson and Johnson used three DNA substrates (containing a T:T, C:T or G:T 
mismatch) under conditions of excess polymerase concentration compared to template 
concentration. The decreases in concentrations of DNA were fit to single exponential curves. 
Excision of DNA containing the T:T, C:T and G:T mismatches occurred at rates of 0.40 ± 0.04 s-1, 
0.31 ± 0.01 s-1, and 0.57 ± 0.03 s-1 respectively (Johnson and Johnson 2001). Since these values 
are similar and kinetics data were not available for all possible mismatched pairs, in our 
simulations we have chosen the value 0.4 s-1 to represent the exonuclease rate for all 
mismatched base pairs. 
 
The disassociation rate kinetics 
The rate-limiting step of single nucleotide incorporation is presumably the 
disassociation of the polymerase enzyme from the DNA. The steady-state rate is determined by 
the slowest step during polymerization, which must occur after the chemical reaction to account 
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for the observation of a pre-steady-state burst. Therefore the DNA disassociation rate of 
polymerase gamma holoenzyme is assumed to equal its steady-state rate of polymerization. The 
reported disassociation rate of polymerase gamma after a correct Watson-Crick base pair is 0.02 
± 0.001 s-1 (Johnson et al. 2000). 
Johnson and Johnson used the EXO− polymerase to examine the rate of release of 
polymerase gamma from a mismatched DNA substrate. The data was fit to a single exponential 
and yield a koff of 0.18 ± 0.02 s
-1 for DNA containing a 3’ T:T mismatch (Johnson and Johnson 
2001). This value is very close to the data listed in another paper (Johnson and Johnson 2001) 
that gave the disassociation rate of polymerase gamma after an incorrect non-Watson-Crick 
base pair as 0.2 s-1. 
 
Kinetics for nucleoside analogs substrates 
To measure Kd and kpol for each nucleoside analog triphosphate, Johnson et al. used an 
exonuclease-deficient (E200A) to reconstitute the human polymerase gamma holoenzyme. As in 
the previous sections, an excess of the polymerase was used in comparison to the template 
concentration. The kinetics of incorporation of nucleoside analog triphosphates were measured 
using this mutant, which was selected based upon studies showing that this single point 
mutation did not alter the kinetics of normal nucleotide incorporation (Johnson et al. 2001). To 
measure the exonuclease kinetics of polymerase gamma for nucleoside analog triphosphates, 
the wild-type polymerase holoenzyme was preincubated with DNA containing a 3’-terminal 
nucleoside analog to initiate the hydrolysis reaction (Johnson et al. 2001). No published study 
that we are aware of has been done to measure the disassociation rate of polymerase gamma 
following the incorporation of an analog triphosphate into the new mtDNA strand. With no 
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experimental data available, we assumed that the disassociation rates following an incorporated 
nucleoside analog were equal to the disassociation rates after a matched Watson-Crick pair. 
The lack of experimental data on the disassociation rate of polymerase gamma following 
the incorporation of a nucleoside analog into the mtDNA may seem like a trivial limitation, but 
the analysis of the enzyme kinetics data through the stochastic simulation shows that this rate is 
actually critical to our understanding of the mitochondrial toxicity of these drugs (Wendelsdorf 
et al. 2009). Since the chemical alteration of these drugs prevents further polymerization after 
the nucleotide analog is incorporated into the DNA strand (“chain termination”), only two 
competing reactions are left, the exonuclease reaction which removes the nucleoside analog 
and the disassociation reaction which ends the mtDNA replication and defines the chain 
termination event. Therefore the disassociation rate following the analog is a fundamental 
determinant of the chain termination probability of the drug. 
 
Problems 
 
As the previous two sections illustrate, the primary problem with using a stochastic 
simulation to analyze the enzyme kinetics of polymerase gamma is the incomplete reaction 
kinetics data. The function of the polymerase, as represented in this simulation model, depends 
on the competition between different reactions which have different reaction rates. The 
outcome of that competition depends on the complete set of reaction rates. A change in the 
reaction rate of any single reaction alters the probability of all of the reactions (see equation 1). 
While this is an explicit feature of the simulation method, it is also a very realistic one and we 
should expect that the same principle should hold for the function of the real polymerase 
enzyme. Lack of knowledge about one reaction does not just affect that one aspect of the 
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polymerase function. It can in principle affect the balance between all of the other reactions 
which compete with that reaction. One very important practical exception to this problem is if 
the reaction with missing enzyme kinetics data is expected to have a very slow reaction rate in 
comparison to the reactions competing with it. In that case, uncertainty in the reaction kinetics 
of that relatively very slow reaction may cause negligible alterations in the probabilities of the 
competing reactions. 
One important example of the limited kinetics data is that there is little data on how the 
template sequence may affect the reaction kinetics of polymerase gamma. As discussed earlier 
in section 3.1, the kinetics data that are currently available were taken from a very limited 
template of either a A:T pair or a T:T pair (to represent kinetics following a non-Watson-Crick 
pair). The lack of experimental data for other templates limits the ability of the model to analyze 
the potential effect of flanking sequences on mtDNA mutation rates, for example. 
 
Equipment 
 
No specialized hardware is required for carrying out these simulations. We have run the 
simulation code on both a relatively standard desktop PC under LINUX with a 4400 Intel CPU 
(dual core, 2.0 GHz with 2.0 GB of RAM) and on a central server (Intel Xeon CPU, 2.33 GHz). 
Typically, we simulate the replication of a single strand of mtDNA and repeat that simulate 
10,000 times in order to gather statistics on rare events, such as specific point mutations. On the 
central server a set of 10,000 simulated mtDNA strand replications would take approximately 10 
minutes of CPU time, and on the desktop PC would take approximately 20 minutes. The 
simulation that we wrote requires less than 7 MB of memory to run.  
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For software development, anyone wishing to carry out this model is faced with the 
basic choice of coding the algorithm in a standard programming language, or using one of 
several packages that exist for developing stochastic biochemical simulations. Two examples of 
these packages are StochKit (Li et al. 2008) and StochSim (Le Novere and Shimizu 2001). The 
advantage of using a prepared package such as these is that the basic algorithm is already 
written and debugged, and no programming knowledge is needed. However, much of the 
capabilities of the advanced packages, such as the relatively new StochKit, are aimed at 
developing approximate methods to handle simulations with large numbers of reacting 
molecules or to include spatial effects. These capabilities are not needed yet for a model of the 
polymerase gamma enzyme kinetics. Anyone using these packages must be careful to use the 
options which are relevant to this particular simulation, which will require at least some 
familiarity with the principles of stochastic simulations. We made the choice to write our own 
simulation code in C++. The decision to write our own code was based on the need for 
maximum flexibility in our definition of the model and in controlling the data output. 
The Gillespie algorithm yields a series of reaction events, chosen from the reaction list of 
the model. For complete information about the simulation, one can choose to save this data in a 
number of ways. One simple choice of format is illustrated in Table I.7. Each line in the file 
represents one reaction event. Column 1 gives the event number. Column 2 gives the sequence 
position of the polymerase. Column 3 gives the template base at that position, Column 4 gives 
the reaction event chosen by the Gillespie algorithm, where and “A”, “C”, “G”, or “T” means the 
insertion of that nucleotide into the new DNA strand, a “^” indicates a disassociation event, and 
a “<” indicates an exonuclease reaction. Column 5 gives the time τ for that step, as defined by 
equation 4. Finally, column 6 gives the sequence context of the event in the format “template / 
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new strand”. The total space needed for the file varies depending on the number of incorrect 
polymerization events which occur, but is generally in the range 0.5 to 1.0 MB. 
 
 
Table I.7. Example format for output file of the simulation. 
 
Event # Sequence position Template Reaction Reaction time, τ (s) Sequence context 
1012 990 T A 0.017525 AGT/TC 
1013 991 T G 0.0809195 GTT/CA 
1014 992 G ^ 3.73018 TTG/AG 
1015 992 G ^ 0.491668 TTG/AG 
1016 992 G < 0.82397 TTG/AG 
1017 991 T A 0.0055691 GTT/CA 
1018 992 G C 0.0246826 TTG/AA 
 
 
Carefully controlling the IO (the storage of data from the program onto the physical 
hard drive of the computer) is an important factor in the final speed of the code. This is a basic 
point, but it is also a common error. We chose to save in the RAM memory a time ordered list of 
every single reaction event that occurred in the simulation of the mtDNA strand, and then we 
analyzed that list for specific properties with a different analysis code, separate from the 
simulation code. It is a mistake to save each reaction event to a file on the hard drive as it is 
calculated in the simulation, as that process of initiating access to the file on the hard drive 
repeatedly a large number of times takes a very substantial amount of time. Instead, the list of 
reactions that occurred in a simulated mtDNA replication should be kept within the memory of 
the program and either downloaded to the hard drive in one piece at the end of the complete 
simulation run of a single strand replication or analyzed at the end of the simulation so that only 
summary statistics are saved to the hard drive. 
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In order to generate reliable statistics on rare events we run large numbers of repeated 
replications of a full mtDNA strand, typically 10,000 repetitions. Since a set of 10,000 mtDNA 
strand replications only takes about 10 minutes to run, and the disk space necessary for saving 
the 10,000 output files would be approximately 10 GB, we analyze the output of each simulated 
strand replication as it finishes, and then we save only the summary statistics for the specified 
quantity of interest for the full set of 10,000 simulated strand replications. These analysis 
programs were written in Perl, as the best choice for programs handling character data. 
 
Troubleshooting 
 
It is necessary to have quantitative and qualitative predictions against which the 
simulation output can be compared. There are statistical properties which the output data of 
the simulation must have, based on the assumptions of the algorithm. These properties should 
be used as checks to see if the algorithm has been properly implemented. 
 
The distribution of reaction times 
The simplest property to check is the distribution of the reaction times. From equation 4, 
the Gillespie algorithm assumes that the reaction times have an exponential distribution with a 
mean value of 1/Rtotal, where Rtotal is the sum of all of the competing reaction rates. If you have 
chosen to keep the dNTP concentrations constant, then the Rtotal will also be constant and the 
distribution of the reaction times calculated by the simulation should have an exponential 
distribution with a mean value of 1/Rtotal. We actually have two sets of reaction rates in this 
model, depending on whether the previous base was a correct Watson-Crick pairing or an 
incorrect Watson-Crick pairing. So for this test the reaction times should be separated into two 
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lists depending on whether the previous pairing was a Watson-Crick pairing or not. Each list of 
reaction times should have an exponential distribution with different means corresponding to 
the correct 1/Rtotal for that list, which can be calculated. 
 
The mutation pattern under equal dNTP concentrations 
When the four substrate dNTP concentrations are equal, it is easy to see from the 
experimental kinetics data in Table I.1 and I.2 that the incorrect polymerization event with the 
highest rate (and thus the greatest probability) is the polymerization of a G opposite to a T, 
forming an A to G transition mutation in the new strand. The second most common 
polymerization error should be the insertion of a T opposite to a G, forming the C to T transition 
on the new strand. All of the transversion mutations should occur at far lower rates than these 
two transition mutations, under equimolar dNTP concentration conditions. This can serve as a 
qualitative test of the accuracy of the simulation of the rare mutation events. Of course, if a 
different set of kinetics values are used than those given in Tables I.1 and I.2, then the 
prediction of the mutation pattern should change based on that data. 
 
Using the Simulation to Analyze Polymerase Gamma Enzyme Kinetics Data 
 
The process of the complete replication of a single strand of mitochondrial DNA by 
polymerase gamma is the result of tens of thousands of individual reactions. The exact sequence 
of reactions that occurs, the number and pattern of the point mutations introduced through 
polymerase errors, the number of exonuclease events and the number of disassociation events 
all have strong random components. The dependence of all of these important quantities on the 
basic measured kinetics of polymerase gamma is complex, and a direct stochastic simulation of 
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the polymerase activity, as described in this paper, is a thorough way of determining the end 
consequences of the measured kinetics values. This simulation should be thought of simply as 
an ordered way of determining the end result of a set of competing reaction rates. This process 
is of particular importance when one is considering the measured kinetics of a variant form of 
the polymerase gamma protein, which may be pathogenic. Many polymerase gamma variants 
are likely to have altered kinetics for more than one of the reactions illustrated in Figure I.1. The 
ultimate effect of multiple changes in the kinetic parameters of the polymerase may be quite 
difficult to predict correctly without the use of a simulation as a tool to test and examine 
hypotheses. 
 
Future Works 
 
Combined the pol γ replication model with a mitochondrial deoxynucleotide metabolism model 
A computational model of mitochondrial deoxynucleotide metabolism and mtDNA 
synthesis has been built (Bradshaw and Samuels 2005). The model includes the transport of 
deoxynucleosides and deoxynucleotides into the mitochondrial matrix space, as well as their 
phosphorylation and polymerization into mtDNA. Different cytoplasmic deoxynucleotide 
concentrations are used to represent different simulated cell types (cancer, rapidly dividing, 
slowly dividing, and postmitotic cells). In our pol γ replication model, the mitochondrial dNTP 
concentrations are fixed values which are not change during the replication. Considering that 
the mitochondrial dNTP pools are fairly stable, it’s a reasonable assumption. However, there are 
much less published data on concentrations of mitochondrial dNTP pools in patients. Most dNTP 
concentrations data were measured in cytoplasm. Therefore, in order to take the advantage of 
these available cytoplasmic dNTP pools data, we need to combine the two models together. By 
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building a combined model, we can analyze the effect of fluctuations of cytoplasmic dNTP pools 
on the replication fidelity of pol γ. 
 
Generalizing this stochastic replication model to other polymerases 
This computational stochastic model of replication of polymerase was designed for 
mitochondria pol γ. However, the model can be generalized to any replication process involving 
polymerase kinetics. One example is to simulate the template replication in Ion Torrent 
sequencer platform. 
Ion Torrent uses the simple sequencing chemistry including natural nucleotides, with no 
enzymatic cascade, no fluorescence, no chemiluminescence, no optics, and no light involved in 
reactions. Briefly, when a nucleotide is incorporated into a strand of DNA by a polymerase, a 
hydrogen ion is released as a byproduct. The charge from that ion will change the pH of the 
solution, which can be detected by ion sensor. Ion Torrent sequencer uses the world's smallest 
solid-state pH meter to transfer chemical information to digital information, and then call the 
base. 
Since there is no terminator, the replication of template strand by polymerase will 
continue without interruption. However, as more and more flow cycles occur, there will be 
more and more leading or lagging templates because replication is a dynamic process. Leading 
or lagging templates are those not in the same ‘phase’, which will cause signal noise called 
‘phase error’. To distinguish the real signal out of background noise and accumulated ‘phase 
error’ noise as the read length gets longer is a real challenge. Ideally, in each time period, if 
there is way to know how many percentage of signal coming from ‘phase error’, that will be 
much helpful to analyze the signal. And this is exactly what a stochastic simulation of replication 
can help us. 
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CHAPTER II 
 
REPLICATION PAUSES OF THE WILD-TYPE AND MUTANT MITOCHONDRIAL DNA POLYMERASE 
GAMMA: A SIMULATION STUDY2 
 
Introduction 
 
The holoenzyme of human pol γ consists of a catalytic subunit and a homodimer of its 
accessory subunit (Yakubovskaya et al. 2006). The catalytic subunit has DNA polymerase, 3’-5’ 
exonuclease and 5’ dRP lyase activities. The accessory subunit is required for tight DNA binding 
and processive DNA synthesis (Lim et al. 1999). Two modes of mtDNA replication have been 
proposed; an asynchronous strand displacement model (Brown et al. 2005; Shadel and Clayton 
1997) and a strand-coupled bidirectional replication model (Holt et al. 2000). 
The replication rate of DNA by a polymerase may not be stable. What is the relationship 
between replication pauses of pol γ and the commonly observed pathological phenotypes of 
mtDNA deletions and depletion? Theoretically, once a replication fork pauses, it can restart to 
continue the replication process without problems. But, a long pause might allow time for low-
probability events such as double strand breaks. A double strand break can be repaired through 
blunt-ended rejoining, or homologous annealing of 5’- and 3’-repeat sequences (Krishnan et al. 
2008), or nonhomologous end-joining (Graziewicz et al. 2006) that will form deleted mtDNA. If 
the double strand break cannot be fixed, it will cause a failed replication. Repeated failed 
                                                          
2 Song, Z., Cao, Y., and Samuels, D. C. (2011). Replication Pauses of the Wild-Type and Mutant 
Mitochondrial DNA Polymerase Gamma: A Simulation Study. PLoS Comput Biol 7(11). Author 
contributions: Conceived and designed the experiments: ZS DCS. Performed the experiments: ZS. 
Analyzed the data: ZS DCS. Contributed reagents/materials/analysis tools: YC. Wrote the paper: 
ZS DCS. Algorithm design: YC ZS. Software: ZS. 
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replications would eventually lead to depletion of mtDNA within the cell. These concepts are 
illustrated in Figure 1 of Introduction Section (page 3). Under the mentioned hypothetical 
mechanism, mtDNA deletions and depletion may both be potential outcomes from the same 
initial event, the pausing of the polymerase. Certainly, other mechanisms for deletion formation 
are also possible (Krishnan et al. 2008). 
Pathogenic mutations in POLG have been identified in patients with many neurological 
or muscular diseases (progressive external ophthalmoplegia (PEO), Alpers syndrome, ataxia-
neuropathy syndromes, idiopathic parkinsonism) and nucleoside reverse-transcriptase inhibitor 
(NRTI) toxicity (Copeland 2008; Hudson and Chinnery 2006). All these diseases were 
characterized by mtDNA deletions and/or depletion in symptomatic tissues (Chan and Copeland 
2009). 
Longley reported that PEO is associated with the depletion of mtDNA and/or the 
accumulation of point mutations and deletions within mtDNA, caused by autosomal dominant 
mutations in POLG (Longley et al. 2005). Nearly all of the autosomal dominant PEO (adPEO) 
mutations in POLG were located in the polymerase domain of pol γ. 
Alpers syndrome is a fatal early onset mitochondrial disorder characterized by tissue-
specific mtDNA depletion (Chan et al. 2005). People identified pol γ mutations in Alpers 
syndrome are either homozygous A467T (MIM 174763.0002) or heterozygous A467T paired in 
trans with other mutations in POLG (Ferrari et al. 2005; Naviaux and Nguyen 2004). 
The A467T mutation has been found in all of the major POLG related diseases (Chan and 
Copeland 2009). The frequency of the A467T mutation varies from less than 0.2% to 
approximately 1% in different European control populations (Horvath et al. 2006; Luoma et al. 
2005; Van Goethem et al. 2001; Winterthun et al. 2005). However in mitochondrial disease 
populations, the A467T allele was estimated to be the most common alleles associated with 
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POLG diseases (Chan and Copeland 2009). People have found the homozygous A467T 
substitution of POLG in several mitochondrial disorders with highly varied phenotypes. For 
example, in Alpers syndrome (Boes et al. 2009; Utzig et al. 2007), two unrelated teenage boys 
with homozygous A467T POLG had ataxia and severe epilepsy. In contrast, in a case of 
concurrent progressive sensory ataxia, dysarthria, and ophthalmoparesis (McHugh et al. 2010), 
two siblings also homozygous for POLG A467T developed disease symptoms only late in life, 
with onset in their 40s. 
The kinetic parameters of the A467T mutant for both polymerase and exonuclease 
activity have been measured experimentally (Chan et al. 2005). Compared to the wild-type 
catalytic subunit, the A467T substitution increased the Km of the enzyme 5-fold while also 
reducing the kpol value approximately 5-fold for DNA synthesis. As determined by the ratio of 
kpol/Km, the A467T substitution reduces DNA synthesis efficiency to 4% of the wild-type activity. 
In contrast, the exonuclease activity of the A467T variant is only decreased 2-fold compared to 
the wild-type (Chan et al. 2005). Besides altering the kinetics of polymerase γ, the A467T variant 
in POLG also decreases the protein’s physical association of the POLG2 subunit (Chan et al. 
2005). 
People created two independent homozygous knock-in mouse models with proof-
reading deficient versions of the catalytic subunit of mtDNA polymerases. One published in 2004 
(Trifunovic et al. 2004) and the other one in 2005 (Kujoth et al. 2005). Both mouse models 
showed similar progeria-like phenotypes and shared the same D257A mutation on the second 
exonuclease domain of PolgA (the mouse homolog of POLG) that caused a profound reduction 
of the exonuclease activity but no decrease in DNA polymerase activity. Both mouse models 
(Kujoth et al. 2005; Trifunovic et al. 2004) were reported to have accumulated mtDNA point 
mutations. 
 44 
 
Using these two mouse models, other mitochondrial genome variations besides point 
mutation have been studied. For the first mouse model, after Trifunovic et al. (Trifunovic et al. 
2004) reported increased mtDNA deletion, Bailey et al. (Bailey et al. 2009) using one- and two-
dimensional agarose gel electrophoresis interpreted these non-replicating linear mtDNAs as the 
result of double-strand breaks of cyclic mtDNA caused by stalled replication intermediates. 
Ameur et al. (Ameur A. et al. 2011) further stated that mutator mice have abundant linear 
deleted mtDNA molecules but extremely low levels of circular mtDNA molecules with large 
deletions. For the second mouse model, Williams et al. (Williams et al. 2010) applying next-
generation sequencing to native mtDNA did not observe the accumulation of mtDNA deletions 
but instead reported multiple copies of the mtDNA control region in brain or heart. However, 
Vermulst et al. (Vermulst et al. 2008; Vermulst et al. 2009) have identified mtDNA deletions as a 
critical driving factor behind the premature aging phenotype in these mouse models and have 
suggested there is a homology-directed DNA repair mechanism directly linked to mtDNA 
deletion formation. As this description shows, the data on the amount of deletions in these two 
mouse models is currently mixed and this is a research area that is rapidly developing.  
To study the replication process of pol γ, we have built a computational model of the 
activity of pol γ (Song and Samuels 2010; Wendelsdorf et al. 2009) (Figure II.1), based on the 
experimental kinetic data. Our computational model of the mitochondrial DNA replication 
process was based on the Stochastic Simulation Algorithm (Gillespie 1976; Gillespie 1977), a 
well-known Monte Carlo simulation method for chemical reactions. Using this stochastic 
simulation, we were able to quantify the pause lengths for the wild-type polymerase and for the 
pathogenic A467T and the exonuclease deficient pol γ variants. 
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Figure II.1. Diagrams of the six competing reactions of pol γ. Example reaction rates are given 
below each reaction name. The line size approximately represents the reaction rate. The bigger 
the reaction rate, the wider the line. (A) For a correct previous base pair, the highest reaction 
rate by far is the correct polymerization. (B) For an incorrect previous base pair, the highest 
reaction rate is the exonuclease reaction, allowing proofreading. All reaction rates in this 
diagram are calculated for dNTP pool levels equimolar at 10 μM. 
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Methods 
 
Pol γ replication model 
In this model, pol γ carries out four basic types of reactions: DNA polymerase activity, 
exonuclease activity, disassociation of the polymerase from the DNA, and reassociation of the 
polymerase with the DNA molecule (Figure II.1). In the DNA polymerase reaction, pol γ adds one 
nucleotide to the new DNA strand. This nucleotide could be either a correct or incorrect (point 
mutation) base. In the exonuclease reaction, pol γ removes one nucleotide from the new DNA 
strand. The exonuclease reaction is an error correction mechanism, as the rate for removal of 
incorrectly incorporated nucleotides is much faster than that of correctly incorporated 
nucleotides, though the removal of both correct and incorrect nucleotides is allowed in the 
model. In the disassociation reaction, the polymerase separates from the DNA molecule. In the 
reassociation reaction (not shown in Figure II.1), the polymerase re-attaches to the DNA 
molecule after disassociation. 
At each position on the replicating mtDNA strand, pol γ randomly undergoes one of a 
series of six possible competing reactions: one correct polymerase reaction, three incorrect 
polymerase reactions, the exonuclease reaction, or disassociation (Figure II.1). Which reaction 
pol γ undergoes at each time is determined by the propensity of each reaction, calculated using 
the reaction rates following the selection formulae as introduced in Gillespie (Gillespie 1976; 
Gillespie 1977). The simulation was implemented in C++ and run under LINUX. 
Michaelis-Menten kinetics was used for all of the DNA polymerization reactions. The 
exonuclease reaction and the pol γ disassociation reaction were set to have constant reaction 
rates. For the two scenarios of a correctly inserted and incorrectly inserted previous nucleotide 
we had separate sets of kinetic parameters for each of the pol γ reactions taken from Lee and 
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Johnson (Lee and Johnson 2006) and Johnson and Johnson (Johnson and Johnson 2001; Johnson 
and Johnson 2001) (Tables 1.1-1.5). These studies have reported an increase in exonuclease and 
disassociation rates, but a decrease in incorporation rates by pol γ following an incorrect 
incorporation. This was included in the simulation model by using two sets of enzyme kinetics 
parameters, one set for reactions following a correct incorporation and another set for reactions 
following an incorrect incorporation. For an extended description of the simulation model, 
please see the Methods paper by Song and Samuels (Song and Samuels 2010). 
 
Simulation method 
In each simulation step, this algorithm calculates the propensity of each reaction and 
generates two random numbers to determine the time between reactions and the identity of 
the next reaction. The original Gillespie algorithm (Gillespie 1976; Gillespie 1977) calculates 
propensities based purely on the substrate species’ population (i.e. integer copy number). In our 
method, since we are only concerned with the dynamics of pol γ, we do not have to convert the 
state variable of every species to its copy number. In this way, the propensity functions are 
calculated from the same formula as the reaction rates for the involved competing reactions. 
These propensities were then used to randomly choose the sequence of reactions that occur, at 
the level of individual molecular reactions following the Gillespie algorithm. 
 
Pol γ kinetics parameters 
Given the complexity of pol γ activity, it should not be surprising that even the large set 
of pol γ kinetic parameters that have been measured is still incomplete. The data used in Tables 
1.1 and 1.2 was measured only in the case where the previous base pair was an A:T. In principle 
the reaction rates could be different for other preceding bases, however in the absence of this 
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data we have applied the measured reaction kinetics to all cases where the previous base pair is 
a standard Watson-Crick pairing. The data on kinetics following a non-Watson-Crick base pair 
are even more limited. The kpol and Km values reported (Johnson and Johnson 2001) for this case 
were only determined for the correct pairing of a C opposite to a G in the template strand, 
where the previous incorrect base pairing was a T:T. We define an approximate model by setting 
the kinetic coefficients for all correct incorporations following an incorrect incorporation to be 
equal to this reported value (Tables 1.3 and 1.4). Reaction kinetics for the incorporation of an 
incorrect nucleotide following an incorrect nucleotide are not available, to the best of our 
knowledge. Values for these parameters in the model (Table 1.3, off diagonal elements) were 
based on the observation from Table 1.1 that kpol values were approximately 1000 times less for 
non-Watson-Crick pairing compared to regular Watson-Crick pairings. Similarly, based on Table 
1.2 Km values were estimated to be approximately 100 times greater for the non-Watson-Crick 
pairings and this was used to estimate Km values in Table 1.4 for the off-diagonal elements. 
There are currently two main groups (Chan et al. 2005; Johnson and Johnson 2001) that 
have independently measured the kinetics of wild-type polymerase γ. One (Johnson and 
Johnson 2001) employed pre-steady state measurement using single-turnover analysis to 
determine dNTP incorporation rate kpol and the dissociation constant Kd of dNTP to bind to the 
polymerase-primer-template complex. The other one (Chan et al. 2005) employed steady state 
kinetic measurement that assumes that the complex of polymerase, primer and template 
behaves as a single enzyme and fit the data to Michaelis-Menten function to determine its kcat 
and Km. There are some disagreements of kinetic values between these two measurements and 
this inconsistency has recently been further addressed in the literature (Estep and Johnson 
2011). We chose not to mix values of wild-type polymerase γ from different measurement 
 49 
 
techniques, and instead we chose to continue to use the pre-steady state values (Johnson and 
Johnson 2001), as we have in several previous publications. 
However, the A467T variant kinetics have only been published using the steady state 
measurement technique (Chan et al. 2005). To make the most reasonable estimation of the 
A467T kinetics based on published values consistent with the experimental methods (Johnson 
and Johnson 2001; Johnson and Johnson 2001) used to determine the wild-type POLG kinetics, 
we followed the observation of Bertram et al (Bertram et al. 2010) that even when polymerase 
enzyme kinetics measurements from different measurements were not in agreement, the 
dimensionless ratios of those kinetics constants often were in agreement. The A467T mutant 
enzyme is reported to have only 4% of wild-type DNA polymerase activity (the kcat decreased 5-
fold and Km increased 5-fold compared to the wild-type) and 50% of the wild-type exonuclease 
activity (Chan et al. 2005). We used these proportions to estimate the A467T variant kinetics 
based on the wild-type kinetics measured by pre-steady state methods (Johnson and Johnson 
2001; Johnson and Johnson 2001). Finally, we modeled an idealized exonuclease deficient 
polymerase by setting the exonuclease activity to zero and keeping the other kinetics values at 
the wild-type values. The exonuclease deficient mice are reported to have normal DNA synthesis 
capacity, but no detectable exonuclease activity (Trifunovic et al. 2004). 
Data regarding the reassociation reaction rate is not available to the best of our 
knowledge. For this model we assume that once disassociation occurs the only possible reaction 
is then reassociation of the polymerase with the DNA template. Without reaction kinetics, the 
time required for this reaction cannot be calculated and is not included in this model. This 
approximation is not important to our results reported here on point mutation rates. The time 
required for reassociation would extend even further the pol γ pausing times that we estimate 
based on the computational model. 
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Substrate Concentrations 
The polymerization reaction rates are functions of the deoxyribonucleotide triphosphate 
(dNTP) concentrations. However, concentrations of dNTP pools in mitochondria vary in different 
species, tissues, cell types and cell cycle phases. Measured dNTP pools in mitochondria of 
quiescent and cycling human fibroblasts are listed in Table II.1 (Ferraro et al. 2005). The units of 
picomoles per 106 cells were converted to μM by using an assumed 200 femtoliters of 
mitochondrial volume per cell (0.2 femtoliters each mitochondria, 1000 mitochondria per cell) 
(Pollak and Munn 1970). The four dNTP concentrations can be set individually in the model. In 
all cases reported here we have kept the four dNTP levels equal at concentrations of either 1 or 
10 μM to approximately represent the conditions of postmitotic and dividing cells respectively 
(Ferraro et al. 2005). The dNTP levels were held constant throughout the simulated mtDNA 
replication. 
 
 
Table II.1. Concentrations of dNTP pools in mitochondria of different human cells.  
 
dNTP (μM) Quiescent skin fibroblasts Cycling skin fibroblasts 
dATP 5.6 14.3 
dCTP 2.5 20.4 
dGTP 1.3 4.6 
dTTP 1.5 19.9 
Data taken from references (Ferraro et al. 2005) 
 
 
mtDNA sequence 
Vertebrate mitochondrial DNA has a highly asymmetric G content. The low-G strand is 
labeled the light strand, with the complement strand called the heavy strand. Sets of simulations 
were carried out separately for the light strand sequence (GenBank NC_001807) and the heavy 
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strand sequence, formed by inverting and complimenting the light strand sequence. We found 
no significant difference in the results reported in this paper between the light strand and the 
heavy strand. The data reported here are based on replication of the heavy strand, which takes 
the light strand as the template. 
 
The time required for a single forward step 
We define the time for pol γ to move from sequence position i to the next position i+1, 
which could include multiple intermediate reaction events, as the “single forward step time”. 
For each simulated mtDNA strand replication, there are 16,570 single forward steps and 16,570 
time intervals. We choose the longest single forward step time to represent the worst 
polymerase pausing event that happened in the strand replication simulation. 
 
The number of simulations 
We have three types of pol γ (the wild-type, A467T and exo-) and two cell type 
conditions (dividing and postmitotic). Since the model is stochastic, the results vary between 
runs with identical parameter values. For each one of the six scenarios, we ran the simulation 
10,000 times to determine the probability distribution of the model results. 
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Results 
 
We modeled three types of pol γ, the wild type and two mutants (the human 
pathogenic variation A467T and the completely exonuclease deficient form exo-). With 
frequencies of the A467T variant in different European control populations of 0.2-1% (Horvath 
et al. 2006; Luoma et al. 2005; Van Goethem et al. 2001; Winterthun et al. 2005), the naturally 
occurring heterozygous A467T alone, without paring in trans with other mutations in POLG, 
causes only mild, if any, pathogenic phenotypes (Ferrari et al. 2005; Naviaux and Nguyen 2004; 
Nguyen et al. 2005; Van Goethem et al. 2004). An exonuclease deficient POLG has never been 
reported naturally in humans or mice This severe POLG variant only occurs in the genetically 
engineered mouse models (Kujoth et al. 2005; Trifunovic et al. 2004). Our hypothesis is that the 
pathogenic severity of a mutated pol γ depends on its susceptibility to replication fork pauses, 
not just its rate of point mutation formation. 
 
The single strand replication time 
We began by measuring the full replication time of a single strand of mtDNA in this 
computational model. The replication time of a single strand is defined simply as the time 
needed for the simulation model to complete the replication of all 16,571 base pairs in the 
mtDNA reference sequence. 
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Figure II.2. Probability distribution of the replication time of a single strand of mtDNA. In these 
examples, the light strand was used as the template. (A) dNTP pool levels equimolar at 10 µM, 
representing dividing cells. The median values of the replication time distributions of the wild 
type (WT, black dots), exo- (magenta open circles), and the A467T variation (blue open triangles) 
are 563 s, 1837 s, and 3355 s respectively. (B) Equimolar 1 µM dNTP concentrations. The median 
values of the distributions of the WT, exo-, and A467T variant are 849 s, 2946 s, and 11465 s 
respectively. 
 
 
After running 10,000 simulations of replication of a single strand, the probability 
distributions of the replication time of wild-type and mutated pol γ are calculated (Figure II.2).As 
expected from the enzyme kinetics, the naturally occurring mutant A467T simulation had a 
much longer replication time than the wild-type pol γ simulation. However, surprisingly, the 
severe pathogenic mutant exo- had a highly variable replication time, ranging from times only 
slightly longer than that of the wild-type to replications taking longer than the A467T mutant 
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simulation. In contrast, both the wild-type and A467T simulations had very tight distributions, 
meaning that the replication time had little random variation. Under the condition of dividing 
cells (Figure II.2A, dNTP = 10 μM), the polymerase reaction rate of the A467T variant is 
approximately 7 times slower than the reaction rate of the wild-type pol γ. Considering the 
difference of kinetics values, the median strand replication time of 564 seconds for the wild-
type and 3355 seconds for the A467T variant were reasonable. 
Compared to dividing cells, postmitotic cells have lower dNTP levels and therefore pol γ 
in these cells has a lower polymerization rate and the replication process proceeds more slowly. 
Under this condition, we expected to see longer strand replication time (Figure II.2B, dNTP = 1 
μM). The median of strand replication time of wild-type pol γ increased 1.5-fold to 849 seconds, 
compared to the rate at dNTP = 10 μM. For the exo- variant, the median replication time 
increased similarly from 1837 to 2946 seconds. For the A467T variant, the median replication 
time increased 3.4-fold to 11,465 seconds (3.2 hours). 
 
The time required for the slowest single forward step of the polymerase 
The total replication time (Figure II.2) is an average quantity, representing the summed 
effect of often tens of thousands of reactions. Pathogenic effects, such as deletion formation, 
may be more directly related to extreme single events that occur during the replication process 
than to this average quantity. To measure this, for each simulated mtDNA strand replication we 
recorded the time required for the longest single forward step of the polymerase (Figure II.3). 
See the Methods section for a precise definition of this measure. We interpret these slowest 
forward steps in the polymerase activity as polymerase pauses. 
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Figure II.3. Frequency distribution of the time required for the longest single forward 
step. The median values of each curve are shown. (A) High dNTP level representing 
dividing cells. (B) Low dNTP levels representing postmitotic cells. 
 
 
The exo- simulation had extremely lengthy maximum single forward step times, 
corresponding to pol γ pauses (Figure II.3). Compared to the wild-type, the exo- polymerase had 
a 30 (Figure II.3A) to 300-fold (Figure II.3B) longer median of the longest single forward step 
time. However, the median of the A467T variant’s longest single forward step time only 
increased slightly compared to the wild-type. This is reasonable because the slow polymerase 
reaction rate of A467T slowed down every forward step of the polymerase, without 
preferentially affecting the extremes. 
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For dividing cell conditions (Figure II.3A, dNTP = 10 μM), the median time of pausing of 
the wild-type polymerase was 7.9 seconds, while it was a similar value of 8.7 seconds for the 
A467T variant. However, the median time of pausing of the exo- polymerase was much longer at 
260 seconds. For postmitotic cell conditions (Figure II.3B, dNTP = 1 μM), the median time of 
pausing of the wild-type polymerase decreased to 3.9 seconds. The median time of pausing of 
the A467T variant increased slightly to 10.1 seconds, however, the exo- pol γ had a dramatically 
increased median pausing time of 1200 seconds. Under both dNTP concentration conditions, the 
exo- polymerase had the slowest “longest single forward step time”, implying the longest pauses 
and the greatest opportunity of deletions to occur. 
 
The reaction events in the longest single forward step 
We further identified what reaction events actually occurred in the longest single 
pausing step (Figure II.4 and II.5). The longest pausing steps usually occurred after incorrect 
polymerase events (Table II.2), which inserted a non-Watson-Crick paired nucleotide into the 
new DNA strand. The exceptions to this (i.e., pauses after correct incorporations) were always 
very brief pauses, which can be seen as the small peaks to the extreme left side in Figure II.3. In 
most of the cases of pausing after the incorrect nucleotide insertion, for both the wild-type and 
A467T variant, the longest single forward time step has one exonuclease reaction (to remove 
the incorrect nucleotide), two polymerase reaction (one to replace the removed nucleotide and 
a later one to move the polymerase forward to the next step), and a variable number of 
dissociation events (Figure II.4).  
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Figure II.4. Events in the longest single forward step. For each pol γ variant, 10,000 simulations 
were carried out and the probability distributions of the events were calculated. Symbol colors 
represent the pol γ variants (black = wild-type, magenta = exonuclease deficient, blue = A467T). 
Symbols represent the reaction events (star = disassociation, triangle = exonuclease, circle = 
polymerization). 
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Figure II.5. An example of events in a typical longest forward step of the polymerase. For the 
wild-type (WT) and the pathogenic A467T pol γ variant, a typical single forward step includes 
several dissociations and reassociations, one exonuclease reaction and two polymerizations. 
 
Table II.2. Strand replication time statistics. 
 
Simulation 
template 
dNTP 
(μM) 
Mean 
replication time 
(s) 
Probability of incorrect 
previous base pair 
Median longest single 
forward step time (s) 
Light strand 1 849.4 92.69% 3.9 
Heavy strand 1 813.2 95.80% 4.4 
Light strand 10 563.8 100.00% 7.9 
Heavy strand 10 542.7 100.00% 8.4 
 
 
For the exo- polymerase, there was one polymerase reaction and a variable but large 
number of dissociation events. In very rare cases, where pol γ replicated the whole strand 
without any error ever occurring, the longest single forward step time was very short and there 
was only one polymerase event and very few dissociation events. 
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We found that the pausing time of pol γ was roughly proportional to the number of 
disassociations events occurring within that pause (Figure II.4). The exo- pol γ had extremely 
long polymerase pauses, with a 30 to 300-fold increase in the time required for the longest 
single forward step of the polymerase compared to the wild-type polymerase, while the 
naturally occurring A467T pol γ variant had only a slight increase in the length of the pauses 
compared to the wild-type pol γ. It is the number of polymerase disassociations occurring in 
each forward step of the polymerase that causes the differences. Due to the lack of competition 
of the exonuclease activity in the exo- pol γ to remove the incorrect incorporation, 
disassociations of pol γ repeatedly recurred in each longest single forward step. The variation in 
the pausing time was almost completely due to variation in the number of disassociation events 
occurring during the pause (Figure II.4).  
 
The effect of a partial loss of pol γ exonuclease activity 
The exo- mutant is an extreme alteration of the polymerase function, which we have 
modeled as the complete loss of exonuclease activity. What if a mutated pol γ lost exonuclease 
activity only partially, not completely? To answer this question, we decreased the exonuclease 
reaction rate in the simulation gradually from 100% activity, equivalent to the wild-type, to 0%, 
equivalent to the exo- mutant simulation (Figure II.6). We calculated the median longest single 
forward step time (Figure II.6A) and the point mutation rate (Figure II.6B) for both dividing and 
postmitotic cell conditions. These two quantities were chosen to represent the two main 
mechanisms for generating mtDNA damage from a defective polymerase: deletions driven by 
polymerase pausing and point mutations. Surprisingly, pol γ has to lose approximately 50 to 90% 
of its wild-type exonuclease activity before there are significant consequences shifting either of 
these measures by more than a factor of two. 
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Figure II.6. The effect of varied exonuclease activity. (A) Median longest forward time step 
occurring within a replication from the mtDNA light strand template (taken over 10,000 
repeated simulations). (B) Point mutation rate per strand replication. With the decreasing of 
exonuclease activity from 100% activity to zero, both the median value of longest forward single 
step time and point mutation rate increased nonlinearly. 
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Discussion 
 
The mitochondrial DNA replication time has been measured in dividing cells in cell 
culture, and approximately one hour is required for replication of both strands (Clayton 1982). 
In our simulation, the light strand replication time under dividing cell condition (dNTP = 10 μM) 
was less than 10 minutes (Figure II.2A), and the heavy strand replication required a similar time 
(Table II.2). The standard asynchronous strand displacement replication model makes the 
double strand replication time (1 + 2/3) fold longer than that of single strand, where the 2/3 
represents the fraction of the mtDNA sequence in the major arc between the heavy strand 
origin and light strand origin. Based on this estimate, the full mitochondrial genome replication 
time in our simulation was only 17 minutes. The simulated double strands replication time is 3-5 
fold less than what has been reported in experiments (Clayton 1982). This fast replication time is 
a direct consequence of the measured enzyme kinetics values for pol γ. However, the kinetic 
parameters we used were measured in vitro (Johnson and Johnson 2001; Johnson and Johnson 
2001), and the actual values in vivo may be different. Another reason why our simulated 
replication time is shorter than expected is that we could not include the reassociation time of 
pol γ with the DNA following a disassociation event, since there is no data on the reassociation 
rate. In addition, we cannot include the effect of the proteins mtSSB, Twinkle and other 
accessory proteins on the replication time, since these accessory proteins were not included in 
the basic experiments measuring the polymerase enzyme kinetics. All replication time in our 
simulation were underestimated for these reasons, which would make the pausing of pol γ in 
reality even worse than calculated from these simulations. Another relevant feature that cannot 
be included in this simulation is the role of DNA secondary structure in polymerase pausing. 
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These secondary structures would cause additional pausing of the polymerase, beyond that 
calculated in this simulation. 
The simulation results gave us a clear picture of how pol γ pauses may happen. For wild-
type and the A467T pol γ variant, the longest single forward step always starts with an incorrect 
nucleotide incorporation. For example if this happens at position i along the DNA strand then an 
exonuclease event will happen with high probability at position i, removing the incorrect 
nucleotide, and the pol γ moves backward one step. After this, two following polymerase events 
are needed to move the polymerase forward to the position i+1. In this case, the longest single 
forward time step from position i to i+1 requires at least three reaction events, one exonuclease 
reaction and two correct polymerizations, as well as any disassociation and reassociation events 
that may have happened between these events (Figure II.5). In principle, there could be N 
exonuclease events and N+1 polymerase events in each single forward step. However, 10,000 
repeated simulations showed that there were almost always only one exonuclease event and 
two polymerase events (Figure II.4). For the exo- polymerase, once an incorrect incorporation 
happens at position i, the polymerase keeps repeating a disassociation-and-reassociation cycle 
until a polymerization happens and moves the polymerase forward to position i+1 (leaving 
behind a point mutation). The disassociation-and-reassociation cycle repeats because the rate of 
polymerization following the incorrect nucleotide incorporation is very low. In the wild-type 
polymerase, the slow polymerization following an incorrect nucleotide incorporation allows 
time for the exonuclease reaction to occur with high probability, repairing the DNA replication 
error. 
Several experiments (Chan et al. 2005; Fan et al. 2006; Johnson et al. 2000) have 
measured the processivity of polymerase gamma. However, there is a fundamental difference 
between processivity as measured in these experiments and the concept of “polymerase 
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pausing” as defined in our simulation. The polymerase processivity experiments (Chan et al. 
2005; Fan et al. 2006; Johnson et al. 2000) always use an unlabeled DNA trap to deliberately 
limit the polymerase to the very first disassociation event. At the first disassociation event the 
polymerase is captured by the DNA trap with very high probability and the polymerase 
reassociation is prevented, ending the DNA replication. In contrast, we define pausing as the 
longest time required to move the polymerase forward one nucleotide along the DNA strand, a 
process that we show in the simulation often includes several polymerase disassociation-
reassociation cycles. Those extreme cases where multiple disassociation-reassociation cycles 
occur (by random chance) are the slowest step in the full mtDNA replication, which we take as a 
representation of polymerase pausing. As we show in Figure II.4, the difference between the 
wild-type POLG and the exonuclease deficient POLG comes in the number of polymerase 
disassociation-reassociation cycles that occur in the slowest forward step of the polymerase on 
the DNA strand. This difference would not be seen in the processivity experiments where 
reassociation is deliberately prevented by the experimental design. Because of this fundamental 
difference, the processivity experiments are not in disagreement with this simulation model. A 
further difference between the processivity experiments and the polymerase pausing is that the 
processivity experiments only measure the behavior of the polymerase over hundreds to a few 
thousand bases (Fan et al. 2006; Johnson et al. 2000), while the polymerase pausing (as we 
define it) is a measure of the most extreme replication event (the slowest forward step) over 
16,600 bases. Those rare events simply could not be observed in the much shorter processivity 
experiments. 
A recent study (Williams et al. 2010) reported at least two orders of magnitude increase 
of point mutations in exo- mice compared to controls in postmitotic tissues – brain and heart. In 
Figure II.6B, under the postmitotic cell condition (dNTP = 1 μM), the point mutation rate with 
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100% wild-type exonuclease activity was 0.01 (number of uncorrected errors per strand 
replication) and the rate increased to 3.2 for the completely exonuclease deficient polymerase 
simulation. This is consistent with the experimentally measured difference between the 
exonuclease deficient mouse and the wild-type mouse (Williams et al. 2010). In an exo- mouse 
model (Trifunovic et al. 2004), the measured mutation load of the exo- polymerase γ was 3-13 
mutations per 10 Kb (approximates to 5-21 mutations per replication) for brain and heart cells 
(which can be taken as postmitotic) and liver cells (which can be taken as mainly mitotic). This 
experimental data is consistent with our simulation results (Figure II.6B), which shows 3.2 
mutations per replication for postmitotic cells (dNTP = 1 μM) and 17 mutations per replication 
for mitotic cells (dNTP = 10 μM). 
Based on this simulation model, a reduced DNA binding effect caused by variants in the 
accessory subunit might also be another reason to cause pausing of the polymerase. There is 
growing interest in variants in POLG2, the gene that encodes accessory subunit p55 of 
polymerase gamma (Young et al. 2009). Reduced DNA binding is not obviously related to mtDNA 
depletion, but our simulations clearly showed that the number of disassociation events that 
occur during the pause directly determines the length of the polymerase pause. Thus, based on 
this simulation model, reduced DNA binding of the polymerase to the mtDNA molecule could 
greatly increase the length of pauses of the polymerase both by increasing the probability of 
disassociation events and by slowing the rate of the reassociation reaction. 
In addition to the altered mtDNA polymerization kinetics, the A467T variant in POLG 
also has altered kinetics in the formation of the protein complex with POLG2 (Chan et al. 2005). 
We deliberately chose to model just the process of replication of the mtDNA, and not the 
preceding process of the formation of the polymerase protein complex from POLG and POLG2. 
Extending the model to include the stage of formation of the polymerase complex would greatly 
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extend the complexity of the model, and would distract from the purpose of the model, which 
was to represent the process of mtDNA replication after replication is initiated. The kinetics 
values used in this model are from experiments (Chan et al. 2005; Johnson and Johnson 2001; 
Johnson and Johnson 2001; Johnson et al. 2000) using POLG and POLG2 together. 
Several presumably pathogenic amino acid substitutions in pol γ have been identified in 
PEO patients, including G923D, R943H (neither are currently in OMIM) and A957S (MIM 
174763.0014). Although all of these have been characterized biochemically (Graziewicz et al. 
2004; Ponamarev et al. 2002) with some limited kinetics, none of them has had its exonuclease 
activity measured yet. Without that critical data, we cannot simulate these variants. Recently, 
the pathogenic pol γ mutation Y955C (MIM 174763.0001), identified in Autosomal Dominant 
Progressive External Ophthalmoplegia, was reported to stall at dATP insertion sites (Atanassova 
et al. 2011). Unfortunately, many important kinetic values of the Y955C pol γ variant are not 
available, such as the exonuclease and dissociation reaction rates, although its polymerization 
kinetics have been reported (Estep and Johnson 2011; Ponamarev et al. 2002). 
 
Future Works 
 
Other pathogenic pol γ mutators 
Y955C mutation was the first adPEO mutations to be discovered(Ponamarev et al. 2002). 
It has been analyzed the effects of the mutation on the kinetics and fidelity of DNA synthesis by 
the purified human mutant polymerase in complex with its accessory subunit(Ponamarev et al. 
2002). As compared with the wild-type enzyme in the presence of the accessory subunit, the 
Y955C pol γ exhibited a 4-fold reduction in overall DNA polymerase activity in a standard DNA 
polymerase assay. Steady state kinetic analyses indicated that the Y955C enzyme retains a wild-
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type catalytic rate (kcat) but suffers a 45-fold decrease in apparent binding affinity for the 
incoming nucleoside triphosphate (Km). The full mutator effect of the Y955C substitution was 
revealed by genetic inactivation of the exonuclease, and error rates for certain mismatches were 
elevated by 10–100-fold. This enhanced mutagenesis is mitigated by a functional intrinsic 
exonuclease activity resulting in only a 2-fold mutator effect for base pair substitutions by the 
exonuclease proficient Y955C enzyme. 
After A467T, the Y955C is the next valuable pol γ mutator to be analyzed. Because its Km 
value decreased dramatically, Y955C is expected to more sensitive to the substrate 
concentrations. It will be interested to simulate and compare the point mutation rate and the 
longest single forward step time of Y955C to wild-type pol γ. Though the exonuclease reaction 
rate of the Y955C mutation has not been measured, we still can make reasonable assumptions 
about this rate to explore its pathogenic effect in adPEO. 
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CHAPTER III 
 
AN ANALYSIS OF ENZYME KINETICS DATA FOR MITOCHONDRIAL DNA STRAND TERMINATION 
BY NUCLEOSIDE REVERSE TRANSCRIPTION INHIBITORS3 
 
Introduction 
 
Recent guidelines for highly active anti-retroviral treatment (HAART) regimens of HIV-
positive patients recommend two drugs of the nucleoside reverse transcriptase inhibitor (NRTI) 
class (Table III.1) (Antiretroviral_Guidelines_for_Adults_and_Adolescents_Panel 2006). This class 
currently consists of: stavudine (d4T), lamivudine (3TC), zidovudine (AZT), zalcitabine (ddC), 
didanosine (ddI), abacavir (ABC), emtricitabine (FTC) and tenofovir (TDF, a nucleotide analog). 
Though zalcitabine (ddC) is still technically approved for treatment its distribution in the United 
States was discontinued by Roche in 2006. In their activated tri-phosphorylated forms, each 
NRTI acts as a nucleotide analog interacting with the HIV viral reverse transcriptase as an 
alternative substrate to the natural nucleotides (Anderson et al. 2004; Ray 2005). Each of these 
analogs lacks the 3’ OH group necessary for incorporation of the next nucleotide thereby 
terminating viral DNA strand elongation. 
  
                                                          
3 Wendelsdorf, K. V., Song, Z., Cao, Y., and Samuels, D. C. (2009). An Analysis of Enzyme Kinetics 
Data for Mitochondrial DNA Strand Termination by Nucleoside Reverse Transcription Inhibitors. 
PLoS Comput Biol 5(1). Author contributions: Conceived and designed the experiments: YC DCS. 
Performed the experiments: KVW ZS. Analyzed the data: KVW ZS. Contributed 
reagents/materials/analysis tools: YC. Wrote the paper: KVW ZS DCS. 
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Table III.1. Nucleoside and nucleotide analogs used in this study. 
 
Drug Abbreviation 
Natural 
nucleoside 
Comment 
Abacavir ABC dG The activated form is CBV-TP 
Acyclovir ACV dG 
Used in treatment against Herpes viruses 
including HSV1 and 2, chickenpox and 
herpes zoster. 
Didanosine ddI dA 
Must be aminated to become ddA, which is 
activated form. The nonactivated form, 
however, has also been shown to 
incorporate into mtDNA.  
Dideoxyadenosine ddA dA The active form of ddI. 
Emtricitabine FTC(-) dC 
The unnatural enantiomer that is approved 
for treatment of HIV. 
Emtricitabine FTC(+) dC 
The natural enantiomer that is more toxic 
and not approved for treatment. 
Lamivudine 3TC(+) dC 
This natural enantiomer of 3TC is not used in 
treatment, but is used in studies that look at 
effects of configuration on toxicity and 
efficacy.  
Lamivudine 3TC(-) dC 
The unnatural enantiomer that is approved 
for treatment of HIV. 
Stavudine d4T T  
Tenofovir PMPA, TDF dAMP A nucleotide analog 
Zalcitabine ddC dC Not currently recommended for clinical use. 
Zidovudine AZT T  
 
 
NRTIs are effective drugs that have helped usher HIV into the category of a controllable 
chronic disease, however, they are also often toxic, inducing side effects such as lactic acidosis, 
peripheral neuropathy, peripheral lipoatrophy, and pancreatitis in patients. Intolerance of such 
side effects is a common reason for treatment discontinuation (d'Arminio Monforte et al. 2000). 
It is a serious concern that any decrease in patient compliance to the treatment regimen can 
lead to an increase in viral resistance and ultimately to treatment failure. The 1st step in 
ameliorating these side effects and preventing them in future antiviral treatments is to 
understand the mechanisms behind the mitochondrial toxicity of the NRTIs that are in use today. 
People have proposed many mechanisms of mitochondrial toxicity which we discuss below. In 
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this paper we specifically consider the plausibility of the most widely accepted hypothesis for 
the NRTIs’ toxicity mechanism - interference of mitochondrial DNA replication. 
 
The polymerase γ hypothesis 
Polymerase γ (pol γ) is the only polymerase responsible for mitochondrial DNA 
replication. While pol γ is not believed to directly regulate mtDNA levels, pathogenic mutations 
in the gene POLG do affect the stability of mtDNA and cause mtDNA depletion (Copeland 2008). 
Polymorphisms found in the POLG gene in the human population may cause a natural variability 
in the activity of this complex enzyme and may conceivably play a role in patient variability in 
NRTI drug toxicities. 
Martin et al. (Martin et al. 1994) reported that the approved NRTIs inhibited various 
host DNA polymerases. Behind the HIV Reverse Transcriptase, the highest affinity of the NRTIs 
was for polymerase γ. Moreover, many of the NRTI side-effects resemble symptoms of 
mitochondrial genetic disorders. All these facts implicated interaction with polymerase γ and 
subsequent depletion of mtDNA as a potential cause of NRTI toxicity giving rise to the 
polymerase γ hypothesis (Lewis et al. 2003). 
Several groups have conducted experiments that demonstrate decreased mtDNA 
amounts in various tissue types of NRTI-treated HIV positive patients (Cherry et al. 2002; Cote et 
al. 2002; Haugaard et al. 2005; Walker et al. 2004). In addition, people observed mtDNA 
depletion in parallel with cell death, mitochondrial morphological changes, and increased 
lactate production in liver, heart, neuron, skeletal muscle, adipose, and blood cell cultures after 
incubation with different NRTIs (Azzam et al. 2006; Benbrik et al. 1997; Biesecker et al. 2003; 
Birkus et al. 2002; Cui et al. 1997; Galluzzi et al. 2005; Pan-Zhou et al. 2000; Setzer et al. 2005; 
Walker et al. 2002). 
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However, other groups published a substantial body of data that are not consistent with 
toxicity mechanisms resulting in depletion of mtDNA. Martin et al. (Martin et al. 1994) showed 
no association between inhibition of polymerase γ by NRTIs and mtDNA depletion. 
Mitochondrial dysfunction has been observed in vitro in mouse muscle, white adipose, brain, 
liver, and heart tissue (Note et al. 2003), hepatoma cell lines (Walker et al. 2002) as well as CD4 
cells (Setzer et al. 2005) after incubation with NRTIs although no significant decrease in mtDNA 
amount was observed. Particularly, incubation of liver and skeletal muscle cells with ddC, ddI, 
d4T, and AZT show a higher rate of lactate production in the presence of AZT, but the least 
amount of mtDNA depletion (Birkus et al. 2002; Pan-Zhou et al. 2000). In clinical practices 
mtDNA depletion has been seen in parallel with normal cytochrome c oxidase activity, a sign of 
correct mitochondrial function (Piechota et al. 2006), and was not associated with lipoatrophy 
(McComsey et al. 2005) (although that study measured mtDNA depletion in blood samples, not 
fat cells). All these findings indicate a weak relationship between mtDNA copy number and 
nucleoside analog toxicity, which warrants a deeper look at the data concerning the interaction 
of different NRTIs with polymerase γ. 
 Lewis et al. suggested three possible polymerase γ dependent toxicity mechanisms that 
comprise the polymerase γ hypothesis, which are (1) direct inhibition of polymerase γ by NRTI-
triphosphate without incorporation into the mtDNA, (2) chain termination of mtDNA replication 
following incorporation of the NRTI triphosphate, and (3) incorporation of the analog 
triphosphate into mtDNA without chain-termination allowing the NRTI to continue as a point 
mutation in mtDNA (Lewis et al. 2006). 
To study the polymerase γ toxicity, we have simulated the DNA replication process of 
mitochondria to examine the impact of NRTIs. Using enzyme kinetics data gathered from 
Johnson et al. (Johnson et al. 2001), Feng et al. (Feng et al. 2004), and Hanes et al. (Hanes and 
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Johnson 2007; Hanes et al. 2007) we have carried out a series of simulations of mtDNA 
replication in the presence of various nucleoside analogs that interact with polymerase γ (Table 
I.6). These simulations bridge the gap between the basic enzyme kinetics data and the 
probability of failure of the mtDNA replication process. 
 
Methods 
 
The drugs included in this study 
Thirteen analogs were used in the simulations (Table III.1). These included eight drugs of 
the NRTI class currently approved for human treatment- stavudine (d4T), lamivudine (3TC(-)), 
zidovudine (AZT), zalcitabine (ddC), didanosine (ddI) (whose active form is dideoxyadenosine 
(ddA) triphosphate) , abacavir (ABC), emtricitabine (FTC(-)) and tenofovir (TDF) 
(Antiretroviral_Guidelines_for_Adults_and_Adolescents_Panel 2006), and one anti-herpes drug, 
acyclovir (ACV). In addition we modeled the effects of the natural enantiomers of FTC(+) and 
3TC(+) that have been used to explore a possible role of stereochemistry in the efficacy of 
strand termination (Feng and Anderson 1999), and ddI in its non-activated form. Since this study 
focuses on strand termination, we have not included FIAU, an anti-hepatitis B drug that 
tragically resulted in the deaths of five patients in phase 2 trials and whose toxicity is believed to 
be due to errors in mtDNA replication (Colacino 1996; Lewis et al. 1996), though not necessarily 
through strand termination (Johnson et al. 2001; Lewis et al. 1996). 
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Computational Model 
Our computational model of the mitochondrial DNA replication process is based on the 
Stochastic Simulation Algorithm (Gillespie 1976; Gillespie 1977). The model is based on four 
reactions; DNA polymerase activity, exonuclease activity, disassociation of the polymerase from 
the DNA, and reassociation of the polymerase with the DNA molecule (Figure III.1). In the DNA 
polymerase reaction pol γ adds one nucleotide to the new DNA strand. This nucleotide may be 
the correct or incorrect (point mutation) base indicated by the template strand. In this model 
this includes the incorporation of nucleoside analog triphosphates. In the exonuclease reaction 
pol γ removes one nucleotide from the new DNA strand. This includes the removal of nucleoside 
analogs from the DNA strand. The exonuclease reaction is an error correction mechanism, as the 
rate for removal of incorrectly incorporated nucleotides is typically faster than that of correctly 
incorporated nucleotides. In the disassociation reaction the polymerase separates from the DNA 
molecule. In the reassociation reaction the polymerase re-attaches to the DNA molecule after 
disassociation. At each position on the replicating mtDNA strand, pol γ will randomly undergo 
one of the first three reactions (polymerase, exonuclease, or dissociation). Which reaction pol γ 
undergoes is determined by the probability of each reaction, calculated using the reactions rates 
and Michaelis-Menten kinetics. 
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Figure III.1. Schematic diagrams of the polymerase γ reactions in this model. A. The four 
reactions possible following a correct incorporation. DNA Polymerase: polymerase γ adds one 
nucleotide to the new DNA strand. This nucleotide may be the correct or incorrect (point 
mutation) base pair for template strand, or a nucleotide analog. Exonuclease: polymerase γ 
removes one nucleotide (correct or incorrect match) from the new DNA strand. This is an error 
correction mechanism. Disassociation: The DNA polymerase can separate from the DNA 
molecule. Reassociation: The DNA polymerase re-attaches to the DNA molecule after 
disassociation. B. The possible reactions after insertion of analog (Z to represent AZT in this 
example): exonuclease activity or dissociation. Our model does not allow further polymerization 
or reassociation once an analog is inserted and not removed by an exonuclease reaction. 
 
 
For the two scenarios of a correctly inserted and incorrectly inserted previous 
nucleotide we have separate sets of kinetic parameters for each of the pol γ reactions (Johnson 
and Johnson 2001; Johnson and Johnson 2001; Lee and Johnson 2006). These studies have 
reported an increase in exonuclease and disassociation rates, but a decrease in incorporation 
rates by pol γ following an incorrect incorporation. This is included in the simulation model by 
using two sets of enzyme kinetics parameters, one set for reactions following a correct 
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incorporation and another set for reactions following an incorrect incorporation. Kinetic 
parameters for the natural nucleotide (dNTP) interaction with pol γ are available in Tables I.1-I.5. 
As data regarding the reassociation reaction rate are not available our model assumes that after 
a disassociation event occurs the reassociation reaction follows, except in the special case 
discussed immediately below. Since the rate for the reassociation reaction is not available, the 
time required for that reaction is not calculated in this model. This approximation is not 
important to our results reported here which focus on strand termination probabilities. 
Upon incorporation of an analog into the new DNA strand the next polymerase reaction 
is blocked. The exonuclease reaction can still occur, removing the analog molecule. However, if 
a disassociation reaction occurs before the analog can be removed, we assume that 
reassociation of the DNA polymerase is also blocked and the mtDNA replication event is 
disrupted resulting in strand termination (Figure III.1). There has been some speculation that the 
drugs, in particular AZT, may be inserted into a replicating mtDNA strand without causing strand 
termination. In this model we take the conservative assumption that all NRTIs that are inserted 
in the mtDNA strand and not subsequently removed cause strand termination. 
Parameters included in the model for incorporation of each analog by pol γ were the 
concentration necessary for binding of 50% of available pol γ (Km), the rate of polymerization 
(kpol),, and the rate of excision (Vexo) of each analog by pol γ. The parameters kpol and Km were 
estimated from the maximum rate of incorporation by pol γ (kcat) and the dissociation constant 
from pol γ (Kd), respectively, obtained under pre-steady state conditions (Feng et al. 2004; 
Hanes and Johnson 2007; Johnson et al. 2001). A recent publication shows that pyrophosphate 
release from AZT is uniquely slow during polymerization and that kinetics measured during 
steady-state conditions give a more accurate kpol estimation (Hanes and Johnson 2007). These 
measurements were carried out on AZT due to the fact that under pre-steady state conditions a 
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decrease in incorporation rate was observed with increased AZT concentration indicating 
reversible binding. This pattern was not seen with any of the other analogs studied (d4T, 3TC(-), 
AZT, ddC, ddI, ddA, ABC, TDF, and 3TC(+)) and for this reason reanalysis of the enzyme kinetics 
for those drugs was not performed in that experiment. Given this continuing evolution in our 
understanding of the AZT kinetics we carried out two simulations for AZT insertion using the two 
available published sets of parameters determined under steady-state conditions in the 2007 
paper by Hanes and Johnson (Hanes and Johnson 2007) and pre-steady state conditions 
published in the 2001 paper by Johnson et al. (Johnson et al. 2001). We distinguished the results 
using these two parameter sets as AZT2001 and AZT2007. These parameter values, as well as those 
for the other analogs, are given in Table I.6.  
 
Triphosphorylated mitochondrial natural nucleotide (dNTP) levels 
The polymerization reaction rates are functions of the dNTP concentrations. For this 
calculation we consider three sets of dNTP concentrations, representing high, medium and low 
concentration conditions. Mitochondrial dNTP levels were estimated following the observations 
of Rampazzo et al and Ferraro et al (Ferraro et al. 2005; Rampazzo et al. 2004) (Table III.2). The 
units of picomole of mitochondrial dNTP per mg of mitochondria or picomoles per 106 cells were 
converted to μM by using an assumed mitochondrial volume of 0.2 femtoliters and density 
measurements from Pollak and Munn (Pollak and Munn 1970). It should be noted that these 
density measurements considered mitochondria as discrete entities not taking in to account any 
change in mitochondrial size due to organelle fission and fusion processes. We use these values 
only as estimates, in order to define the three categories of dNTP concentrations given below. 
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Table III.2. Mitochondrial dNTP concentrations and Km values 
 
dNTP level dATP (μM) dCTP (μM) dGTP (μM) dTTP (μM) 
high 22.5 28 19.5 26 
medium 1.675 1.644 0.47 0.76 
low 0.1675 0.1644 0.047 0.076 
Km with polymerase γ* 0.8 0.9 0.8 0.6 
*from reference (Lee and Johnson 2006). 
 
 
High dNTP levels: As an estimate for the natural nucleotide concentrations within 
mitochondria of actively dividing cells, concentrations of natural nucleotides in mitochondrial 
pools from a cycling cell culture of 3T3-L1TK1+ (a mouse fibroblast line) were used. (Rampazzo 
et al. 2004). The units of dNTP measurement were converted to μM units by estimating the 
volume of a 3T3-L1 cell from images in Friis et al. (Friis et al. 2005). 
Medium dNTP Levels: As an estimate of the natural nucleotide concentrations within 
mitochondria of resting or slowly dividing cells values for rat liver cells were used (Ferraro et al. 
2006). 
Low dNTP levels: A third set of simulations were carried out using natural nucleotide 
levels at 1/10th those estimated for the liver cells. This is meant to represent the low dNTP 
concentrations in postmitotic cells. 
 
Simulation sets 
Vertebrate mitochondrial DNA has a highly asymmetric G content. The low-G strand is 
labeled the light strand, with the complement strand called the heavy strand. Sets of simulations 
were carried out separately for the light strand sequence (NCBI, gi 17981852) and the heavy 
strand sequence. On each template three separate simulation sets were carried out using the 
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high, medium, or low natural nucleotide concentrations described above and varying the 
concentration of activated triphosphorylated analog. Each simulation was repeated 1000 times. 
The number of simulated mtDNA strand replications ending in a strand termination event 
(caused by a nucleoside analog incorporation) was recorded. The concentrations of the four 
dNTP pools and the activated analog were held constant throughout each simulated replication. 
 
Results 
 
The purpose of this study was to explore the plausibility of the pol γ hypothesis by 
calculating the probability of insertion of the nucleotide analog into the replicating mtDNA 
strand, leading to strand termination. We constructed a model based on the mitochondrial 
genome length and sequence, mitochondrial dNTP concentrations, and the measured enzyme 
kinetics of pol γ. With this model we simulated mitochondrial DNA replication in the presence of 
different analogs determining the dose response curves and the IC50 values of DNA termination 
for each drug. The simulation results were compared to reports of mitochondrial toxicity, and 
specifically to reports of mtDNA depletion. 
 
Dose response curves and IC50 values 
By measuring the probability of strand termination in the simulation as a function of the 
activated drug concentration, dose response curves for each drug were calculated. Figure III.2 
shows the dose response curves obtained for the strand termination probability of each 
clinically approved analog as a function of the analog mitochondrial concentrations. The 
concentration at which these dose response curves passed 50% defined the IC50 values for each 
activated drug (Table III.3). In our model, replication was terminated once an analog was 
 78 
 
inserted and failed to be removed by exonuclease activity. Based on these simulated IC50 values 
the list of analogs in the order of decreasing probability of mtDNA strand termination on the 
light strand was:  
ddC = ddA = d4T > FTC(+) > 3TC(+) > ACV > ddI > 3TC(-) = TDF >= AZT2001 >> FTC(-) > ABC = AZT2007, 
in which “>>” indicates a 10 fold difference or more, “>” indicates a 2 to 10 fold difference and 
“=” indicates a less than 2 fold difference. Note that ddA is the activated form of ddI. Of this list 
only d4T, ddI, ddC, 3TC(-), TDF, AZT, ABC, ACV and FTC(-) are approved for therapeutic use. The 
IC50 list showed that the “di-deoxy drugs”, meaning ddC, d4T, and ddA, had the highest 
probability of causing mtDNA strand termination during replication while FTC(-), ABC and AZT2007 
showed the least. Of those drugs approved for HIV treatment there was an observed difference 
of more than 800 fold between the di-deoxy drugs (ddC, ddA, and d4T) and other approved 
drugs (3TC, TDF, AZT, ABC, and FTC(-)) in the activated drug concentration necessary for 50% 
probability of mtDNA strand termination. 
The only difference seen in the simulation of heavy strand replication (Table III.4) was 
that acyclovir had a slightly higher probability of termination than 3TC(+) and ABC had 
approximately equal probability of termination as FTC(-). Since there was little difference in the 
results for the two strands of the mtDNA molecule, we concentrated on results from the light 
strand. For the readers’ convenience in interpreting these IC50 values, reported ranges of 
intracellular concentrations (Barry et al. 1996; Becher et al. 2004; Becher et al. 2002; Kewn et al. 
2002; Moore et al. 1999; Piliero 2004; Pruvost et al. 2005) for activated nucleoside analog drugs 
measured in peripheral blood mononuclear cells in patients are given in Table III.5. Where 
necessary, values were converted to units of μM using the conversion of Kewn et al (Kewn et al. 
2002). However it should be kept in mind that these concentrations are intracellular values, not 
the concentration values in the mitochondria which may be different. 
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Figure III.2. The dose-response curves for incorporation probability of analogs approved for 
treatment. Circles are the probability of strand termination calculated from a set of 1000 
simulations for each point and the curves are dose-response curves fit to the data points. There 
is a large difference of incorporation probability between the di-deoxy drugs (ddC, ddI, and d4T) 
and other approved anti-retrovirals (3TC, TDF, AZT, ABC, and FTC). The anti-herpes drug, 
acyclovir, falls in the middle of these two extremes, but shows little mitochondrial toxicity in 
clinical use possibly due to the fact it is dependent upon viral proteins for activation. AZT2001 
probabilities were determined using kinetic parameters from reference (Johnson et al. 2001) 
and AZT2007
 probabilities were determined using newly reported kinetic parameters from 
reference (Hanes and Johnson 2007). 
 
Table III.3. IC50 values for light strand termination calculated from the simulation. Analogs are 
listed in order of increasing IC50. IC50 values are calculated for three different sets of 
mitochondrial dNTP levels; high, medium and low, as defined in Table III.2. NA – not applicable. 
 
Analog triphosphate 
IC50 values (μM) Reported mtDNA depletion 
High dNTP Medium dNTP Low dNTP 
ddC-TP 3.42x10-4 2.38x10-4 5.80x10-5 Yes 
ddA-TP 4.42x10-4 2.89x10-4 7.47x10-5 Yes 
d4T-TP 7.92x10-4 4.65x10-4 9.76x10-5 Yes 
FTC(+)-TP 5.90x10-3 4.20x10-3 9.80x10-4 No data 
3TC(+)-TP 3.54x10-2 2.26x10-2 6.30x10-3 No data 
Acyclovir-TP 6.78x10-2 2.58x10-2 3.81x10-3 No data 
ddI-TP 0.25 0.17 4.60x10-2 No data  
3TC(-)-TP 0.56 0.40 8.40x10-2 No 
TDF-TP 1.18 0.87 0.22 No 
AZT2001-TP 3.95 2.38 0.50 No 
FTC(-)-TP 778.9 58.59 7.57 No 
ABC-TP NA NA 8.10 No 
AZT2007-TP NA NA NA No 
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Table III.4. IC50 values (μM) for the strand termination on the mtDNA heavy strand. NA – not 
applicable, meaning that the probability of strand termination never exceeded 50%. 
 
Analog triphosphate 
IC50 values (μM) 
High dNTP Medium dNTP Low dNTP 
d4T-TP 6.75x10-4 3.60x10-4 7.50x10-5 
ddA-TP 5.20x10-4 4.00x10-4 9.80x10-5 
ddC-TP 8.90x10-4 5.80x10-4 1.30x10-4 
FIAU-TP 1.44x10-3 8.30x10-4 1.60x10-4 
FTC(+)-TP 1.40x10-2 1.00x10-2 2.20x10-3 
acyclovir-TP 2.85x10-2 1.14x10-2 1.79x10-3 
3TC(+)-TP 8.8x10-2 5.60x10-2 1.36x10-2 
ddI-TP 0.33 0.23 5.75x10-2 
3TC(-)-TP 1.50 1.00 0.19 
TDF-TP 1.45 1.06 0.26 
AZT2001-TP 3.00 1.94 0.37 
AZT2007-TP NA NA 143 
CBV-TP NA NA 2.22 
FTC(-)-TP NA NA 30.9 
 
Table III.5: Reported intracellular concentrations of the activated (triphosphate) form of the 
nucleoside and nucleotide analogs, measured in peripheral blood mononuclear cells in 
patients. 
 
Analog triphosphate Intracellular concentration range (mM) 
3TC-TP 35.4 - 51.2 
FTC(-)-TP 0.40 - 4.50 
AZT-TP 0.84 - 1.2 
ABC-TP 0.04 - 0.75 
TDF-TP 0.27 - 0.39 
ddA-TP 0.013 – 0.078 
d4T-TP 0.016 – 0.082 
Acyclovir-TP Not available 
ddC-TP Not available 
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Abacavir, Emtricitabine, and Zidovudine2007 
For most analogs, the simulated dose response curve increases to 100% probability of 
strand termination if the analog concentration is raised high enough. AZT2007, ABC and FTC(-) 
behaved differently from the other analogs in that they reached the point of saturation below 
100% probability of strand termination (Figure III.2), and in some cases the strand termination 
probability saturated below 50%, meaning that no IC50 values could be defined in those cases 
(the blank entries in Table III.3). These three analogs interact so poorly with pol γ that over the 
finite length of the mtDNA sequence (approximately 16,600 base pairs) these analogs have too 
few chances to incorporate into the growing mtDNA strand for the probability of strand 
termination to approach 100%, even with very large concentrations of the activated drug in the 
mitochondrion. 
When the recently revised steady-state derived parameters for kcat and Km for AZT 
(Hanes and Johnson 2007) were used in the simulation, AZT2007 did not reach a 50% probability 
of strand termination in the presence of normal to high dTTP levels, instead saturating at a 23% 
probability. This grouped AZT2007 with ABC as having the least probability of causing termination 
of the replicating mtDNA. 
 
Specificity constant 
A common measurement for the relative likelihood of strand termination by each 
analog is the specificity constant (Johnson et al. 2001) determined by the ratio kcat/Km for the 
incorporation of an analog by pol γ. This is a common measurement used for predicting the 
discrimination of analogs by pol γ over the natural nucleotide substrate (Feng et al. 2004; Hanes 
and Johnson 2007; Hanes et al. 2007; Johnson et al. 2001). The drawback in taking this 
measurement of direct interaction with pol γ as a predictor for the actual incorporation into the 
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replicating mtDNA strand is that the specificity constant does not consider exonuclease activity, 
mitochondrial dNTP levels, nor strand length, all of which can affect the probability that an 
analog will be incorporated. All of these factors of the system are integrated into our 
computational model and the resulting IC50 values. Previous studies (Feng et al. 2004; Hanes and 
Johnson 2007; Hanes et al. 2007; Johnson et al. 2001) provide a list of increasing specificity 
constants of: ddC > ddA > d4T >> ACV > 3TC(-) > TDF > AZT >> ABC = FTC(-). The order of this list 
agreed quite well with our list given above based on simulated mtDNA strand termination. This 
agreement validates the use of kcat/Km values as an appropriate proxy for the relative probability 
of incorporation of these NRTIs by pol γ. A quantitative comparison between the specificity 
constant and our calculated IC50 for strand termination is given in Figure III.3. 
 
 
 
Figure III.3. The relationship between the IC50 values and the specificity constant, kcat/Km. The 
specificity constant is a measurement of direct interaction with polymerase γ often used as 
prediction for analog incorporation. The IC50 values are a more direct measure of incorporation 
probability taking exonuclease activity and other features into account. This relationship shows 
that the specificity constant is a useful proxy for incorporation probability. 
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Removal of nucleoside analogs from the mtDNA 
The very low exonuclease reaction rate for each analog is the primary reason why the 
specificity constant serves as a reasonable prediction of mtDNA strand termination. The 
exonuclease reaction rates used in this study were taken from Johnson et al. (Johnson et al. 
2001). Low excision rates for NRTIs have also been documented in the case of ddC (Longley and 
Mosbaugh 1991) and using yeast mtDNA polymerase with ddC and AZT (Eriksson et al. 1995). 
However, 3TC has a non-negligible measured exonuclease rates (Table I.6) (Johnson et al. 2001). 
Whenever an analog is inserted into the DNA strand, our pol γ model assumed that only the 
exonuclease and pol γ dissociation reactions can occur. Based on this model, in Table III.6 we 
give the predicted probability Pexo of the analog removal  
 /exo exo exo disP V V V   
where Vexo is the rate of exonuclease reaction for the analog and Vdis is the rate of disassociation 
of the polymerase. To test these predictions, we carried out a set of simulations with the analog 
exonuclease reactions removed. The ratio of the IC50 value in the full model to the IC50 value in 
the exonuclease deficient model was in very good agreement with the 1-Pexo values (Table III.6). 
As predicted, only the two 3TC forms showed significant effects from the removal of the analog 
exonuclease reaction. Even in these cases the effect of the exonuclease reaction only shifted the 
IC50 value by a factor of 2 or less. 
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Table III.6. The effect of the exonuclease reaction for each nucleoside or nucleotide analog, in 
order of increasing Vexo. 
 
Analog Vexo (s
-1) Pexo 1-Pexo IC50 / IC50(exo-) 
ddC 0.00002 0.00040 0.9996 1 
d4T 0.0004 0.0079 0.9921 0.98 
AZT2001 0.0004 0.0079 0.9921 1.038 
AZT2007 Not reported - - - 
ddA 0.0005 0.01 0.99 1.086 
ddI 0.0007 0.014 0.986 1.059 
TDF 0.0007 0.014 0.986 0.942 
ABC 0.0016 0.031 0.969 - 
Acyclovir 0.0021 0.040 0.96 0.919 
FTC(-) 0.0048 0.088 0.912 0.964 
FTC(+) 0.0048 0.088 0.912 0.867 
3TC(-) 0.015 0.23 0.77 0.725 
3TC(+) 0.02 0.29 0.71 0.69 
 
 
Effects of multiple nucleoside analogs 
The current therapy for HIV infections involves a combination of nucleoside analog 
drugs, along with another class of drug such as a protease inhibitor. It has been reported that 
combining nucleoside analogs increases toxicity (Chan et al. 2007; Venhoff et al. 2007). The pol γ 
model is a series of reactions occurring as the DNA polymerase moves along the template strand. 
At each position on the DNA strand different nucleoside analogs would be able to be 
incorporated into the DNA strand. For example, AZT triphosphate molecules would only have a 
reasonable rate of incorporation opposite an A on the template strand, while 3TC triphosphate 
molecules would only have a reasonable rate of incorporation opposite a G on the template. 
Considering this, it is unlikely that there could be a combined effect of two analogs of different 
nucleosides on strand termination through the pol γ interaction alone. To test this, we modeled 
the effects of two analogs, AZT and 3TC, separately and in combination (Figure III.3). The 
combination of AZT and 3TC has been shown to have enhanced toxicity (Chan et al. 2007; 
Venhoff et al. 2007), though neither of these two studies found any significant mtDNA depletion 
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associated with this toxicity. If we define PAZT as the probability of strand termination from a 
given concentration of AZT triphosphate and P3TC as the probability from a given 3TC 
triphosphate concentration, then the combination of the two drugs should result in a strand 
termination probability of  
)1)(1(1 33 TCAZTTCAZT PPP   
This equation assumes there is no interaction between the two nucleoside analog drugs (this is 
known as the Webb fractional effect (Martinez-Irujo et al. 1998)). Note that PAZT+3TC is here 
defined as one minus the probability that neither AZT nor 3TC independently cause strand 
termination. A set of 1000 simulations was repeated 10 times, using the medium dNTP 
concentrations defined in Table III.2, and mean and standard deviations for the probabilities PAZT, 
P3TC and PAZT+3TC were measured. The results for PAZT+3TC were consistent with the probability 
expected assuming no interaction between the two drugs (Figure III.4). This indicates that any 
synergistic effects of multiple NRTIs on mitochondrial toxicity are not consequences of direct 
strand termination. Alternative explanations for synergistic effects may include competitive 
inhibition of deoxynucleotide phosphorylation, which is outside the limits of this computational 
model. 
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Figure III.4. The computed probability of strand termination for an AZT and 3TC combination. 
Computed probabilities are shown for AZT-TP alone (at 0.5 μM), 3TC-TP alone (at 0.1 μM) and 
the combination of both drugs at those concentrations (solid bars).  The error bars represent 
standard deviations from 10 repeated sets of 1000 simulations. Also shown is the predicted 
probability of strand termination for the combined drugs (hatched bar) with the assumption of 
no interaction between the two drugs, calculated from the equation given in the text. 
 
 
Discussion 
 
Our simulated IC50 values of mtDNA strand termination for AZT-TP, CBV-TP (ABC), FTC(-)-
TP and TDF-DP were approximately 1,000-fold or more higher than those of the di-deoxy drugs. 
This agrees with the lack of observed mtDNA depletion in liver, fat, and PBMC samples from 
patients on regimens comprised of NRTIs that are not di-deoxy analogs (Cherry et al. 2002; Cote 
et al. 2002; Walker et al. 2004). The herpes drug Acyclovir (ACV) fell between the di-deoxy drugs 
and the others in terms of probability of causing mtDNA strand termination. ACV is not 
associated with mitochondrial toxicity clinically. This is believed to be due to the fact that the 
drug must be activated by a viral-encoded kinase (Coen and Schaffer 1980). As herpes 
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replication tends to occur in waves with long latent periods, this may not lead to the long term 
effects on mitochondria seen with NRTI use for HIV treatment. 
 
The dideoxy drugs 
The dideoxy NRTIs (ddC, ddA, and d4T) showed the greatest risk of strand termination in 
our simulations, indicated by their predicted low IC50 values. This agrees with previous studies 
showing they are the NRTIs most associated with mtDNA depletion in vitro (Biesecker et al. 2003; 
Birkus et al. 2002; Cote et al. 2003; Cui et al. 1997; Pan-Zhou et al. 2000; Setzer et al. 2005) and 
mitochondria-related toxicities clinically placing them as alternative drugs for adults and 
adolescents in the federal guidelines 
(Antiretroviral_Guidelines_for_Adults_and_Adolescents_Panel 2006). In both muscle and 
subcutaneous fat biopsies of HIV+ patients, mtDNA levels were significantly lower in those on 
dideoxy drug regimens as opposed to those on non-dideoxy NRTI regimens (Cherry et al. 2002; 
Walker et al. 2004). Even though the toxic side effects of dideoxy drugs are well known and the 
in vitro effects on tissue mtDNA levels of these drugs are in agreement with our simulation 
results, the very low IC50 values for these drugs of approximately 3 x 10
-4 μM warrant discussion. 
The low IC50 value for ddC is in agreement with findings that this drug is not readily metabolized 
in the cell to its active form (Cui et al. 1997; Piliero 2004), implying that the concentrations of 
the activated drug in the cell may be quite small. There is evidence, however, that d4T and ddI 
are activated to a significant degree as the concentration of their triphosphorylated forms in 
patient peripheral blood mononuclear cells are above the predicted IC50 values by 
approximately 100-fold (Becher et al. 2004; Becher et al. 2002) (Table III.5, note that the 
experimentally measured value is the activated drug concentration in the cytoplasm, not in the 
mitochondria). Given that d4T and ddI are still recommended drugs for HAART 
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(Antiretroviral_Guidelines_for_Adults_and_Adolescents_Panel 2006) they are obviously 
tolerable to a large number of patients who do not experience the serious side-effects of lactic 
acidosis and neuropathy. One plausible explanation for this tolerance in the face of the striking 
affinity of these drugs for pol γ is that there exists a significant barrier to dideoxy drug entry into 
the mitochondrion or drug activation within the mitochondrion allowing activated dideoxy drug 
mitochondrial concentrations to remain low in the majority of patients treated with these drugs. 
We know of no reports of measured levels of the triphosphate form of these dideoxy drugs 
within mitochondria. 
 
AZT 
The experimental data indicates that AZT interacts poorly with pol γ as shown by the 
high Km and low kcat values (Table I.6) for this drug. An explanation for the slow rate of 
incorporation of AZT was recently published (Hanes and Johnson 2007). AZT demonstrates 
unusually slow pyrophosphate release upon incorporation by pol γ rendering polymerization 
readily reversible even upon binding to the template:primer molecule. In the cases of natural 
nucleotides this subreaction is fast enough to be considered negligible indicating that pre-steady 
state kpol values are a good approximation for kcat. Yet, in the case of AZT, this slow 
pyrophosphate release rate has a significant effect on kcat so that a measurement of kpol during 
steady-state conditions is more appropriate for estimating kcat. The kpol and Kd determined in the 
recent Hanes and Johnson study (Hanes and Johnson 2007) with steady-state conditions, that 
theoretically take the slow pyrophosphate release rate in to account, indicate a kcat 100-fold 
lower than that determined from the kpol calculated under pre-steady state conditions (Johnson 
et al. 2001). We carried out the simulation for both sets of parameters separately and in both 
cases AZT shows a poor probability of mtDNA strand termination (Figure III.2). The IC50 values 
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generated by this study show that AZT should not be toxic through mtDNA strand termination as 
it has a higher IC50 value than 3TC(-) and TDF, neither of which are associated with mitochondrial 
toxicity. 
The low probability of strand termination by AZT is supported by the fact that although 
AZT has consistently been associated with positive markers for mitochondrial toxicity, 
substantial evidence exists that the extent of AZT-induced mitochondrial toxicity is 
disproportional to the amount of mtDNA depletion it causes. The analogs ddC, d4T and ddI 
(activated to ddA) cause significantly more mtDNA depletion and decreased protein subunit 
expression of various electron transfer chain proteins with essential subunits encoded in the 
mtDNA, as would be expected from their increased interaction with pol γ compared to other 
analogs (Figure III.2). Yet AZT still manages to demonstrate a cytotoxicity that is equal to or 
greater than ddA, ddC, and d4T at comparable concentrations in various studies. In human liver 
and cardiac muscle cells incubation with AZT lead to cytotoxicity and increased lactate levels 
with no sign of mtDNA depletion (Cihlar et al. 2002; Lund et al. 2007; Pan-Zhou et al. 2000). 
Similar results are seen in blood cells and adipose cells (Mallon et al. 2005; Setzer et al. 2005; 
Stankov et al. 2007). Szabados et al. (Szabados et al. 1999) showed significant toxic effects on 
cardiac muscle cells including increased ROS, abnormal mitochondrial structure, and decreased 
ATP/ADP ratio after two weeks of exposure of cells in medium with no effects on mtDNA levels. 
In fact, AZT is actually associated with slight increase in mtDNA levels in cell culture (de Baar et 
al. 2007; Hobbs et al. 1995), PBMCs (Cote et al. 2002), and liver tissue samples (Walker et al. 
2004). Our model, however, does not address subreactions that influence pol γ binding of the 
analog, meaning our results cannot disprove the possibility that AZT toxicity is due to 
deactivating pol γ either through irreversible binding or induction of a conformational change in 
the enzyme. However, the high Kd determined by both Hanes and Johnson and Johnson et al. 
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(Hanes and Johnson 2007; Johnson et al. 2001), along with the cited studies showing toxicity 
independent of mtDNA depletion, make this an improbable mode of toxicity. It is our conclusion 
that based on the measured kinetic coefficients of AZT with pol γ that AZT toxicity is not 
dependent upon mtDNA strand termination. Indeed, various pol γ independent hypotheses 
have been proposed for AZT mitochondrial toxicity. These include inhibition of the enzymes of 
the mitochondrial salvage pathway causing nucleotide pool imbalances (Lynx et al. 2006), 
binding to ADP-ATP translocator (Valenti et al. 2000), and direct inhibition of components of the 
electron transport chain (Pereira et al. 1998). 
 
TDF 
Tenofovir is associated with renal dysfunction without significant mtDNA depletion 
(Karras et al. 2003; Zimmermann et al. 2006). In a retrospective study of HIV positive patients 
taking TDF and those not taking TDF, no significant differences in mtDNA levels of kidney 
biopsies were observed (Cote et al. 2006). Similarly, in human renal proximal tubule cells (Vidal 
et al. 2006), TDF was not associated with cytotoxicity, mtDNA depletion, or COII mRNA depletion. 
In our simulations mitochondrial TDF triphosphate IC50 values were in the range 0.2 to 1.2 μM, 
depending on the natural dNTP levels. Since these concentrations are not unusually high, our 
conclusion is that Tenofovir might be able to cause some moderate mtDNA depletion, 
depending on how well the activated drug is concentrated within the mitochondrion. 
 
Conclusions 
 
A number of hypothesis with supporting evidence have been proposed for NRTI toxicity 
experienced during HAART. Possible pol γ mediated pathways include the direct inhibition of pol 
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γ by NRTI-triphosphate without incorporation of the analog; chain termination by incorporation 
of NRTI triphosphate into mtDNA; and incorporation without chain termination of the analog-
triphosphate allowing it to remain as a point mutation in mtDNA. Our model only addresses the 
case of chain termination. There is not enough data on the subreactions that comprise analog 
binding to pol γ for this model to explore the possibility that some analogs cause toxicity 
through inhibition of the pol γ enzyme directly, either by irreversible binding or induction of 
conformational change, as opposed to strand termination. 
The specificity constant, kcat/Km, (Johnson et al. 2001) is commonly used as an 
approximate indicator of mitochondrial toxicity through strand termination of mtDNA. Before 
this model, this has been a bit of a leap as the specificity constant does not take genome length, 
exonuclease activity, nor dNTP concentration into account, and no direct predictions or 
measurements of strand termination probabilities have previously been given. We fill this gap in 
our understanding by providing a model that includes all of these factors and that predicts 
strand termination probabilities. The consistence between our simulation model results and the 
qualitative ordered list of NRTI drug toxicity based on the specificity constant is a validation of 
the model results. However, the simulation model goes far beyond the specificity constant by 
predicting IC50 values and quantitative dose-response curves (Fig. 2) for these drugs. 
Furthermore, the specific definition of strand termination used in this model raises the 
hypothesis that dissociation of Polymerase γ after an NRTI is incorporated into the mtDNA 
strand is a critical step in strand termination. In this particular model we chose to define strand 
termination as the dissociation of Polymerase-γ after the incorporation of an NRTI, under the 
assumption that re-association of the polymerase after the NRTI could not occur. Of course, it is 
possible that in-vivo there may be other currently unknown factors which may alter the 
polymerase γ dissociation kinetics (or any other kinetics for that matter) from the measured 
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values. If our assumption that pol γ re-association is blocked after NRTI incorporation was 
changed, and re-association of the polymerase was to be allowed, then more exonuclease 
events of the NRTIs would occur. However, it is not clear to us then what the definition of 
“strand termination” would be since the exonuclease activity would eventually remove all 
incorporated NRTIs given enough time. Johnson et al (Johnson et al. 2001) used that assumption, 
where all NRTIs incorporated into the mtDNA were eventually removed by exonuclease activity, 
to define a toxicity index based on a calculation of the amount of additional time required for 
these NRTI exonuclease events. Based on this definition of a toxicity index, Johnson et al 
(Johnson et al. 2001) also defined an ordered list of NRTI drug toxicity which was similar to our 
list and similar to the lists based on the specificity constants. An important use of any 
computational model is to raise questions for further experimental study. This simulation raises 
the following questions. Is strand termination defined by the dissociation of the polymerase 
after insertion of an activated NRTI? If not, what is the proper definition of strand termination? 
NRTI toxicity appears perplexingly specific to cell type 
(Antiretroviral_Guidelines_for_Adults_and_Adolescents_Panel 2006) and the mechanism for 
this tissue specificity is currently unclear. As natural nucleotide concentrations within the 
mitochondrion can differ greatly across cell types, we sought to observe how incorporation of 
NRTIs may differ in the presence of varying mitochondrial dNTP levels, which we broke down 
into three sample categories; high dNTP levels, medium dNTP levels and low dNTP levels (Table 
III.2). Although the IC50 values for strand termination measured in this simulation did depend on 
the concentrations of the natural nucleotide triphosphates, the relative ordering of the 
nucleoside analogs by IC50 was the same for all three dNTP conditions (Table III.3). The 
simulations made with low dNTP concentrations, representing post-mitotic tissues, did have 
lower IC50 values, consistent with a greater sensitivity of these tissues to damage by nucleoside 
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analog drugs. However, these results would not explain why some tissues are susceptible to 
toxicity from a particular analog. We have limited this simulation model to the activity of the 
mitochondrial DNA polymerase acting on the tri-phosphate form of the four natural 
deoxyribonucleosides and the tri-phosphate form of the drugs. Since the tissue dependence of 
the toxicity of the drugs was not reproduced in this model, this implies that the source of this 
tissue dependence lies outside the bounds of this particular model. This includes the possible 
interference of the various phosphate states of the drugs with the metabolism within the 
mitochondria that produces the natural deoxyribonucleoside tri-phosphates, potentially altering 
the relative levels of the four natural dNTPs. 
Although mitochondrial toxicity from NRTIs is common, the more severe forms of this 
toxicity are certainly not universal. Current research is revealing that the gene for polymerase γ 
is the site of a large number of mutations and polymorphisms that alter its enzyme kinetics and 
function (Graziewicz et al. 2007; Graziewicz et al. 2006; Horvath et al. 2006; Hudson and 
Chinnery 2006). The natural variability in this crucial gene may be an important source of the 
individual variation in the susceptibility of patients to this toxicity, and perhaps to the 
phenotypic variation which occurs. Although the interaction of nucleoside analogs with 
polymerase γ has been recognized for almost 15 years now (Martin et al. 1994), we still know 
surprisingly little about the levels of activated drugs within mitochondria (Lynx et al. 2006) or 
about the transport mechanism by which these drugs enter the mitochondrion (Kang and 
Samuels 2008; Lindhurst et al. 2006). 
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CHAPTER IV 
 
ENRICHING TARGETED SEQUENCING EXPERIMENTS FOR RARE DISEASE ALLELES4 
 
Introduction 
 
Genome-wide association studies (GWAS) are based on the premise that densely 
genotyped common alleles will have statistical power to detect causal associations with traits at 
nearby, ungenotyped common mutations through short-range linkage disequilibrium (LD). The 
basis for this strategy is the common disease common variant (CDCV) hypothesis (Reich and 
Lander 2001). This approach has been proven to be effective in many scenarios for mapping 
small genomic regions to traits (see the National Human Genome Research Institute Catalog of 
Published Genome-Wide Association Studies) (Manolio et al. 2008; McCarthy et al. 2008). 
However, the predominantly small effect sizes encountered thus far in investigations of most 
traits have provided no explanation for a large proportion of the trait variance attributable to 
heritable factors (Maher 2008; Manolio et al. 2009). Some effort to describe this phenomenon 
has suggested that hundreds or thousands of SNPs may each have a very subtle influence on the 
risk of some psychiatric traits (Purcell et al. 2009). These observations seem to support an 
adjustment of the CDCV model to allow for the possibility that rare alleles might also exert a 
major influence on common traits (Bodmer and Bonilla 2008; Pritchard 2001; Schork et al. 2009). 
This modification of CDCV, known as common disease rare variant (CDRV), postulates that 
                                                          
4 Edwards, T. L., Song, Z., and Li, C. (2011). Enriching targeted sequencing experiments for rare 
disease alleles. Bioinformatics 27(15), 2112-2118. Author contributions: Conceived and designed 
the experiments: TLE CL. Performed the experiments: ZS. Analyzed the data: ZS TLE. Contributed 
reagents/materials/analysis tools: TLE CL. Wrote the paper: TLE CL. Algorithm design: TLE CL 
Software: ZS. 
 95 
 
alleles with strong effects on traits are likely to be rare due to purifying selective pressure and 
recent time to coalescence due to the rapid expansion of human populations (Pritchard 2001). 
Additionally, it has been shown in simulations that multiple rare alleles with strong effects can 
stochastically aggregate onto the haplotypic background of a common allele and produce 
genome-wide significant association signals, a scenario termed synthetic association (Dickson et 
al. 2010). Further support for the CDRV hypothesis comes from observational studies where the 
average allele frequency of SNPs with predicted effects on proteins was smaller than the 
average allele frequency of intronic or synonymous variants (Cargill et al. 1999; Gorlov et al. 
2008; Wong et al. 2003). Estimates from human Mendelian traits, human–chimpanzee 
divergence data and human genetic variation suggested that ~53% of new missense mutations 
have mildly deleterious effects, and that up to 70% of low-frequency missense alleles are mildly 
deleterious (Kryukov et al. 2007). 
A rare trait allele may not be annotated in the databases of common variants 
maintained by the International HapMap Organization or dbSNP, thereby excluding the 
possibility of detecting that SNP through imputation and subsequent association analysis. The 
constellation of causal alleles may also be unique for each population of human subjects, where 
sensitive functional gene or regulatory regions are perturbed by independent sets of rare 
mutations that occurred after geographic or cultural barriers led to increased genetic distance 
(Tishkoff et al. 2009). Thus, the same associated allele from GWAS across multiple ethnic groups 
does not necessarily imply the same underlying architecture of causal alleles in LD. Furthermore, 
our simulations suggest that rare disease-causing variants may not be captured at all by the 
modest samples of each population isolate from the 1000 Genomes Project, regardless of the 
high error rates for rare genotype calls from that study due to low coverage. Resequencing is 
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then the best available means of discovering these rare SNPs in a GWAS sample and ultimately 
detecting the relationship between these alleles and traits. 
To successfully discover the mutations that determine trait susceptibility, detailed 
assays that directly capture all genetic variation in a region are required (Cirulli and Goldstein 
2010). This can be accomplished most efficiently using next-generation sequencing technology 
to resequence subjects for the implicated loci (Service 2006). While next-generation sequencing 
technologies have substantially decreased the financial cost of resequencing large genomic 
regions relative to Sanger sequencing technology, it is still not generally feasible to resequence 
all the subjects that were used to isolate a genomic region via GWAS. Thereby, some strategy is 
necessary for employing sequencing technology that is cost-effective. One possibility is to 
resequence a small number of cases and controls or persons with extreme trait values and 
evaluate the observed genetic variation for association with traits to screen rare variants prior 
to larger genotyping experiments; however, this approach will suffer from low statistical power 
at the screening step due to the infrequent exposure rate of rare alleles, and potentially suffer 
from inflated type I error rates (Li and Leal 2009) as a result of ascertainment bias in cases. An 
alternative approach is not to attempt to associate alleles from resequencing data with the trait, 
but to discover rare alleles by resequencing, and then assay these SNPs with conventional 
genotyping methods in the entire available pool of study subjects. The effectiveness of this 
approach will be limited by the power to capture rare alleles in the targeted loci, which is 
directly related to the selection of subjects for the resequencing experiment (Li and Leal 2009). 
For SNP discovery, targeted resequencing study designs can be tailored for efficient capture of 
rare disease alleles in small samples, by using the information available at nearby trait-
associated SNPs. 
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In this chapter, we present SampleSeq, an algorithm for enriching the yield of rare or 
uncommon disease alleles in a sample of unrelated study subjects by choosing subjects 
according to their observed associated alleles and trait information. When multiple regions are 
to be sequenced, SampleSeq selects subjects with a balanced representation of all the regions. 
SampleSeq can also estimate the sample size required to detect a hypothetical disease allele, 
and thus can optimize a resequencing study to preserve resources for subsequent genotyping or 
other investigations. 
 
Methods 
 
We first describe our method for selecting subjects for sequencing a single region. We 
then extend the method to sequencing multiple regions. Finally, we describe simulation 
strategies for evaluating our method. 
 
Sequencing a single region 
Let A be a disease-associated common SNP, with alleles A and a and allele frequencies 
pA and pa, respectively. Let D be the true disease SNP close to SNP A, with alleles D and d and 
allele frequencies pD and pd, respectively. SNP D may not have been genotyped in previous 
stages of the investigation, and the common SNP A serves as a proxy for SNP D. The assumption 
of a single disease SNP simplifies the derivation, but it does not appear to be necessary as will be 
shown in our simulation results. As our method seeks to calculate the expected count of disease 
variants for each subject by conditioning on his SNP A genotype and affection status, we assume 
genotypes at SNP A are available for all subjects, and further that resequencing will be 
performed at sufficient depth to accurately call rare genotypes in small sample sizes. Suppose 
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allele a is the ‘risk’ allele, in positive LD with allele d and is either the major or minor allele at 
SNP A, and allele d is the real disease variant. When d is a rare variant, it is reasonable to 
assume that it originated on the background of allele a and almost no recombination has since 
occurred between them; we describe the rationale for this assumption in section Discussion. 
Then pd<pa, and the four haplotype frequencies are pdA, pda=pd−pdA, pDa=pa−pd+pdA and 
pDA=pA−pdA. Since almost no recombination has occurred between the two loci, it is reasonable 
to assume pdA is much smaller than pd, otherwise the LD between the two loci would be too 
weak to make SNP A a good proxy and be identified in a GWAS. When pdA≈0 , we have pda≈pd, 
pDa≈pa−pd and pDA≈pA. This assumption is not required for the calculations below, although it is 
implemented in the current version of our software for ease of computation. Our simulations 
did not have this requirement either (see section Simulation strategy). Let Ga and Gd be the 
genotypes at the loci: Ga=0,1,2 for AA, Aa, aa and Gd=0,1,2 for DD, Dd, dd, respectively. We 
assume Hardy–Weinberg equilibrium (HWE) at the SNPs in the population. Let Y be the disease 
status, 1 for cases and 0 for controls. Let fi=P(Y=1|Gd=i) (i=0,1,2) be the penetrances for 
genotypes DD,Dd and dd, respectively, and K be the disease prevalence in the population. 
Our goal is to calculate the expected count of allele d, E(Gd|Ga,Y), given each subject's 
genotype at SNP A and affection status, and select subjects accordingly. To achieve this, we first 
calculate P(Gd=g|Ga,Y) for g=0,1,2. Note that  
( , , )
( | , )
( , )
d a
d a
a
P G G Y
P G G Y
P G Y
   
where the denominator is P(Ga,Y)=∑GdP(Gd,Ga,Y) and the numerator is 
P(Gd,Ga,Y)=P(Gd,Ga)P(Y|Gd,Ga)=P(Gd,Ga)P(Y|Gd). The genotype probabilityP(Gd,Ga) is a function of 
haplotype frequencies under HWE. The probabilityP(Y|Gd=i)=fi when Y=1, and 1−fi when Y=0. We 
now show how to obtain fi. Note that  
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where P(Ga=i|Y=1) is the case frequency for genotype Ga=i. Since  
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and can solve for f0, f1, f2 using these linear equations. 
In the above calculation, the case genotype frequencies P(Ga=i|Y=1) can be estimated 
from the data at hand. The haplotype frequencies depend on the allele frequencies at SNPs A 
and D. The SNP A allele frequencies pA and pa can be estimated as weighted averages of case 
and control allele frequencies; for example, 
, ,
ˆ ˆ ˆ(1 )A A case A controlp Kp K p   , where ,ˆA casep  and 
,
ˆ
A controlp  are the frequencies of allele A in the cases and controls, respectively. When the 
disease prevalence is very low, 
,
ˆ ˆ
A A controlp p . The investigator needs to specify pd, for which we 
will show that often a range is sufficient. We also need the information on disease prevalence K, 
which often is available from external sources and also can be specified as a range. 
Once we have calculated P(Gd|Ga,Y), the expected count of allele d can be easily 
calculated as ( | , ) ( | , ) ( 1| , ) 2 ( 2 | , )d a d a d a d a
g
E G G Y E G g G Y g P G G Y P G G Y      . 
If we focus on a single region, then the subjects can be ranked according to their 
expected count of allele d. The top ranked subjects can be selected for sequencing to ensure the 
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highest chance of detecting rare disease variants. We will discuss stopping criteria and sample 
size determination at the end of the next section. 
 
Sequencing multiple regions 
In practice, investigators may want to fine map multiple regions simultaneously. Our 
method can be extended for this scenario. We assume there are M regions to sequence and 
they are unlinked to each other. For subject i and region j (i=1,…,n and j=1,…,M), let Gijd and Gija 
be the genotypes at the real disease SNP and the reported associated common SNP, respectively. 
Because the regions are unlinked, the above calculations can be carried out separately for each 
region, with Eij=E(Gijd|Gija,Yi). One might want to rank the subjects according to the expected 
number of disease variants over all regions, 
1
M
i ik
k
E E

  and select top ranked subjects. 
However, as the regions can differ in key characteristics such as risk allele frequency and 
strength of disease association, the top ranked subjects may contribute unevenly to the regions. 
As a result, this selection strategy may lead to overrepresentation of one region and lack of 
representation for another. A more efficient procedure is to select the top ranked subjects one 
at a time, each time tallying the cumulative expected count of disease variants for each region, 
denoted by Cj for region j. Once a region j has reached Cj≥c, a prespecified target number of 
disease variants, we re-rank the remaining subjects based on 
: k
ikk C c
E
 , calculated by 
excluding the region, and continue to select top ranked subjects. This process is repeated every 
time a region reaches C≥c. 
We may stop the process when all regions have reached C≥c. The number of selected 
subjects is the sample size needed to have C≥c for all regions. If the number of selected subjects 
is fewer than planned, the resources could be preserved for subsequent follow-up. If the 
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investigator wants to select more subjects, he may either raise the target value c and redo the 
selection or continue selecting from the remaining subjects according to their Ei. Although this 
algorithm allows investigators to determine the sample size needed to reach C≥c for all regions, 
as the disease variant frequency pd that is used in calculation of Eik may be different than the 
real disease variant frequency, the target value c may be far from the true number of disease 
variants in the selected subjects, as will be seen in our simulation results. However, our 
simulations also showed that even when pd was misspecified, SampleSeq performed well 
compared to the alternative approaches we simulated. 
 
Missing and imputed genotypes 
In practice, missing genotypes exist due to various reasons. In SampleSeq, when 
genotype Gija is unavailable, Eij is calculated as a weighted average  
( | , ) ( | )j ijd ija i ija i
g
Ei E G G g Y P G g Y   , 
where P(Gija=g|Yi) is the estimated genotype frequency of g in cases or controls, depending on 
the value of Yi. Similarly, a missing genotype may be imputed from the haplotype distribution of 
the population and observed haplotypes in the study subjects. When genotype Gija is imputed, 
Eij can be calculated as a weighted average using the posterior probabilities of the imputed SNP 
as weights: 
( | , ) ( | )j ijd ija i ija F
g
Ei E G G g Y P G g G   , 
where GF denotes flanking marker genotypes. 
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Simulation strategy 
We simulated case–control data with one or multiple disease regions, each harboring 
one or multiple disease variants with additive effects on trait risk. For rare variants, additive 
effect is practically equivalent to dominant effect as there are mostly only two genotypes, DD 
and Dd. To simulate realistic sequence-level genetic data from human populations, we 
employed the coalescent simulation software cosi, with parameters developed to calibrate the 
LD profile of simulated data to the observed LD profile from human populations (Schaffner et al. 
2005). Additionally, we used the recombination map from the International HapMap Project to 
model the probability of recombination in specified genomic regions. We randomly chose five 
disease regions between 125 kb and 250 kb in length, and for each region, we used cosi to 
generate a pool of 25 000 haplotypes. It is possible that associations between rare variants and 
common proxies might extend over longer physical distances than 250 kb; however, these 
simulations were computationally intensive to perform on a large scale. We note that there is 
no size limitation for our method and software. 
We simulated three scenarios: (i) CDRV with one rare disease variant per region; (ii) 
synthetic association (Dickson et al. 2010) with 10 rare disease variants per region; and (iii) 
CDCV with one common disease variant per region. For the CDRV scenario, we simulated various 
settings of prevalence (K=0.01, 0.05, 0.1, 0.2) and disease variant minor allele frequencies (MAFs, 
range 0.0025–0.01, denoted as MAFmin and MAFmax), with odds ratios (ORs) in the range 2–6 
(denoted by ORmin and ORmax). The OR of a disease variant was determined according to its MAF 
through the following formula: 
min
min max min
max min
MAF -MAF
OR =OR +(1- )(OR -OR )
MAF -MAF
i
i . 
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For the synthetic association scenario, we simulated one level of prevalence (K=0.01), and 
placed 10 random rare disease alleles with MAF in the range 0.0025–0.01 in each of five 
independent genomic regions, with OR in the range 2–6. For the CDCV scenario, we simulated 
one prevalence (K=0.01) with OR in the range 1.1–1.5, and various disease allele frequencies 
(0.01, 0.05, 0.15, 0.25). 
For each combination of prevalence and ORs, a disease model was established with 
0 1 1 2 2
0 1 1 2 2
...
1 2 ...
( 1| , ,..., )
1
M M
M M
G G G
M G G G
e
P Y G G G
e
   
   
   
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 

, 
where (G1,G2,…,GM) is an individual's joint genotype at the M disease SNPs, and the coefficients 
βj were determined based on the prevalence and ORs. 
To simulate a control, a pair of haplotypes from each region was randomly drawn, and a 
random number in (0, 1) was drawn and compared to the penetrance from the disease model to 
determine if the subject is a control. To simulate cases, the probability of a having a multilocus 
genotype conditional on being a case was calculated for all possible genotypes from the M 
disease SNPs using the equation: 
1 2 1 2
1 2
( 1| , ,..., ) ( , ,..., )
( , ,..., | 1)
( 1)
M M
M
P Y G G G P G G G
P G G G Y
P Y

 

. 
A multilocus genotype across all disease SNPs was then randomly selected according to this 
conditional distribution, and haplotypes consistent with that genotype were randomly chosen 
from the haplotype pools simulated by cosi. 
For each scenario and each prevalence level, we generated 100 replicates of 2000 cases 
and 2000 controls. We then identified a proxy marker (i.e. SNP A) for each region with 
1.1<OR<1.5 and 0.2<MAF<0.4. These criteria were chosen to emulate typical associations from 
GWAS, and to allow the association between disease and SNP A to arise naturally as a result of 
LD between SNPs A and D, which were calibrated to resemble the LD profile of European-
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ancestry populations. On average the D′  between SNPs A and D was 0.88, with a range of 0.8–
1 across all CDRV simulations; in other words, pdA could be non-zero in our simulated data. For 
the synthetic association scenario, we did not impose any restrictions on the relationship 
between SNP A and the real trait SNPs, so that some of the risk alleles might fall on the low-risk 
background of SNP A. 
In addition to SampleSeq, we also considered other approaches to selecting the same 
number of subjects, including (i) random selection of controls; (ii) random selection of cases; (iii) 
selection of subjects ranked by dosage of proxy marker risk alleles; and (iv) selection of cases 
ranked by dosage of proxy marker risk alleles. For all these approaches, we counted the total 
number of disease variants per region that were captured in the selected subjects for sample 
sizes from 50 to 500 in increments of 50 subjects. For the simulated data, we also counted the 
maximum number of disease variants that can be carried for each given sample size. 
 
Results 
 
For all simulated scenarios, we calculated the number of rare disease alleles captured. 
For the CDRV scenarios, where the allele frequency of the trait locus is well-estimated, the 
SampleSeq algorithm consistently provided higher yields of captured disease alleles than the 
other methods for all sample size thresholds (Figures IV.1-IV.4, Tables IV.1-IV.4). These results 
demonstrate the benefit in efficiency that SampleSeq can provide over the other alternatives. 
The yield of rare disease alleles provided by SampleSeq is a little higher over all sample sizes 
than by ranking case subjects by their burden of risk alleles. The other three alternative 
approaches were less efficient than SampleSeq by large percentages. Among the four 
alternative approaches, those relying on the burden of the proxy marker risk alleles were better 
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than those not using this information, and those focusing on cases were better than those not 
limited to cases. These results are as expected as both the burden of marker risk alleles and 
disease status are informative for the likelihood of carrying real disease variants. As SampleSeq 
is able to appropriately combine these two pieces of information, it often results in a more 
efficient selection of subjects than the alternatives. When only one piece of information was 
used, using the burden of proxy marker alleles performed similarly to the random selection of 
cases, with the former being slightly better when the prevalence was K=0.01 and 0.05 and the 
latter slightly better when K=0.1 and 0.2. We also observed that as trait prevalence increased, 
the total number of captured rare disease alleles decreased (Tables IV.1-IV.4). This was due to 
the fact that the same number of disease variants with similar effects would account for a high 
fraction of heritability for a low prevalence disease than for a high prevalence disease, which 
resulted in a higher likelihood for a patient of a low prevalence disease to carry a disease variant 
in the targeted regions in our simulations. We also simulated a single region of size 1 Mb with a 
single disease variant; the results followed the same pattern (data not shown). 
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Figure IV.1. (CDRV) Percent change of disease alleles captured compared to SampleSeq using 
alternative methods, K=0.01, assuming a disease allele frequency of 0.01 in calculation of Eik. 
 
Table IV.1 (CDRV) Ratio of average counts of disease alleles captured to the average maximum 
possible disease alleles (percent change relative to SampleSeq), K=0.01, assuming pd=0.01 in 
calculation of Eik 
 
Size SampleSeq Case Burden Proxy Burden Random Cases Random Controls 
50 0.31 0.31(-0.61) 0.19(-38.20) 0.15(-51.43) 0.04(-86.93) 
100 0.33 0.33(0.52) 0.21(-35.34) 0.17(-47.78) 0.05(-85.95) 
150 0.37 0.37(-0.11) 0.25(-32.41) 0.20(-45.43) 0.05(-85.32) 
200 0.40 0.40(-1.33) 0.27(-32.96) 0.22(-43.67) 0.06(-84.84) 
250 0.41 0.41(-1.98) 0.27(-34.40) 0.24(-42.16) 0.06(-84.44) 
300 0.42 0.41(-2.56) 0.27(-34.99) 0.25(-40.86) 0.07(-84.09) 
350 0.43 0.41(-2.93) 0.28(-34.99) 0.26(-39.69) 0.07(-83.77) 
400 0.43 0.41(-3.46) 0.28(-34.77) 0.26(-38.53) 0.07(-83.46) 
450 0.43 0.41(-3.65) 0.28(-34.25) 0.27(-37.44) 0.07(-83.16) 
500 0.43 0.41(-4.06) 0.28(-34.03) 0.27(-36.68) 0.07(-82.96) 
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Figure IV.2. (CDRV) Percent change of disease alleles captured compared to SampleSeq using 
alternative methods, K=0.05, assuming a disease allele frequency of 0.01 in calculation of Eik. 
 
Table IV.2 (CDRV) Ratio of average counts of disease alleles captured to the average maximum 
possible disease alleles (percent change relative to SampleSeq), K=0.05, assuming pd=0.01 in 
calculation of Eik 
 
Size SampleSeq Case Burden Proxy Burden Random Cases Random Controls 
50 0.28 0.27(-2.70) 0.17(-41.18) 0.13(-53.60) 0.04(-87.09) 
100 0.34 0.33(-3.35) 0.22(-34.89) 0.17(-49.94) 0.05(-86.07) 
150 0.37 0.35(-4.96) 0.23(-36.96) 0.19(-48.25) 0.05(-85.60) 
200 0.38 0.36(-4.60) 0.24(-37.13) 0.20(-45.65) 0.06(-84.87) 
250 0.38 0.36(-3.90) 0.24(-37.21) 0.21(-43.84) 0.06(-84.37) 
300 0.38 0.36(-4.06) 0.24(-35.75) 0.22(-42.16) 0.06(-83.90) 
350 0.38 0.36(-4.71) 0.25(-34.44) 0.22(-41.07) 0.06(-83.60) 
400 0.38 0.36(-4.44) 0.25(-34.11) 0.23(-39.82) 0.06(-83.25) 
450 0.38 0.36(-5.33) 0.25(-34.21) 0.23(-38.95) 0.06(-83.01) 
500 0.37 0.35(-5.03) 0.24(-34.27) 0.23(-37.72) 0.06(-82.67) 
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Figure IV.3. (CDRV) Percent change of disease alleles captured compared to SampleSeq using 
alternative methods, K=0.1, assuming a disease allele frequency of 0.01 in calculation of Eik. 
 
Table IV.3 (CDRV) Ratio of average counts of disease alleles captured to the average maximum 
possible disease alleles (percent change relative to SampleSeq), K=0.1, assuming pd=0.01 in 
calculation of Eik 
 
Size SampleSeq Case Burden Proxy Burden Random Cases Random Controls 
50 0.24 0.24(-0.41) 0.14(-42.71) 0.13(-43.79) 0.03(-86.22) 
100 0.27 0.26(-0.83) 0.16(-41.74) 0.16(-41.02) 0.04(-85.54) 
150 0.27 0.27(-2.04) 0.16(-39.88) 0.17(-38.98) 0.04(-85.04) 
200 0.28 0.27(-1.68) 0.16(-40.30) 0.17(-37.46) 0.04(-84.67) 
250 0.28 0.27(-2.33) 0.16(-40.49) 0.18(-36.29) 0.04(-84.38) 
300 0.28 0.27(-2.76) 0.16(-41.03) 0.18(-35.44) 0.04(-84.17) 
350 0.28 0.27(-3.59) 0.16(-40.24) 0.18(-34.51) 0.04(-83.94) 
400 0.27 0.26(-3.53) 0.16(-39.47) 0.18(-33.18) 0.04(-83.62) 
450 0.27 0.26(-4.08) 0.17(-38.85) 0.18(-32.41) 0.05(-83.43) 
500 0.29 0.28(-3.64) 0.18(-37.29) 0.20(-31.05) 0.05(-83.10) 
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Figure IV.4. (CDRV) Percent change of disease alleles captured compared to SampleSeq using 
alternative methods, K=0.2, assuming a disease allele frequency of 0.01 in calculation of Eik. 
 
Table IV.4 (CDRV) Ratio of average counts of disease alleles captured to the average maximum 
possible disease alleles (percent change relative to SampleSeq), K=0.2, assuming pd=0.01 in 
calculation of Eik 
 
Size SampleSeq Case Burden Proxy Burden Random Cases Random Controls 
50 0.20 0.20(3.01) 0.11(-43.57) 0.13(-35.88) 0.03(-83.38) 
100 0.22 0.22(0.76) 0.13(-43.18) 0.15(-35.03) 0.04(-83.16) 
150 0.23 0.23(-0.81) 0.14(-40.73) 0.15(-33.51) 0.04(-82.76) 
200 0.23 0.23(-0.16) 0.14(-40.10) 0.16(-31.34) 0.04(-82.20) 
250 0.23 0.23(-0.92) 0.14(-38.93) 0.16(-30.15) 0.04(-81.89) 
300 0.23 0.22(-2.06) 0.14(-39.29) 0.16(-29.22) 0.04(-81.65) 
350 0.23 0.22(-2.56) 0.14(-39.07) 0.16(-28.40) 0.04(-81.44) 
400 0.23 0.22(-2.53) 0.14(-38.59) 0.16(-27.55) 0.04(-81.22) 
450 0.24 0.24(-2.09) 0.15(-38.03) 0.18(-26.61) 0.05(-80.98) 
500 0.27 0.26(-2.01) 0.17(-37.42) 0.20(-25.69) 0.05(-80.74) 
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We note that SampleSeq is sensitive to very low values of pd as the algorithm is involved 
with solving linear equations, for which the solutions will be highly variable due to nearly 
singular matrices at very small values of pd Our experience is that pd should be at least
20
2( )case controln n
. For example, to select subjects from a pool of 2000case controln n   subjects, 
setting pd =0.005 is good but the performance will become less optimal for pd <0.005. This 
limitation is computational. Our simulations showed that assuming pd =0.01 was relatively 
robust to misspecification of the true frequency of d within the range we simulated, and 
performed well over all scenarios (data not shown). 
When we simulated the synthetic association (SA) scenario (Figure IV.5, Table IV.5), we 
observed similar patterns as for the CDRV scenario, although all methods captured a higher 
proportion of the maximum number of possible disease alleles than the CDRV scenario. 
SampleSeq captured an average of 75% of the maximum possible disease alleles over all sample 
sizes. In our simulated scenario, the random selection of cases performed much better than 
using the burden of proxy marker alleles. This is most likely due to the large number of disease 
alleles to be found among the cases on both allelic backgrounds of SNP A compared to the 
number of causal alleles in controls. 
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Figure IV.5. (SA) Percent change of disease alleles captured compared to SampleSeq using 
alternative methods, K=0.01, assuming a disease allele frequency of 0.01 in calculation of Eik. 
 
Table IV.5 (SA) Ratio of average counts of disease alleles captured to the average maximum 
possible disease alleles (percent change relative to SampleSeq), K=0.01, assuming pd=0.01 in 
calculation of Eik 
 
Size SampleSeq Case Burden Proxy Burden Random Cases Random Controls 
50 0.66 0.66(-0.11) 0.54(-18.58) 0.63(-4.95) 0.14(-78.65) 
100 0.69 0.69(-0.08) 0.54(-21.58) 0.65(-4.58) 0.15(-78.57) 
150 0.72 0.72(-0.18) 0.58(-19.79) 0.69(-4.30) 0.15(-78.51) 
200 0.74 0.74(-0.33) 0.59(-20.40) 0.71(-4.08) 0.16(-78.46) 
250 0.76 0.75(-0.40) 0.58(-22.80) 0.73(-3.88) 0.16(-78.41) 
300 0.77 0.76(-0.28) 0.57(-25.03) 0.74(-3.69) 0.17(-78.37) 
350 0.77 0.77(-0.31) 0.58(-25.22) 0.75(-3.52) 0.17(-78.33) 
400 0.78 0.78(-0.26) 0.59(-24.47) 0.76(-3.32) 0.17(-78.29) 
450 0.80 0.80(-0.21) 0.61(-23.69) 0.78(-3.15) 0.17(-78.25) 
500 0.82 0.81(-0.32) 0.62(-23.58) 0.79(-3.08) 0.17(-78.23) 
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For the CDCV scenario, we compared SampleSeq to the alternative methods when the 
disease alleles were not rare, but we assumed that pd =0.01 in our calculations. In these 
experiments, SampleSeq was slightly more efficient than the burden of proxy alleles in cases, 
and was slightly less efficient than the burden of proxy risk alleles regardless of case status 
(Figure IV.6, Table IV.6). This was also true when pd was close to the true frequency of d. Also 
notable was the generally smaller magnitude of differences among the other three methods. 
These results are due to the presence of many disease alleles in both cases and controls, as a 
result of the subtle effect sizes simulated in this scenario. 
We further summarized the results of these simulations by comparing the average 
expected counts of disease alleles as determined by SampleSeq, E(d), to the average count of 
observed disease alleles, d, for each scenario and sample size (Table IV.7). As the calculation of 
Eik is based on a hypothetical disease variant frequency (pd=0.01 in our calculations), E(d) may 
not match the true number of disease alleles. For the CDRV scenarios, where the frequency of d 
was between 0.0025 and 0.01, the ratio of the average expected to observed alleles across 
sample sizes were 1.7 for K=0.01, 2.0 for K=0.05, 2.9 for K=0.1, and 2.7 for K=0.2. When the 
allele frequency of d was constrained to fall within the range 0.009–0.011, and pd was set to 
0.01, the ratio of E(d) to d was 1.3 for K=0.01. However, for the SA scenario, the ratio of average 
E(d) to d was 0.41, although this value is counting the observation of all disease alleles in a 
region, where there were 10 disease alleles in the simulation per region. Also for the CDCV 
scenario, the ratio of average E(d) to d was 0.27, demonstrating that our method is based on 
finding rare disease alleles, and that if the disease alleles are common, they will occur much 
more often than expected by SampleSeq assuming a rare pd. 
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Figure IV.6. (CDCV) Percent change of disease alleles captured compared to SampleSeq using 
alternative methods, K=0.01, assuming a disease allele frequency of 0.01 in calculation of Eik. 
 
Table IV.6 (CDCV) Ratio of average counts of disease alleles captured to the average maximum 
possible disease alleles (percent change relative to SampleSeq), K=0.01, assuming pd=0.01 in 
calculation of Eik 
 
Size SampleSeq Case Burden Proxy Burden Random Cases Random Controls 
50 0.9 0.90(-0.13) 0.91(1.22) 0.48(-46.88) 0.40(-55.27) 
100 0.91 0.92(0.26) 0.93(1.82) 0.51(-43.86) 0.43(-52.72) 
150 0.91 0.91(-0.18) 0.94(2.45) 0.53(-41.74) 0.45(-50.94) 
200 0.91 0.90(-0.92) 0.93(2.13) 0.54(-40.22) 0.46(-49.66) 
250 0.9 0.89(-1.35) 0.92(1.57) 0.55(-39.06) 0.46(-48.68) 
300 0.91 0.90(-1.66) 0.92(1.21) 0.57(-38.06) 0.48(-47.84) 
350 0.92 0.90(-1.95) 0.93(1.28) 0.58(-37.04) 0.49(-46.98) 
400 0.93 0.91(-2.48) 0.94(1.41) 0.59(-36.13) 0.50(-46.21) 
450 0.93 0.90(-2.90) 0.94(1.62) 0.60(-35.17) 0.51(-45.40) 
500 0.93 0.90(-3.15) 0.95(1.92) 0.61(-34.18) 0.51(-44.57) 
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Table IV.7. The average cumulative expected count of disease alleles, denoted E(d), and the 
actual observed average count of disease alleles, denoted d, for each scenario in Figures IV.1–
IV.6, denoted IV.1–IV.6, for each of 10 sample sizes. 
 
Size 
CDRV 
IV.1 E(d) IV.1 d IV.2 E(d) IV.2 d IV.3 E(d) IV.3 d IV.4 E(d) IV.4 d 
50 60.61 33.01 57.77 27.37 54.19 17.20 41.11 13.29 
100 112.43 61.40 106.16 50.73 100.19 32.44 76.66 26.24 
150 159.77 88.14 150.05 73.62 142.48 47.04 109.77 38.54 
200 203.92 113.85 190.93 93.46 182.28 61.19 140.98 49.65 
250 245.86 138.59 229.21 113.05 219.95 75.08 170.25 61.00 
300 286.01 162.67 266.24 131.73 256.05 88.91 197.91 72.24 
350 323.93 186.10 302.01 150.83 290.30 102.26 225.60 83.32 
400 360.35 208.67 335.85 168.82 322.98 114.54 252.02 94.10 
450 394.54 230.64 376.42 187.19 353.79 127.40 276.51 104.51 
500 429.20 253.22 398.36 203.89 385.89 138.76 300.98 114.68 
 
Size 
SA CDCV 
IV.5 E(d) IV.5 d IV.6 E(d) IV.6 d 
50 126.25 250.83 91.49 326.19 
100 236.61 499.71 171.66 617.27 
150 339.02 747.42 249.07 892.26 
200 433.72 994.22 318.45 1159.36 
250 523.99 1240.19 385.29 1421.55 
300 611.43 1485.35 449.50 1678.27 
350 696.42 1729.79 509.24 1926.32 
400 779.41 1972.88 569.92 2170.27 
450 859.65 2215.47 634.62 2405.16 
500 936.72 2459.95 676.23 2632.34 
 
 
Although Eik changes as the hypothetical disease variant frequency changes, using these 
estimates to rank subjects when an incorrect allele frequency is used in the calculation is still an 
effective means of selecting subjects. To demonstrate this, we calculated E(d) under pd =0.1, 
0.01 and 0.001, using the simulation parameters from the experiment in Figure IV.1, and present 
their correlation coefficients in Table IV.8. While the magnitude of the value of E(d) is 
proportional to the assumed value of pd, the ranking of subjects is similar even when pd is 
misspecified. 
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Table IV.8. Correlation coefficient between E(d) from three settings of pd. 
 
 pd=0.1 pd=0.01 pd=0.001 
pd=0.1 - 0.908 0.841 
pd=0.01 0.938 - 0.988 
pd=0.001 0.928 0.999 - 
Five regions, one rare disease variant per region, K=0.01. Correlations for cases are in the upper 
triangle and those for controls are in the lower triangle. 
 
 
Discussion 
 
Targeted resequencing using next-generation sequencing technology allows 
investigators to fine map regions identified in GWAS to localize true variants. Since it is generally 
not feasible for an investigator to sequence everybody in a large GWAS, questions arise as to the 
optimal design of follow-up studies aimed at identifying novel, particularly rare, variants that 
may explain the GWAS signals: the optimal balance between numbers of subjects, depth of 
sequencing and sizes of regions; follow-up by further sequencing of selected variants or 
imputation; whether to use DNA pooling or family-based designs; choice of specific subjects for 
sequencing, etc. (D.Thomas and F.Yang, personal communication). We developed SampleSeq to 
address the last issue. 
We have conducted a simulation study of several scenarios that have been postulated 
to represent the genetic architecture of common complex traits in human populations. We 
explored individual rare variants with strong effects, the synthetic association scenario with 
multiple rare variants per region and the CDCV model to evaluate our approach for capturing 
causal alleles. We demonstrated that SampleSeq can estimate the count of rare causal alleles in 
a sample of subjects from a case–control study, estimate the sample size required to capture a 
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specified number of alleles in each region of interest and select subjects to optimize and balance 
the capture of alleles across an arbitrary number of regions. 
When designing a next-generation resequencing study, a compromise must be struck 
between read depth and sample size. Regardless of the balance between these parameters, the 
allele frequency in the sample will be the primary determinant of whether genotypes are called 
accurately. By increasing the frequency of a disease allele in a sample of subjects, the accuracy 
of genotype calls and the chance that any resequencing study design will detect the presence of 
that allele will be improved. To increase the chance of detecting disease variants in a targeted 
resequencing study, an intuitive strategy is to select cases according to the dosage of risk alleles 
at the reported associated SNP (Thomas et al. 2009). Our results showed that this is indeed a 
good strategy compared to random selection of cases or controls. However, because of 
incomplete penetrance, a control subject homozygous for risk alleles at several loci may have a 
higher chance of carrying a real disease variant than a case subject who is heterozygous for 
some of those risk alleles. SampleSeq allows us to quantify their probabilities of carrying real 
disease variants and then select subjects accordingly. 
We observe that compared to random controls, samples of random cases have much 
better performance for discovering rare disease alleles, which is consistent with previous studies 
(Li and Leal 2009). Some investigators may choose to evaluate a set of controls in order to 
perform screening with association tests before proceeding to large-scale variant-based 
genotyping. This is likely the most effective strategy when resources are abundant for 
resequencing studies and sample sizes are large. However, when sample sizes are small, we 
would expect most of the ability to detect the presence of rare disease alleles in the population 
to come from the cases. As the majority of samples selected by SampleSeq will be cases, in 
some situations, it may be reasonable to resequence some controls to augment the SampleSeq 
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selection. The control subjects could then be used to screen variants for frequency differences 
and prioritize for genotyping. This comparison would be biased due to the frequency 
enrichment achieved by SampleSeq, but could help discern the SNPs that should be tested for 
association with the trait with unbiased approaches, such as genotyping in the full cohort. 
However, reallocating resources to sequence additional controls would also lower the chance of 
seeing real disease variants in the cases. If the number of subjects that can be resequenced is 
small, we advocate also using the sequence context and putative biological impact of variants to 
prioritize SNPs for genotyping, as there will not be a large amount of statistical information for 
comparing rare variant frequencies in small samples. 
Some recent research has shown that association testing from sequence data may 
provide slightly more statistical power than variant-based genotyping on a per-subject basis (Liu 
and Leal 2010) using two recently developed tests of association (Li and Leal 2009; Madsen and 
Browning 2009). However, we note that due to the large difference in the cost of resequencing 
to the cost of variant-based genotyping, on a per-unit of resources basis, many more subjects 
could be genotyped with variant-based methods than could be resequenced. Thereby, the 
statistical power to detect an association might be considerably better in a large sample of 
variant-based genotypes than in a small sample of sequence-based genotypes, utilizing the same 
resources. The goal of this work is to optimize the resources expended for resequencing studies, 
preserving DNA samples and financial assets for subsequent steps in investigations. 
The key element of the model that provides SampleSeq with a performance advantage 
over counting common risk alleles is the assumption of rare ancestral recombination between 
SNPs A and D. We assumed that disease variant d originated on the ‘risk’ allele a background, 
which resulted in three haplotypes, AD, aD and ad. To break up the LD between the SNPs 
through recombination, the recombination event needs to occur in the double heterogyzotes, 
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for which the frequency is quite low as d is rare. Moreover, if the two SNPs are close enough to 
have very low recombination fraction between them, then the chance of breaking up the LD 
between the SNPs will be small. This is supported by our simulation data; the recombinant 
haplotype frequency averaged 3.7×10−4 across all our CDRV haplotype pools, suggesting pdA≈0 
is a reasonable assumption. It is implemented in our software for the ease of computation. In 
simulations where this assumption was badly violated, such as the CDCV scenario, the 
performance of SampleSeq was still competitive with the burden of risk alleles in cases. 
We also noted that as the prevalence in our simulations increased, but the ORs of rare 
disease variants was held constant, the proportion of cases not carrying any risk alleles at any of 
the target disease loci increased. This observation is a result of our simulation strategy, but it is 
perhaps worthy of note that high-prevalence traits may require many more rare risk alleles than 
low-prevalence traits for the CDRV model to account for most of the trait heritability for a highly 
heritable common trait. Thereby, if there are not a large number of associated regions identified 
for a high-prevalence trait, it is possible that the yield of rare disease alleles from a resequencing 
study of that trait may be small, as additional trait variation may be due to untargeted regions 
or environmental influences. 
As next-generation sequencing technology matures, the need for targeted resequencing 
of association study-implicated regions for fine-mapping of mutations may eventually expire. 
However, for researchers who do not have access to tremendous financial resources or the most 
current sequencing platforms, targeted resequencing followed by variant-based genotyping of 
candidate SNPs is likely the most direct and cost-efficient means of fine-mapping of causal rare 
mutations. Additionally, this approach capitalizes on previous discoveries, rather than pursuing 
agnostic resequencing of whole genomes or exomes. While agnostic approaches to discovery 
will and should be taken, we believe there is also a role for hypothesis-based resequencing 
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studies in human genetic epidemiology in the foreseeable future. The SampleSeq software is 
available at http://biostat.mc.vanderbilt.edu/SampleSeq 
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CHAPTER V 
 
EFFICIENT DETECTION OF TUMOR SOMATIC MUTATIONS USING NEXT-GENERATION 
SEQUENCING DATA5 
 
Introduction 
 
Cancer is a class of complex genetic diseases that are responsible for one in eight deaths 
worldwide (Blecher et al. 2008). It is characterized by uncontrolled proliferation of malignant 
cells that can intrude into surrounding tissues and metastasize to distant organs because of 
somatically accumulated mutations and epigenetic changes (Esteller 2007; Stratton et al. 2009). 
Cancer somatic mutations encompass distinct classes of DNA and chromosomal changes, 
including base substitutions, insertions and deletions (indels), copy number variants (CNVs), and 
inter- and intra-chromosomal rearrangements. Cells in some cancer types may also have 
obtained exogenous DNA from viruses (Talbot and Crawford 2004). 
Somatic mutations are distributed across the genome (Stratton 2011). Only a small 
subset of mutations has been implicated in oncogenesis. The type and rate of somatic mutations 
may vary by cell type and can be influenced by mutagenesis exposures endogenously and 
exogenously. As a result, different cancer types have different mutation profiles. Some cancer 
types display very disordered genomes while others have few genomic aberrations (Stratton 
2011). It is important to understand the overall mutation profiles for different cancer types and 
                                                          
5 Song, Z., Long, J. He, J., Shi, J., Shu, X., Cai, Q., Zheng. W., and Li, C. (2011). Efficient Detection 
of Tumor Somatic Mutations using Next-Generation Sequencing Data. (submitted). Author 
contributions: Conceived and designed the experiments: ZS CL. Performed the experiments: ZS. 
Analyzed the data: ZS CL. Contributed reagents/materials/analysis tools: JL JH JS XS QC WZ. 
Wrote the paper: ZS CL. Algorithm design: ZS CL Software: ZS. 
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in different patients as they may influence choice of treatment as well as a patient’s reaction to 
a treatment. In early cytogenetic studies of cancer, most mutations found were chromosomal 
translocations and CNVs. Thanks to the development of next-generation sequencing (NGS) 
technologies, we are on the edge of creating a complete catalogue of mutations for each cancer 
type (Singer 2011) by screening the cancer genome at the finest resolution. 
The NGS technologies have recently been used to study somatic mutations in melanoma 
(Pleasance et al. 2010), lung cancer (Lee et al. 2010; Pleasance et al. 2010), colorectal cancer 
(Timmermann et al. 2010), renal carcinoma (Varela et al. 2011), breast cancer (Ding et al. 2010; 
Shah et al. 2009), acute myeloid leukemia (Mardis et al. 2009), mesothelioma (Bueno et al. 
2010), and prostate cancer (Berger et al. 2011). Although the methods for mutation detection 
differ in details, these studies all relied on comparing SNP calls across samples in their primary 
mutation screening. 
Efficient analysis tools for NGS data have been developed. The Genome Analysis Toolkit 
(GATK) (McKenna et al. 2010), for example, is a suite of tools for sequence data processing and 
genotype calling, and provides a rich software library for developing additional analysis tools. 
The GATK Unified Genotyper and some other SNP calling programs do an excellent job of calling 
genotypes for homogeneous samples such as blood and normal tissues. In cancer genomes, 
however, cells taken from a tumor tissue may include non-cancer cells. In addition, cancer cells 
in a tumor sample can be heterogeneous with respect to somatic mutations. As a result, a 
somatic mutation may exist only in a fraction of cells in a tumor sample, lowering the likelihood 
of detecting it through genotype calls. The resulting allelic imbalance may also lead to tumor 
genotype calls being flagged as problematic and excluded from analysis. However, existing tools 
for detecting somatic mutations mostly rely on genotype calls for tumor samples. For example, 
VarScan (Koboldt et al. 2009) screens data for mutation sites by comparing genotype calls 
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between normal and tumor samples, and SomaticSniper (Mardis et al. 2009) uses a genotype 
likelihood model (Li et al. 2009) to calculate the probability that the tumor and normal 
genotypes are diﬀerent. VarScan (Koboldt et al. 2009) does use allele frequency information to 
evaluate significance, but only for sites that show genotype difference between normal and 
tumor samples. 
We develop and implement novel algorithms for detecting two major types of somatic 
mutations, base substitution and loss of heterozygosity (LOH), by directly examining the 
sequence reads of tumor samples. We applied our methods, named Somatic Mutation Gleaner 
(SMUG), to whole exome sequencing data of eight breast cancer tumors and their matched 
blood samples, and detected somatic mutations that are missed by comparison of genotype 
calls between normal and tumor samples. 
 
Method 
 
We consider patients of the same type of cancer, each with NGS data available for a 
tumor sample and a normal sample (e.g., from blood or normal tissue). In SMUG, we first 
process each normal-tumor sample pair and then aggregate information across patients. Before 
applying our methods, general filtering criteria can be employed such as setting thresholds for 
base, mapping, and genotype quality scores. The depth for a site is defined as the number of 
remaining bases at the site after filtering. 
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Detection of Base Substitutions 
We seek to identify sites that are homozygous in the normal sample but have mutant 
alleles in the tumor sample. For each patient, we first walk through the tumor sequence data to 
look for sites with more than one type of nucleotide bases, and then check normal sample 
genotypes and keep the sites that are homozygous in the normal sample. As base substitutions 
can appear as an artifact during sample preparation (e.g., PCR error), sequencing (e.g., reading 
error), and data processing (e.g., alignment error), one may want to ignore sites with very few 
copies or very low fraction of “mutant” alleles; this will reduce noise as well as the amount of 
computation down the road. To obtain genotypes in the normal sample, forced calling may be 
necessary as SNP callers often do not output results for sites deemed monomorphic. 
For each selected site j, the fraction of mutant alleles could be estimated as xj/nj, where 
nj is the depth at the site and xj is the number of bases at the site that are different from the 
allele in the normal sample homozygous genotype. Both nj and xj are counts of bases after 
filtering. However, this ratio can have very different accuracy depending on the denominator; 
for example, a site with x = 30 and n = 200 may be more likely to carry a real somatic mutation 
than a site with x = 3 and n = 20 although they have the same fraction of mutant alleles. This 
issue can be addressed by employing an empirical Bayes (EB) approach, in which the mutant 
allele count is assumed to follow a binomial distribution, xj ~ Bin(nj, θj), where θj is the true 
fraction of mutant alleles and follows a prior distribution Beta(α, β). The posterior distribution 
for θj is Beta(xj + α, nj – xj + β) and the EB-estimate of the fraction of mutant alleles is the 
posterior mean rj = (xj + α)/(nj + α + β). The adjustment will be small for sites with high depth and 
relatively high for sites with low depth. As a result, the EB-estimate for a site with x = 30 and n = 
200 is often higher than that for a site with x = 3 and n = 20. The parameters α and β are 
obtained as the maximum likelihood estimates of the marginal likelihood function, 
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             ,where              
 
 
           
      
        
               and the 
product is over all the selected sites. The parameters α and β may vary across samples. 
A site identified by this approach may also carry “mutant” alleles in the normal sample 
even if it is called homozygous with a genotype quality score high enough to pass filtering. For 
example, for one of our patients (patient 8), position 28241838 on chromosome 20 was called 
homozygous C/C in blood but there were 55 copies of C and 7 copies of T after filtering by base, 
mapping, and genotype quality scores. The presence of multiple copies of T could be due to 
contamination, somatic mutation in the normal sample, sequencing error, or alignment error. 
We implement two filters for removing these sites. One is to apply the procedure described 
above to the normal sample and calculate the adjusted EB-estimate, r1j – r0j, where r1j and r0j are 
the EB-estimates for the tumor and normal samples, respectively, at site j. Another is to 
calculate the p-value for a t-statistic for each site,         
  
 
  
  
    
 
  
 
 
  
       , where x1 is the 
number of mutant alleles and n1 is the depth in the tumor sample, x0 and n0 are their 
counterparts for the normal sample, and p = (x1 + x0)/(n1 + n0). Our experience shows that the 
former works reasonably well while the latter can result in a misleadingly significant p-value for 
a site with high depth. 
A somatic mutation that occurs in multiple patients is likely to be relevant to tumor 
development or progression. We thus aggregate information across patients for each base 
substitution site. One measure is the total adjusted EB-estimates across the patients for whom 
the site was selected. Another measure is the p-value for the composite t-statistic      , 
where the sums are over the patients for whom the site was selected. These measures are 
analogous to the filters developed above. Our program can output sorted site- and gene-level 
summaries that are ready for further annotation using programs such as ANNOVAR (Wang et al. 
2010) or PolyPhen-2 (Adzhubei et al. 2010). 
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The results will be useful for selection of sites for further replication; for example, one 
may select sites that have adjusted EB-estimate ≥0.1 in ≥20% of the patients. Its false discovery 
rate (FDR), the fraction of false positives among the selected sites, can be estimated using a 
permutation procedure. Let Si be the set of qualifying sites (e.g., sites with adjusted EB-estimate 
≥0.1) for patient i. Let S be the union of Si over all patients. For each patient, we permute the 
sites in S; different patients are permuted independently. Then we apply the same selection 
criterion (e.g., qualifying sites in ≥20% of the patients) to the permuted data. This procedure is 
repeated multiple times, and the average number of selected sites across permutation 
replicates is an estimate of the number of false positive sites. The FDR can then be estimated as 
the number of false positive sites divided by the number of sites selected from the real data. 
 
Detection of Regions with Loss of Heterozygosity 
Ideally, LOH could be detected by looking for sites that are heterozygous in the normal 
sample and homozygous in the tumor sample. However, as for base substitutions, a tumor 
sample may be a mixture of tumor and non-tumor cells, and loss of an allele may not occur in all 
tumor cells. As a result, an LOH region may not manifest a total loss of an allele in the tumor 
sample, and thus may not be detectable through comparison of genotype calls between normal 
and tumor samples. A partial loss of an allele will result in a departure of allele counts from 
50:50. We develop a method to capture this information. 
For each patient, we focus on sites that are heterozygous in the normal sample. If there 
is no LOH, the tumor sample base counts should follow a binomial distribution with probability 
0.5 for each of the two alleles in the normal sample. A significant departure from this 
distribution is evidence of LOH, which can be quantified by defining an LOH score. We first 
compute a two-tailed p-value for the observed base counts and convert it to the Phred scale, Ph 
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= –10log(p), rounded to the nearest integer and capped at 99. The LOH score is defined as Ph – 
E(Ph | d), where E(Ph | d) is the expected Phred score under no LOH given depth d at the site. 
The expected Phred score depends on depth because the distribution of Phred scores varies as 
the depth changes. At depth d, there are d + 1 possible outcomes, x = 0, …, d, each having a 
probability px and a Phred score Phx under no LOH. The expected Phred score is the weighted 
average of these d + 1 scores, E(Ph | d) = p0Ph0 + … + pdPhd. 
The LOH score defined above allows us to identify potential LOH sites and regions. For 
example, one may apply a threshold sLOH to LOH scores and select sites with LOH score ≥ sLOH as 
potential LOH sites. An LOH region can then be defined as a contiguous region that contains ≥ 
nLOH LOH sites without interruption, that is, all normal sample heterozygous sites in the region 
have an LOH score ≥ sLOH. Higher values of the thresholds sLOH and nLOH result in more stringent 
criteria. The boundaries of an LOH region can be conservatively defined as the positions of its 
first and last LOH sites. We note that correct identification of an LOH region relies both on 
successful detection of normal sample heterozygous sites inside the region and on strong 
evidence of LOH in the tumor sample. When there is not enough information (e.g., due to low or 
no coverage), a normal sample heterozygous site may not be reliably called or the evidence of 
LOH may not be strong enough in the tumor sample. In this situation, an LOH region may not be 
detected due to a lack of supporting LOH sites, and multiple LOH regions may be identified as a 
single one due to a lack of sites breaking them apart. 
The overall evidence of LOH for a site can be obtained by adding individual LOH scores 
over patients heterozygous in the normal sample. This is justified by the fact that the p-values 
are independent across subjects and under no LOH, –2ln(p) ~   
 , a chi-squared distribution with 
two degrees of freedom. Since –10log(p) = –2ln(p)×(5/ln10) and the sum of k independent   
  
statistics follows    
 , the sum of Phred scores over k patients is expected to follow  
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  under no LOH. Thus the total LOH score can reflect the overall evidence of LOH. 
Our program can output sorted site- and gene-level LOH results that are ready for further 
annotation. 
 
Results from the Shanghai Breast Cancer Study 
 
We applied SMUG to whole exome sequencing data for blood and tumor samples from 
eight breast cancer patients. We evaluated the performance of SMUG and the approach of 
comparing genotype calls between normal and tumor samples; the latter will be referred to as 
CALL for brevity. The same filtering criteria were used in both SMUG and CALL: mapping quality 
score ≥ 20, base quality score ≥ 20, and genotype quality score ≥ 20. Similar patterns of results 
were observed when alternative threshold values were used. 
 
Samples and Exome Sequencing 
We selected eight breast cancer patients from the Shanghai Breast Cancer Study (SBCS) 
for whole exome sequencing of their blood and tumor DNA samples. The SBCS is a large-scale, 
population-based case-control study conducted in urban Shanghai (Gao et al. 2000). Seven 
patients have early-onset (28-32 years old) breast cancer and one has early-onset (39 years old) 
plus first-degree family history of breast cancer. Their breast cancer TNM (Tumor, Node, 
Metastasis) stages ranged from I to III (Table V.1). Tumor DNA was extracted from buffy coat 
and snap frozen breast cancer tissue using QIAmp DNA Kit (Qiagen, Valencia, CA) following the 
manufacturer’s protocols. 
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Table V.1. Data summary. Patient characteristics: age (years old), family history, tumor stage. Exome data: number of aligned reads, median 
depth in target regions, α and β. Blood genotypes: overall and heterozygous consistency rate with chip-based SNP calls. 
 
Patient Age 
Family 
history 
TNM 
stage 
Blood  Tumor 
#aligned 
(×106) 
Depth 
Consistency 
rate (%) 
Het 
consistency 
rate (%) 
α β  
#aligned 
(×106) 
Depth α β 
1 31 0 IIa 29.7 43 99.31 97.99 1.22 28.14  10.6 16 4.41 29.80 
2 28 0 III 34.6 46 99.71 99.35 1.56 33.19  16.9 25 7.66 67.98 
3 31 0 IIa 31.5 44 99.51 98.58 1.22 31.95  16.3 22 4.13 29.10 
4 32 0 IIb 36.9 48 99.51 98.72 1.28 27.50  10.1 15 6.04 44.20 
5 32 0 IIb 34.4 48 99.65 99.06 0.88 21.91  15.8 23 6.46 52.77 
6 30 0 I 35.7 49 99.58 98.85 0.75 20.48  18.7 27 5.88 49.39 
7 28 0 IIa 32.6 43 99.63 99.08 0.61 17.14  12.5 19 9.93 84.08 
8 39 1 III 31.3 43 99.22 98.75 1.06 28.94  16.4 23 3.59 25.19 
 
 
 129 
 
DNA enrichment was done using Agilent SureSelect Human All Exon kit v1 (Gnirke et al. 
2009), which was designed to target 165,637 genomic regions (37.8 million bases, or 1.22% of 
the human genome). The consensus coding sequence database has 27.8 million bases, 97.4% of 
which are covered by the assay’s target regions. Exome sequencing was conducted at the 
HudsonAlpha Institute for Biotechnology. The data were 72-base paired-end reads generated 
from Illumina GA IIx machines (Bentley et al. 2008). Each sample was run on a single lane of a 
flow cell. The median depth in target regions was on average 45x for the blood samples and 21x 
for the tumor samples (Table V.1). 
We shifted the Illumina base quality score to the Sanger scale and performed initial 
alignment to the NCBI human reference genome version 36 using BWA (Li and Durbin 2009). We 
then marked duplicates with Picard, carried out regional realignment and quality score 
recalibration using GATK (McKenna et al. 2010). We used GATK Unified Genotyper to call SNPs, 
which were then filtered to remove low quality calls. The blood and tumor samples were 
processed separately. The blood DNA samples were also genotyped using the Affymetrix 6.0 
chip in our previous genome-wide association study (Zheng et al. 2009). The chip-based and 
sequence-based SNP calls were compared for SNPs overlapping the two platforms, and the 
consistency rate was over 99% for all samples, suggesting very good quality of our sequencing 
data (Table V.1). 
 
Detection of Base Substitutions 
For the CALL approach, we obtained genotype calls for the blood and tumor samples. 
Sites that were heterozygous in a tumor sample but had no call in the corresponding blood 
sample were force-called in the blood sample to check if the blood genotype was homozygous 
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with high quality. For each patient, the CALL list of base substitutions consisted of sites that 
were homozygous in blood and heterozygous in tumor after filtering. 
For the SMUG approach, we screened each tumor sample for sites that had depth ≥5, at 
least 3 “mutant” alleles with fraction ≥ 0.05. These putative mutation sites were force-called in 
blood samples. For each patient, her SMUG list consisted of the putative mutation sites that 
were homozygous in blood after filtering. The parameters α and β were estimated (Table V.1) 
and the EB-estimates of the fraction of mutant alleles were calculated for all SMUG sites. 
In both approaches, we focused on mutation sites that were observed in at least two 
patients. For SMUG sites, we required ≥ 0.15 total adjusted EB-estimates over mutant carriers. 
SMUG identified 1,111 sites and CALL found 614. Among the 465 sites that were identified by 
both methods, 221 had the same number of supporting patients, 228 had more supporting 
patients in SMUG, and only 16 had more supporting patients in CALL. SMUG identified 646 
additional sites that were missed by CALL. There were also 149 sites that were identified by CALL 
but not by SMUG; all these sites had either very few mutant alleles or very low adjusted fraction 
of mutant alleles. 
Further examination of the base counts at the identified sites provided some insight on 
why SMUG performed differently from CALL. Table V.2 contains a few examples. (1) Position 
180434779 on chromosome 3 is a well-known non-synonymous breast cancer somatic mutation 
site in the PIK3CA gene. Both SMUG and CALL identified evidence of base substitution at this site 
in three patients. (2) In many situations, a low fraction of mutant alleles makes it difficult to 
detect mutations through genotype calls. For position 42589657 on chromosome 17 in the 
CDC27 gene, SMUG found evidence of non-synonymous somatic mutation in six patients while 
CALL could detect only three of them. This is because the tumor samples of the other three 
patients were called homozygous, although they each had multiple copies of the putative 
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mutant alleles. (3) A low fraction of mutant alleles can also result in allelic imbalance, which can 
lead to low quality genotype calls for tumor samples. One example is position 132744647 on 
chromosome 2, for which CALL had low quality genotype calls for two tumor samples. (4) We 
also examined the sites that were identified by CALL but missed by SMUG. These sites failed the 
criteria we used in SMUG due to either too few “mutant” alleles or very small adjusted EB-
estimate; one example is position 30958603 on chromosome 10 (Table V.2). 
We also compared the results from SMUG and CALL with the Catalogue of Somatic 
Mutations in Cancer (COSMIC) database (Bamford et al. 2004; Forbes et al. 2011) release v52, 
which contains 19,224 sites and 8,951 genes related to human cancers, among which 1,638 sites 
and 1,030 genes were related to breast cancer. SMUG identified two COSMIC sites and one in 
breast cancer, the PIK3CA site described above; CALL only identified the PIK3CA site. At the gene 
level, the SMUG sites were inside 67 COSMIC genes (10 breast cancer genes), while the CALL 
sites hit 41 COSMIC genes (7 breast cancer genes) (Table V.3). We further stratified the 
identified sites by their annotated functions. SMUG consistently hit more COSMIC genes than 
CALL did for non-synonymous, synonymous, and stop gain mutations. We did not find any stop 
loss substitution in COSMIC genes (Table V.3). 
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Table V.2. Examples of sites for comparison between SMUG and CALL for detection of base substitutions. Base counts and genotype calls for 
both blood and tumor samples for all identified base substitutions are shown. 
 
Chr Position Total EB-estimate Pt. 1 Pt. 2 Pt. 3 Pt. 4 Pt. 5 Pt. 6 Pt. 7 Pt. 8 
3 180434779 0.5932 86,0,0,0 112,0,0,0 80,0,0,0      
 (PIK3CA)  15,0,7,0 40,0,12,0 19,0,34,0      
 (nonsyn)  A/A;A/G A/A;A/G A/A;A/G      
17 42589657 0.6168   0,0,0,68 0,0,0,81 0,0,0,74 0,0,0,87 0,0,0,70 0,0,0,70 
 (CDC27)    0,0,7,40 0,0,4,16 0,0,7,45 0,0,3,53 0,0,3,39 0,0,5,55 
 (nonsyn)    T/T;T/G T/T;T/G T/T;T/G T/T;T/T T/T;T/T T/T;T/T 
2 132744647 0.5615  0,0,15,0  0,0,26,0 0,0,25,0 0,0,12,0 1,0,30,0 0,0,14,0 
    3,0,36,0  6,0,26,0 7,0,40,0 3,0,21,0 9,0,43,0 3,0,30,0 
    G/G;G/G  G/G;A/G G/G;A/G G/G;./. G/G;A/G G/G;./. 
10 30958603 - 0,1,0,67  1,5,0,56      
   0,2,0,11  0,6,0,22      
   T/T;C/T  T/T;C/T      
SNP1 0.4108   0,1,0,27 0,0,0,48 0,3,0,41    
     0,6,0,13 0,5,0,17 0,9,0,21    
     T/T;C/T T/T;C/T T/T;C/T    
SNP2 0.3252    0,0,30,1   0,0,28,2 0,0,34,1 
      0,0,8,3   0,0,21,3 0,0,15,6 
      G/G;G/T   G/G;./. G/G;G/T 
SNP3 0.2885    2,0,26,0 1,0,29,0    
      9,0,11,0 7,0,14,0    
      G/G;A/G G/G;A/G    
Under patients: Row 1: counts of bases A, C, G, T, respectively, in blood; Row 2: base counts in tumor; Row 3: blood genotype followed by 
tumor genotype. No call is denoted as “./.”. Base counts and genotypes are after filtering. Base substitutions identified by CALL are marked by 
a line above genotypes. Base substitutions missed by SMUG are in italics. 
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Table V.3. Comparison of SMUG and CALL for detection of base substitutions at COSMIC sites 
and genes. 
 
 CALL  SMUG 
 Total Breast cancer  Total Breast cancer 
COSMIC sites 1 1  2 1 
COSMIC genes: 41 7  67 10 
Non-synonymous 25 5  45 6 
Synonymous  41 7  67 10 
Stop gain  0 0  2 0 
Stop loss  0 0  0 0 
 
 
Base Substitution Result Validation and Replication 
We collected DNA samples for normal breast tissue and tumor breast tissue for 3 
patients (patients 1-3) in this study and 104 additional patients in the Shanghai breast cancer 
study. These samples were genotyped for a set of SNPs in a different study. Three SNPs were in 
the top list of our SMUG results (called SNP1, SNP2, and SNP3, respectively in Table V.2). We 
evaluated these three SNPs to see if our results could be validated for patients 1-3 and 
replicated in the independent set of 104 patients. 
Genotyping was performed using the iPLEX Sequenom MassArray platform (Cai et al. 
2011; Long et al. 2010; Zheng et al. 2009). Polymerase chain reaction (PCR) and extension 
primers were designed using the MassARRAY Assay Design software (Sequenom, Inc). PCR and 
extension reactions were performed according to the manufacturer’s instructions, and 
extension product sizes were determined by mass spectrometry using the Sequenom iPLEX 
system. On each 96-well plate, two negative controls (water), two blinded duplicates, and two 
HapMap samples were included. The median consistency rate was 100% for both the duplicate 
samples and the HapMap samples when compared with their genotypes in the HapMap 
database. 
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After quality control filtering, 93 of the 104 patients had genotype at SNP1 for both 
normal and tumor breast tissues. Among them, 11 patients were homozygous in normal tissue 
and heterozygous in tumor tissue, resulting in an estimated mutation incidence rate of 11.8%. 
For SNP2, 67 patients had genotype available for both tissues and 5 (7.5%) had different 
genotypes between tissues. For SNP3, 81 patients had genotype available for both tissues and 9 
(11.1%) had different genotypes between tissues. We note that a mutation incidence rate is 
calculated across patients, which is different from the fraction of mutant alleles calculated 
within a patient. Since the normal and tumor tissues from a patient may be genetically more 
similar than between her blood and tumor tissue, the number of differences in genotype 
between blood and tumor tissue could be higher than those observed above. Therefore these 
replication results are encouraging and show the potential of our method. 
The Sequenom genotype data also allowed us to see if our results at SNP1-SNP3 for 
patients 1-3 could be validated. As shown in Table V.2, only patient 3 had a base substitution 
detected at SNP1. This was validated by our Sequenom data: patient 3 was homozygous in the 
normal tissue and heterozygous in the tumor tissue. For all the other eight combinations of 
patient and SNP, both normal and tumor tissues were homozygous. 
 
Allelic Imbalance for Base Substitution Sites 
As we explained earlier, a tumor sample may contain a mixture of tumor and non-tumor 
cells, and a somatic mutation may not be present in all tumor cells. Thus, a somatic mutation 
may be present in only a fraction of cells in a tumor sample. The resulting allelic imbalance can 
make it inefficient to identify somatic mutations through genotype calls, as was previously 
shown. We evaluated the extent of allelic imbalance by comparing two types of sites that were 
called heterozygous in tumor: those with the same heterozygous genotype in blood and those 
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homozygous in blood. The former should mostly be genuinely heterozygous in tumor with no 
allelic imbalance. The latter were base substitutions identified by the CALL approach, and should 
mostly display allelic imbalance if the phenomenon we described above was present. 
We calculated the p-value for allelic departure from 50:50 at these sites in tumor. The p-
value should follow a uniform distribution over the interval [0,1] if there is no allelic imbalance 
and should be near zero if allelic imbalance exists. Figure V.1 contains the results for tumor 
heterozygous sites with depth ≥ 20 for patient 2; the results for the other patients were similar. 
The distribution for the base substitution sites (right panel) shows strong allelic imbalance, with 
p ≤ 0.05 for 87% of the sites. In contrast, among the genuinely heterozygous sites (left panel), 
only 26% had p ≤ 0.05; the distribution was consistent with a mixture of sites with no allelic 
imbalance (78%) and sites with allelic imbalance (22%). We expect these allelic imbalance sites 
are potential LOH sites, although their LOH scores might not be high enough to pass our LOH 
detection threshold. 
 
 
 
 
Figure V.1. Allelic imbalance at base substitution sites in tumor samples. 
These results demonstrate that most base substitution sites can manifest significant 
allelic imbalance in tumor samples, at least in our tumor DNA samples. This may generate a 
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dilemma for the CALL approach since allelic imbalance has been a commonly used tool for 
genotype quality control. Filtering genotypes based on allelic imbalance may lower the chance 
of detecting base substitutions by CALL. We have shown that CALL identified 614 base 
substitution sites in our data. When an allelic balance filter (AB ≤ 0.75) was used, only 310 sites 
remained. When the allelic balance filter was applied only to blood samples but not tumor 
samples, 395 sites were identified by CALL. 
 
Detection of Regions with Loss of Heterozygosity 
For exome sequencing data, heterozygous sites outside exons may not be reliably called 
due to gaps of coverage for many genomic regions. In this situation, as was explained in the 
Methods section, an LOH region may not be detectable due to a lack of supporting sites, and 
multiple LOH regions may be identified as a single one due to a lack of sites breaking it apart. 
This is true for both SMUG and CALL. Nonetheless we applied both approaches to our exome 
data and compared their performance. 
For the CALL approach, we first obtained genotype calls for blood and tumor samples. 
For each patient, her CALL list of LOH sites consisted of sites that were heterozygous in blood 
and homozygous in tumor. A CALL LOH region was defined as a contiguous region that 
contained at least two LOH sites and no interrupting site (i.e., sites heterozygous in both blood 
and tumor) in the region. The boundaries of an LOH region were the positions of its first and last 
LOH sites. 
For the SMUG approach, we first obtained genotype calls for blood samples using the 
same filtering criteria as in the CALL approach. For each patient, we calculated the tumor LOH 
score for every site heterozygous in blood, and generated her SMUG list of LOH sites as those 
sites with LOH score ≥30. A SMUG LOH region was defined as a contiguous region that contained 
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at least two LOH sites and no interrupting site (i.e., sites heterozygous in blood but with LOH 
score <30). Its boundaries were defined similarly as above. 
SMUG reported an average of 354 LOH regions per patient, while CALL reported 51 
(Table V.4). SMUG also reported more LOH regions covering the COSMIC genes (Table V.4). LOH 
has been widely reported in breast cancer. 
 
 
Table V.4. Comparison of SMUG and CALL for detection of LOH regions. 
 
Patient 
Call  SMUG 
# of 
LOH 
regions 
Inside  
COSMIC 
genes 
Inside 
support 
intervals 
 
# of 
LOH 
regions 
Inside COSMIC 
genes 
Inside 
support 
intervals 
1 34 3 4  234 28 10 
2 37 4 2  314 34 15 
3 59 8 5  519 130 30 
4 33 3 2  230 26 8 
5 43 7 3  321 28 21 
6 58 6 4  399 45 21 
7 55 4 3  265 23 13 
8 87 16 4  554 118 27 
Average 50.8 6.4 3.4  354.5 54 18.1 
 
 
Compiling data from 151 LOH studies of breast cancer, Miller et al. (Miller et al. 2003) 
developed a likelihood-based approach to identify loci with preferential loss. They reported 19 
support intervals (Table V.5) that had strong evidence for LOH in breast cancer, and stated that 
the list was not exhaustive due to the limited resolution of LOH mapping. SMUG identified more 
LOH regions falling in these intervals than CALL did (Table V.4). As detailed in Table V.5, SMUG 
identified a total of 145 LOH regions that fell in 12 of the 19 support intervals, while CALL found 
27 LOH regions that hit 4 support intervals. For all the support intervals with at least one 
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identified LOH region, SMUG identified more patients with LOH regions falling in the interval. 
These results suggested that SMUG is more powerful than CALL at detecting LOH regions. 
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Table V.5. Comparison of SMUG and CALL for detection of LOH regions in the 19 support 
intervals reported in Miller et al. 
 
 
Support 
interval 
(position 
in Mb) 
CALL  SMUG 
Candidate TSGs 
(position in Mb) #Patients 
#LOH 
regions 
 #Patients 
#LOH 
regions 
1p36.3 0-10.5      SKI (1.5), TP73 (3.5) 
2q22.1 
134.5-
137.7 
     
FLJ11857 (135.5), LRP1B 
(138.5) 
3p24.1 22.1-40.4 1 1  4 8 TGFBR2 (32.6) 
3p14.2 59.3-63.6    1 1 FHIT (63.5) 
4q35.1 
182.9-
189.2 
   3 3 FAT (187.6) 
6q25.1 
151.8-
170.3 
2 2  5 5 
ESR1 (159.3), IGF2R 
(167.3) 
7q31.2 
115.7-
119.0 
     
TES (116.2), CAV1 
(116.5), ST7/MET 
(117.0) 
8p21.3 18.5-23.0      
N33 (15.6), PDGFRL 
(17.8), LZTS1 (18.6), 
FGF17 (20.4), DBC2 
(23.2) 
9p21.3 26.2-27.5    1 1 
CDKN2A/p16 (23.8), 
IFNA (24.5) 
13q14.11 38.8-42.1    2 2 BRCA2 (38.2), AS3 (38.5) 
16q22.1 69.4-72.2    4 6 
CDH3 (71.3), CDH1 
(71.5) 
16q24.1 72.9-89.8    4 8 WWOX (83.9) 
16q24.3 90.3-94.3      
CDH13 (88.5), CBFA2T3 
(92.5), CDH15 (92.7), 
FANCA (93.2) 
17p13.3 0-1.5      
ABR (.8), OVCA1 (1.7), 
HIC1(1.7) 
17p13.2 0-22.8 6 8  8 49 
TP53 (8.0), MAP2K4 
(13.6) 
18p11.32 0-3.0 7 16  8 60 DAL1/EPBB41L3 (5.8) 
18q21.2 51.7-54.8      DPC4 (51.1), DCC (53.3) 
19p13.3 4.6-6.9    1 1 SAFB (7.6) 
21q11.1 15.5-18.8    1 1 BTG3 (15.6) 
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Discussion 
 
We have developed SMUG, a set of methods for detecting base substitutions and LOH 
regions using NGS data for normal-tumor pairs. The methods are applicable to both whole 
genome and whole exome sequencing designs. We demonstrated application of SMUG using 
whole exome data for blood and tumor samples from eight breast cancer patients, and showed 
that SMUG detected more somatic mutations than the conventional approach that relies on 
comparing genotype calls between normal and tumor samples. For three base substitution sites 
identified by SMUG, we had genotypes for the normal and tumor breast tissues from an 
independent set of breast cancer patients, which replicated our finding that these sites may be 
breast cancer somatic mutation sites. The result is encouraging, although further investigation is 
warranted. We are following them up in a separate study. 
Somatic mutations may not be detectable through genotype comparison because a 
tumor sample may contain a significant fraction of non-tumor cells and a somatic mutation may 
not be present in all tumor cells of a tumor sample. Although laser capture microdissection can 
be used to purify the selection of tumor cells in sample preparation, its usage may be limited for 
certain tissues and the selected tumor cells may still be heterogeneous with respect to somatic 
mutations. 
With multiple sequence reads at each position, the NGS technologies allow a 
quantitative examination of mutations. While we take advantage of the quantitative nature of 
NGS data for tumor samples, our methods rely on genotype calls for normal samples. This 
probably is a good choice when the normal samples are homogeneous. For a homogeneous 
diploid sample with only three genotypes underlying sequencing data, genotype calling may 
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serve as a de-noising tool. In fact, current genotype callers such as that in GATK can achieve a 
very good accuracy. 
For detection of base substitutions, we proposed an empirical Bayes approach to 
remove the effect of depth on estimation of the fraction of mutant alleles. Since systemic 
sequencing and alignment errors may also appear as base substitutions in tumor, we developed 
filters that use the normal sample data as a baseline. We also showed that strong allelic 
imbalance can exist for base substitution sites. This raises an issue for the conventional CALL 
approach of comparing genotype calls because allelic imbalance has been a common tool for 
filtering genotypes. If one chooses to use the CALL approach, it might be more effective not to 
use allelic imbalance as a filtering criterion, at least not for tumor samples. Other genotype 
filtering tools developed for homogeneous samples also may not work well for tumor samples. 
One example is transition/transversion ratio, which may have different target values for tumor 
mutations than those established for germ line polymorphisms. 
For detection of LOH regions, we proposed to calculate LOH scores to facilitate 
identification of LOH regions. Our method focuses on sites that are heterozygous in the normal 
sample. This probably works well for large LOH regions that harbor multiple heterozygous sites 
in the normal sample, but it may not be as powerful at detecting short LOH regions. Short LOH 
regions could be detected by studying depth using algorithms similar to those for detecting 
CNVs. However, as depth varies along the genome and across samples, appropriate 
normalization will be needed. We plan to extend our method to take depth into account for 
detecting LOH regions. The incorporation of depth information may also allow us to distinguish 
deletion LOH and copy-neutral LOH. 
Our methods are especially useful for non-purified tumor samples that contain non-
tumor cells. The fraction of non-tumor cells in a tumor sample is often unknown but could be 
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estimated. Methods have been proposed to use SNP chip data to estimate the fraction of non-
tumor cells in a tumor sample. We plan to develop methods for estimating tumor cell fraction 
using NGS data and to incorporate this information into our mutation detection algorithms. 
We have focused on two major types of somatic mutations: base substitution and LOH. 
Other types of mutations such as indels, inter- and intra-chromosomal rearrangements, and 
CNVs, can also be similarly detected quantitatively. We are developing methods for detecting 
these types of mutations. The methods described in the paper have been implemented in 
software Somatic Mutation Gleaner (SMUG), which is publicly available at 
http://biostat.mc.vanderbilt.edu/SMUG. 
 
Future Works 
 
There are some limitations of the current implementation of SMUG. For detection of 
base substitutions, at this point, SMUG cannot detect sites that are homozygous in normal but 
also homozygous in tumor with different allele. We plan to improve and extend SMUG to deal 
with this situation. 
The detected LOH regions could be incorrect as well. Due to lack of supporting sites that 
are heterozygous in blood sample and has high LOH score in tumor sample, an LOH region may 
not be detected. On the other hand, multiple LOH regions may be identified as a single one due 
to lack of supporting sites breaking them apart. We plan to extend SMUG to take depth into 
account for detecting LOH regions. The incorporation of local depth information may also allow 
us to distinguish deletion LOH and copy-neutral LOH regions.  
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